Time-Resolved Phosphoproteomics Unravel the Dynamics of Intracellular Signaling by Kubiniok, Peter
 Université de Montreal 
 
 
 
 
 
 
 
Time-Resolved Phosphoproteomics Unravel the Dynamics of 
Intracellular Signaling 
 
 
 
 
 
par 
Peter Kubiniok 
 
 
 
 
Département de Chimie  
Faculté des Arts et des Sciences 
 
 
 
 
 
Thèse présentée à la Faculté des études supérieures et postdoctorales  
en vue de l’obtention du grade de 
Philsosophiæ Doctor (Ph.D.)  
en chimie 
 
 
 
 
 
 
 
 
Mai 2018 
© Peter Kubiniok, 2018

 Resumé 
 
La phosphorylation des protéines est une modification post-traductionnelle très abondante qui 
cible les acides aminés sérine, thréonine et tyrosine. Les groupements phosphates sont ajoutés 
aux protéines par les kinases et retirés par les phosphatases. La phosphorylation d’une protéine 
régule sa conformation structurelle; ce qui modifie ses fonctions. C’est un vecteur de 
signalisation intracellulaire, impliqué notamment dans la régulation des interactions protéine-
protéine et de l’activité des enzymes. La prolifération, la différenciation et la morphologie 
cellulaires sont autant de processus régulés par des événements de phosphorylation. Une 
meilleure compréhension des voies de phosphorylation est ainsi importante pour faire avancer la 
recherche contre le cancer. L’étude de la phosphorylation des protéines a grandement bénéficié 
de l’amélioration des techniques de protéomique basées sur la spectrométrie de masse, qui 
permettent d’analyser en quelques heures des milliers de sites de phosphorylation. Les 
expériences de spectrométrie de masse permettent habituellement d’étudier les effets de stimuli 
extracellulaires sur le phosphoprotéome en prenant des mesures à un seul temps post-stimulation 
donné. Ce type d’analyse ne permet toutefois pas de suivre les changements de phosphorylation 
dans le temps, ce qui serait utile pour comprendre le fonctionnement des voies de signalisation. 
La présente thèse décrit le développement et l’application de nouvelles techniques de 
phosphoprotéomique permettant de mesurer la phosphorylation avec une grande résolution 
temporelle. Cette approche a permis d’identifier de nouvelles voies de signalisation dépendantes 
de stimuli et de mieux caractériser certains réseaux de phosphorylation déjà connus.  
 
Tout d’abord, une analyse temporelle du phosphoprotéome a été effectuée pour déterminer les 
effets de stress thermiques sur Saccharomyces cerevisiae dans les 30 minutes post-stimulation. 
15 profils cinétiques différents ont été identifiés. Ces profils de phosphorylation ont permis de 
mieux définir des interactions kinase-substrat. L’information temporelle a notamment permis de 
caractériser les réseaux de signalisation des kinases Cdc28 et PKA suite à un choc thermique. De 
grands changements d’état de phosphorylation ont été observés pour des protéines impliquées 
dans la transcription, le repliement des protéines et la progression du cycle cellulaire.  
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Dans une seconde étude, des cellules humaines de cancer du côlon contenant des mutations 
somatiques de BRAF ou KRAS ont été traitées avec un inhibiteur de BRAF, le Vermurafenib. 
L’utilisation de la phosphoprotéomique temporelle a permis d’identifier de nouveaux substrats 
de la voie BRAF-RAS-ERK. De fait, il a été démontré que les facteurs de transcription MKL1/2 
et TEAD3 sont des cibles directes de la kinase ERK.  
 
Enfin, les effets sur le phosphoprotéome de petites molécules activatrices de la protéine 
phosphatase 2 A (PP2A) ont été étudiés. Des cellules hématopoïétiques murines ont été traitées 
avec les sphingolipides anti-oncogéniques C2-ceramide et SH-BC-893 ainsi qu’avec l’inhibiteur 
spécifique de PP2A, le LB-100. Les sphingolipides utilisés sont des activateurs connus de PP2A 
qui causent la mort cellulaire en privant les cellules de nutriments. De fait, les deux 
sphingolipides causent la perte de transporteurs de nutriments. SH-BC-893 mène en plus à la 
formation de vacuoles, un phénotype lié à la mobilisation de nutriments. La dynamique du 
phosphoprotéome a été suivie pendant les 60 minutes suivant le traitement, révélant une 
activation différentielle de PP2A en présence des sphingolipides. En comparant ces réponses 
avec le phosphoprotéome de cellules traitées avec le LB-100, il a été possible d’identifier des 
sites de PP2A sur de nombreuses GTPases et protéines du cytosquelette d’actine, notamment 
Arhgef2 et Paxilin. De plus, la privation de nutriments s’est avérée être partiellement  
dépendante de la polymérisation de l’actine induite par les sphingolipides. Finalement, les 
phosphoprotéines lysosomales associées au kinase AKT et impliquées dans le recyclage des 
endosomes sont régulées différent par SH-BC-893 et C2-ceramide, ce qui explique partiellement 
pourquoi C2-ceramide ne cause pas la formation de vacuoles.  
 
Somme toute, l’analyse temporelle du phosphoprotéome a permis d’étudier différents processus 
plus en profondeur que ce que permettent les techniques de phosphoprotéomique traditionnelles. 
Elles ont permis d’élucider des mécanismes biologiques d’importance pour la recherche contre le 
cancer. 
 
Mots clés: Phosphoprotéomique, Signalisation intracellulaire, Spectrométrie de Masse, 
Cancer, Petites Molécules médicamenteuses. 
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Abstract 
 
Protein phosphorylation is a highly abundant post translational modification primarily observed 
on the amino acids Serine, Threonine and Tyrosine. Phosphate residues are transferred through 
kinases and are removed by protein phosphatases. Phosphorylation regulates the structural 
conformation of proteins, therefore modifying their function. It functions as an intracellular 
signaling mediator that regulates key processes such as protein-protein interactions and the 
activity of enzymes. Cell proliferation, differentiation and morphology are some of the most 
important cellular machineries regulated through phosphorylation signaling. Knowledge about 
phosphorylation pathways therefore is of high importance for cancer research. The study of 
protein phosphorylation has greatly benefited from the implementation of mass spectrometry 
based proteomics techniques that allows for the profiling of thousands of protein phosphorylation 
sites in a matter of hours. When investigating the effects of extracellular stimulations on the 
phosphoproteome, mass spectrometry experiments are typically designed by taking a snapshot of 
the phosphoproteome at a given time post stimulation. This type of analysis, however, does not 
allow to follow the temporal characteristics of phosphorylation that could explain the functioning 
of signaling pathways. This thesis describes the development and application of 
phosphoproteomics techniques that monitor phosphorylation signaling at high temporal 
resolution. This approach allowed the discovery of stimulation dependent signaling pathways 
and aided the refinement of already characterized phosphorylation networks.  
 
At first, temporal profiling of the phosphoproteome was applied to study the effects of heat and 
cold stress on Saccharomyces cerevisiae within the first 30 minutes post stimulation. Fifteen 
different kinetic trends were discovered. Kinase-substrate interactions could be unraveled based 
on kinetic patterns of phosphorylation. In more detail, temporal information allowed the 
characterization of the signaling network of the kinases Cdc28 and PKA following temperature 
stress. These responses were associated with extensive changes in phosphorylation on proteins 
involved in transcription, protein folding and cell cycle progression.  
 
In a second study, human colon cancer cells harboring somatic BRAF or KRAS mutations were 
subjected to treatments with the BRAF kinase inhibitor Vemurafenib. Temporally resolved 
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phosphoprotoemics aided the discovery of novel targets of the BRAF-RAS-ERK signaling 
pathway. The transcription factors MKL1/2 and TEAD3 were found to be direct target of the 
kinase ERK. ERK mediated phosphorylation of MKL1/2 could be associated to actin binding, 
regulating their activity.  
 
Third, a study investigating the effects of protein phosphatase 2 A (PP2A) small molecule 
activators on the phosphoprotoeme is described. Hematopoietic mouse cells were treated with 
the anti-oncogenic sphingolipids C2-ceramide and SH-BC-893 as well as the specific PP2A 
inhibitor LB-100. The investigated sphingolipids are known activators of PP2A that starve 
cancer cells to death. Both sphingolipids cause nutrient transporter loss, leading to cell 
starvation. In addition, SH-BC-893 causes vacuolation, a phenotype that is linked to nutrient 
mobilization. Phosphoprotoeme dynamics were monitored within 60 minutes post stimulation 
and unraveled differential activation of PP2A with sphingolipids. Comparison of sphingolipid 
response to the LB-100 perturbed phosphoprotoeme revealed PP2A directed phosphorylation on 
numerous GTPase and actin cytoskeletal proteins including Arhgef2 and Paxilin. Cell starvation 
was found to be partially dependent on sphingolipid induced actin polymerization. Lysosomal 
phosphoproteins affiliated with the kinase AKT and endosome recycling were differentially 
regulated by SH-BC-893 and C2-ceramide, partially explaining why C2-ceramide does not 
induce vacuolation. 
  
Overall, temporal profiling of the phosphoproteome improved the depth of knowledge gained 
from phosphoproteomics experiments compared to conventional studies, and lead to the 
discovery of yet unknown biological mechanisms that are of importance to cancer research.  
 
Keywords: Phosphoproteomics, Intracellular signaling, Mass spectrometry, Cancer, Small 
Molecule Drugs. 
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 Chapter 1  
 
Introduction 
 
1.1 Intracellular Signaling 
 
Intracellular signaling is the process in which information is transferred within the cell. In the 
natural habitat of cells, intracellular signaling begins outside the cell through a stimulation or 
stress and is transduced inside the cell causing a reaction. In cell biology, intracellular signaling 
is defined as “A chain of reactions that transmits chemical signals from the cell surface to their 
intracellular targets” [1]. These chemical signals often originate from receptor proteins at the cell 
surface that recognize changes in the extracellular space. Receptor proteins are usually large 
proteins that are embedded into the lipid bilayer membrane and stick out at both the intracellular 
and extracellular sides of the cell membrane. Translation of an extracellular stress into an 
intracellular response mostly happens through conformational changes of the intracellular protein 
domain on the receptor protein. This, in turn, allows for the receptor protein to interact with an 
abnormal set of intracellular proteins or enzymes. Once these intracellular proteins interact with 
the receptor, their activity changes and induces a cascade of chemical signals.  
 
1.1.1 Stress response and signaling 
 
Research over the past two decades has found that extracellular stress often activates intracellular 
signaling cascades through G-protein coupled receptors [2]. The binding of a ligand to the 
extracellular part of a G-protein coupled receptor can change the conformation of the 
intracellular domains that are linked to G-proteins. G-proteins are guanine nucleotide binding 
proteins acting as molecular switches through hydrolysis of guanosine triphosphate (GTP – ON 
state) to guanosine diphosphate (GDP – OFF state). Upon ligand binding to a receptor, the GDP 
bound to the G-protein is phosphorylated to GTP and, in turn, can induce the activation of 
various signaling cascades [3, 4]. Depending on the type of stress, distinct receptors are 
activated, leading to the activation of stress-specific signaling pathways [5]. An obvious, day-to-
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day example of intracellular signaling is receptor-mediated activation of nerve cells through light 
and heat [6]. Due to the large diversity of cells in the body, different cell types contain different 
receptors that are prone to react to specific types of stimuli.  In addition to the activation of 
signaling cascades through extracellular stresses and receptors, when enzymes that normally 
mediate the chemical signals within a cell are impaired, they can cause similar perturbations to 
signal transduction mimicking stress or growth conditions. These can be induced through 
activity-changing mutations on proteins or through treatment with exoogenous chemicals, such 
as chemotherapeutics, which bind to target proteins with the intent to induce cytotoxic signaling 
events. All signaling cascades are of extremely high complexity and do not occur in a linear 
fashion. Accordingly, the impacts from impaired and altered signaling cascades on the biological 
system can vary from allergic reactions and the perception of pain to the growth of tumors. Thus, 
it is important to understand disease-associated signaling events in great detail in order to 
decipher those that can be targeted for treatments. This thesis is focused on studying targeted and 
general stress responses in yeast, a model organism, as well as signalling in mammalian tumor 
cells, with the aim of gaining knowledge on cancer-specific cell signaling.  
 
1.1.2 Types of intracellular signaling 
 
Intracellular signaling can be mediated through numerous classes of chemicals. Here, we will 
discuss the classes that are most important for intracellular signaling. Accordingly, hormones, 
cytokines and growth factors, which are all signaling molecules of the endocrine (extracellular) 
system, will not be discussed. 
 
Intracellular signaling molecules transform stimulations into biochemical chains of action. These 
signalling cascades can be carried out through post-translational modification (PTM) of proteins. 
Chemical modifications of proteins occur through the covalent addition of functional groups or 
small proteins. Acetylation, glycosylation, methylation, ubiquitination, sumoylation, 
phosphorylation, and proteolysis, the enzymatic cleavage of proteins, are amongst the most 
important chemical modifications to proteins [7-9]. These post-translational modifications can 
change the activity and chemical properties of modified proteins. The change in activity of one 
protein affects the activity of the downstream interactor of the protein and thus, results in the 
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spread of a signal. One of the most abundant types of post-translational modification is 
phosphorylation, which is highly involved in the regulation of protein cascades that regulate 
cellular processes including proliferation, differentiation, and cell death [10]. 
 
1.1.3 Occurrence and mediation of protein phosphorylation 
 
Protein phosphorylation is a post-translational modification that occurs mostly through the 
phosphorylation of the amino acids Serine (Ser) and Threonine (Thr), which make up an 
estimated 79.3% and 16.9% of all phosphosites found, respectively. Less commonly found is 
Tyrosine (Tyr) phosphorylation, at 3.8% [11]. Studies also suggest that non-canonical 
phosphorylation occurs on Histidine (His), Aspartic acid (Asp), Glutamic acid (Glu), Lysine 
(Lys) and Arginine (Arg), but these are far less studied due to the thermal instability of the 
respective phosphor ester bonds [12]. The insertion of a phosphogroup into a protein causes an 
increase in negative charge and a concomitant decrease in hydrophobicity, which, in turn, can 
alter the conformation, and thus the activity, of the protein [13]. Phosphorylation can 
simultaneously occur at different places within a protein and often affects the three-dimensional 
conformation of a protein in various ways [14]. Recent studies suggest that there are about 
20,000 protein encoding genes in human cells (5,400 in yeast), of which about 13,000 (3,000 in 
yeast) are regulated through phosphorylation [15]. Most phosphoproteins can be phosphorylated 
at multiple amino acid residues, creating a large pool of ~230,000 (~40,000 in yeast) estimated 
phosphorylation sites [15]. At present, scientists can unravel key stress response pathways within 
this large pool of possible phosphorylation patterns that are causes and results of major diseases, 
including cancer [16]. Phosphorylation is performed by protein kinases that are bound to 
adenosine triphosphate (ATP), which can transfer one phosphogroup to either of the 
aforementioned amino acids on a protein. Most kinases are specific to phosphorylation of either 
Ser/Thr or Tyr [17, 18]; they are thus said to harbour serine-threonine-kinase or tyrosine-kinase 
activity although some outlier kinases display both activities and are said to be dual-specificity 
kinases. The transfer of phosphogroups from a kinase to its substrate happens in the active site of 
protein kinases, and is schematically depicted in Figure 1.1 [19]. 
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Figure 1.1. The transfer of phosphogroups by protein kinases.  
A) Key residues interactions in the active site of protein kinase A (PKA). B) Associative and dissociative reaction transition 
states for protein kinases. Figure adapted from reference [19]. 
 
The process of protein-catalyzed transfer of phosphorylation was first discovered in 1954 by 
Eugene P. Kennedy [20], while the breakthrough in understanding the biological relevance of 
reversible protein phosphorylation occurred in the late 1980s and early 1990 through the 
purification of JAK kinases [21]. Since then, kinases have been found to phosphorylate specific 
substrate proteins through different types of recognition mechanisms. Initially identified was the 
recognition of substrates via amino acid motifs that increases the affinity to the catalytic pocket 
of the kinase [22]. Kinase recognition motifs were found in close proximity to the 
phosphorylation site and are specific for certain types of kinases. Early research on this topic 
found that the kinases CDK2, ERK2, PKA, twitchin and casein kinase each phosphorylate 
peptides with distinct amino acid sequences [23]. Songyang et al. (1996) found that the acidity, 
basicity and hydrophobicity of the amino acids surrounding the phosphorylation sites are of great 
importance for substrate recognition. Recognition motifs are generally well-conserved and thus, 
phosphorylation sites surrounded by conserved motifs are more likely to be important for protein 
functionality [24, 25]. In addition to kinase recognition by amino acid motifs near the 
phosphorylation site, recurring strings of amino acids have been found on protein substrates that 
increase the kinase-substrate affinity and thus, the likelihood of phosphorylation. This second 
type of kinase-substrate recognition motif does not necessarily occur close to the 
phosphorylation site and these motifs are referred to as “docking motifs”. A well-investigated 
example are the “Kinase Interaction Motif” (KIM) docking motifs of mitogen-activated protein 
(MAP) kinases, which significantly increase the kinase-to-substrate affinity [26]. The two 
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combined recognition mechanisms guide the phosphorylation landscape of kinases and thus 
explain the specificity by which intracellular signaling is mediated. Differential regulation of 
kinases alters the abundance of phospho-sites on a specific population of proteins, which can, in 
turn, affect the proportion of active cellular machineries. Kinase-induced signals typically result 
in a snowball effect, spreading information within the cell, and are termed signaling cascades 
[27]. A general example of such a cascade is a system where protein kinase A phosphorylates 
protein kinase B, which in turn phosphorylates protein C. Each of these protein kinases can have 
several substrates and thus, a simple stimulation can result in complex signaling cascades [28]. 
Initial studies were performed on the cyclic AMP-dependent protein kinase, which mediates 
receptor-induced signaling [29]. At present, 518 kinases, of which 90 are Tyrosine and 428 are 
Serine/Threonine protein kinases, have been mapped in the human proteome [30].  Amongst 
these, 13 kinases with dual specificity have been identified. With the combined information 
about protein kinases, mass spectrometry based proteomics can be utilized to investigate stress 
response pathways regulated by certain kinases and assess their association with major diseases, 
including cancer [16]. 
 
1.1.4 Protein de-phosphorylation 
 
Kinases regulate cellular processes through the transfer of phosphate residues to proteins with 
regulatory functions. The reverse reaction, the de-phosphorylation of amino acid residues, is 
accomplished by protein phosphatases through hydrolysis of the phosphate ester bonds. 
Accordingly, phosphatases are integral to signaling cascades in a similar fashion to kinases. The 
mechanism of de-phosphorylation was discovered by Cori and Green in 1943, about a decade 
before the discovery of kinases [31]. However, the biological significance of phosphatases was 
studied much later, when techniques became available that allowed the cloning of proteins in 
model organisms, such as yeast [32, 33]. Further investigations manifested that phosphatases can 
be grouped into three different classes based on the mechanism by which the phosphor ester 
bond is hydrolysed. The first class of phosphatases requires magnesium ions and an aspartate 
residue in close proximity to the catalytic cleft and these are referred to as phosphatases of the 
Fcp/Scp family. These phosphatases are mostly single protein phosphatases that do not contain 
other protein subunits. The second family of phosphatases depends on metal-catalyzed 
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hydrolysis mediated through either Mg2+ or Mn2+ ions that dephosphorylate Ser/Thr residues. 
These are further sub-classified into mostly single subunit phosphatases (PPM) and the multi-
subunit protein phosphatases (PPP) family. These PPP’s regulate most of the Ser/Thr-directed 
de-phosphorylation, which makes up about 80% of the phosphosites in the proteome. The third 
group is the protein tyrosine phosphatases (PTPs), which regulate mostly Tyrosine 
phosphorylation. The catalytic mechanisms are summarized in Figure 1.2 [34]. 
 
Figure 1.2. Catalytic mechanisms of protein phosphatases.  
A) Mechanism of the Fcp/Scp family phosphatases. B) Mechanisms of the PPP/PPM family phosphatases. M1 and M2 depict 
Mg2+ ions. C) Catalytic mechanism of PTP phosphatases. Figure adapted from reference [34]. 
 
In the human genome, there are 107 PTPs  [35] and around 30 Serine and Threonine protein 
phosphatases (PPP and PPM family) [36] that counteract the activity of 90 Tyrosine and 428 
Serine/Threonine protein kinases [30]. The dichotomy in number of Ser/Thr kinases versus 
Ser/Thr phosphatases is explained through the mechanism by which the phosphatases become 
substrate specific. The most important Ser/Thr phosphatases (PPP family) are multimeric, 
comprising of a catalytic subunit (the phosphatase itself), as well as regulatory subunits that 
determine the substrate specificity. Accordingly, numerous regulatory subunits generate different 
substrate specificities for the same protein phosphatase. At present, these multimeric 
phosphatases are well studied and have been found to regulate major phosphorylation pathways 
involved in cell proliferation, cell cycle regulation, and nutrient transport processes involved in 
diseases such as cancer. The most prominent of the multimeric PPP family phosphatases is the 
protein phosphatase 2 A (PP2A) [37]. 
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1.2 Cancer and protein phosphorylation 
 
1.2.1 Causes of cancer 
 
Simply put, cancer is the uncontrolled proliferation of cells [38]. Uncontrolled cell proliferation 
often is a result of mutations in genes that regulate signaling pathways involved in cell growth. 
Genomic mutations can be inherited or are acquired during the life cycle of cells through factors 
such as tobacco, viruses or ultraviolet radiation from the sun [39]. Random errors during cell 
division can also cause genetic mutations [40]. Usually, cancers are formed in the presence of 
multiple mutations that, in combination, activate the proliferation machinery and deactivate 
cellular defense and repair mechanisms [41]. Cellular defense mechanisms induce cell death 
(apoptosis) in malfunctioning cells to prevent the outgrowth of unhealthy cells. In the case of 
mutational deactivation of these defense mechanisms, combined with constitutively activated 
proliferation machineries, the growth of tumor cells is likely to occur [42]. Researchers found 
that cancer contains, on average, 60 gene mutations, of which only a few are relevant to cancer 
growth [43, 44]. At present, genomic screens can identify at least 125 cancer-driving mutations 
amongst 3,284 tumor genomes [45]. Several of these mutations have been studied intrinsically 
with the aim to unravel target genes and affiliated pathways that could be chemically blocked. 
Noteworthy examples of mutations often found in malignant cancers are amino acid substitutions 
in active regions of the small GTPase Ras and the kinase Raf, as well as the tumor suppressor 
proteins PTEN and p53. Intriguingly, Ras and Raf are activators of phosphorylation-mediated 
signaling pathways that induce proliferation [46] while PTEN negatively regulates the cell cycle 
through its lipid phosphatase activity. In more detail, PTEN prevents cells from proliferating by 
reducing the amount of a phosphorylated lipid (phosphatidylinositol-3,4,5-trisphosphate), which 
is an activator of the proliferation-inducing kinases Akt/PKB [47]. The protein p53 is a tumor 
suppressor found to be altered in over 50% of cancers [48], and the functional deactivation of 
p53, through either mutation or phosphorylation, is most likely to support tumor growth [49, 50]. 
Together, these findings depict how mutations in the signal transduction machinery, which is 
strongly regulated by phosphorylation, can result in unchecked cell growth and the development 
of cancer. In fact, several researchers state that cancer does not only arise from genetic 
mutations, but also from epigenetic changes that induce defects in the signal transduction 
 
8 
machinery [51]. Thus, the study of signaling pathways that are dysregulated in cancers is of 
crucial importance for the development of novel therapeutic strategies that target cancers.  
 
1.2.2 Mitogen activated kinase (MAPK) pathway 
 
Mutations in kinases that impact enzymatic activity can lead to constitutively active or inactive 
signaling pathways. Kinases harboring such mutations have been found through genetic 
screenings of cancer cells [52]. At present, several kinases and associated signaling pathways 
that are evolutionary conserved amongst biological species have been identified to be the cause 
of several cancers. One of the most frequently studied kinase pathways involved in cancer is the 
mitogen-activated protein kinase (MAPK) pathway. In healthy cells, the MAPK pathway 
regulates cell proliferation through receptor-mediated communication with the cell’s immediate 
environment. Receptor proteins such as receptor tyrosine kinases (RTKs) can recognize tissue 
injuries, and other factors that require healthy tissues to grow, and, in turn, activate the MAPK 
pathway to induce cell proliferation [53]. The activation of receptors through the binding of 
extracellular ligands then leads to the activation of Ras-type guanylyl exchange factors which, in 
turn, activate Raf kinases through the support of several co-factors [54]. Following the activation 
of Raf, the signal proceeds through a phosphorylation cascade transmitted to the downstream 
kinases MEK1/2, followed by extracellular signal-regulated kinase 1 and 2 (ERK1/2). The latter 
kinases have been found to positively regulate cell proliferation through the phosphorylation of 
several cellular effectors including  nuclear transcription factors such as TCF and ELK1 (Figure 
1.3) [55]. 
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Figure 1.3. The mitogen activated kinase (MAPK) pathway.  
Figure adapted from reference [10]. 
 
In addition, ERK1/2 has been found to indirectly activate additional transcription factors by 
activation of ribosomal s6 kinase (RSK). The activation of these transcription factors induces cell 
proliferation programs and inhibits apoptotic cell death [56]. In healthy cells, the proliferation 
stops with a decrease in receptor activity when the extracellular stimulation stalls. In cancer cells, 
however, mutations in MAP kinase pathway genes constitutively activate signaling, resulting in 
uncontrolled proliferation of cells. Across all tumor types, the most frequent genetic lesions 
leading to constitutive MAP kinase pathway signalling occur in the BRAF gene (the most 
common being BRAF V600E; substitution of valine 600 to glutamic acid) and in the KRAS gene 
(the most frequent being G12D and G13D substitutions; mutations of glycine 12 or glycine 13 to 
aspartic acid)  [57-59]. The clear causal relationship between MAPK pathway activation and 
cancer development and progression has raised scientific and clinical interest in understanding 
the mechanisms by which this pathway affects tumor growth. 
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1.2.2.1 The kinase ERK 
 
The MAP kinases ERK 1/2 (extracellular signal-regulated kinase 1 and 2) are the key distributors 
of intracellular information that arrives through the MAPK pathway. Numerous scientific studies 
have found that ERK1/2 regulate the proliferative and survival machineries of cells [60]. It has 
been found that ERK1/2 primarily phosphorylate Ser/Thr [61] residues in close proximity to 
proline, and that docking sites on ERK1/2 substrates, referred to as the KIM docking motifs, 
confer increased substrate specificity [26]. Upon activation through MAPKs, ERKs activate the 
proliferative machinery through activation of cytoplasmic RSK as well as through the 
phosphorylation of a battery of transcription factors in the nucleus. Nuclear translocation of 
ERK1/2 commences upon phosphorylation at Thr202/Tyr204 by MEK [62, 63]. A portion of 
activated ERK1/2 then translocate to the nucleus, where they remain during the completion of 
cell division [64, 65]. It has been found that nuclear ERKs are necessary for cell division and 
proliferation due to their role in activating the phosphorylation of several growth-stimulating 
kinases and transcription factors. For example, nuclear ERKs activate mitogen- and stress-
activated protein kinases (MSKs) that have been shown to positively regulate gene translation by 
directly phosphorylating Histone H3 Ser10 and Ser28 [66]. Amongst the best characterized 
transcription factors activated by ERKs are the ternary complex factors (TCFs), of which Elk-1 
is amongst the best studied, as well as the proto oncogene c-Myc. The Elk-1 transcription factor 
is activated upon phosphorylation of Ser383 by ERK1 or ERK2 [67] and, in turn, it increases the 
expression of mitogen-inducible genes. The proto oncogene c-Myc can be activated through 
ERKs by phosphorylation on Ser62, leading to the expression of growth regulating genes [68]. In 
addition to the stimulation of the proliferative machinery through the MAPK pathway, ERK has 
been found to positively regulate cell survival through the inactivation of components of the cell 
death machinery and through deactivation of tumor supressing transcription factors of the FOXO 
transcription complex [69]. Altogether, the ERK kinases activate cellular proliferation and 
concomitantly dysregulate tumor supressing machineries, explaining their involvement in the 
cause of malignant cancers. At present, tumors treated with chemotherapeutic agents targeting 
MAPK to prevent unchecked cell growth through activated ERK consistently become resistant to 
the inhibition of MAPK [70, 71]. There is a therefore urgent clinical need for a better 
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understanding of these mechanisms, as well as the identification of downstream ERK targets that 
could be targeted for treatment. This could, to some extent, be achieved through a more detailed 
profiling of ERK-dependent signaling in different types of cancer cells. 
 
1.2.3 Tumor-supressing phosphatases 
 
Kinases regulate cellular processes through the transfer of phosphate residues to proteins. 
Dynamic regulation of these biochemical reactions is assured through protein phosphatases, 
which invert phosphorylation reactions through hydrolysis of phosphate ester bonds. 
Phopshatases are therefore involved in regulating the same mechanisms as kinases, making them 
key regulators of cancers, in a similar fashion to kinases. As described in the chapter “Protein 
De-phosphorylation”, the family of Ser/Thr phosphatases (PPPs and PPMs) regulates the 
majority of protein phosphorylation sites within the cell [34]. Aberrant activity of several 
members of these Ser/Thr phosphatases has been linked to several diseases, such as diabetes, 
cancer, and Alzheimer’s [72-74], making them promising targets for treatment of these 
conditions. Of high interest for drug design are the multimeric Ser/Thr phosphatases (PPPs) that 
regulate key processes in the cell cycle [37]. Amongst the highly regulatory phosphatases of this 
group are protein phosphatase 1 (PP1), PP2A, PP2B, PP4, PP5, PP6 and PP7, which all exhibit 
high sequence homology [37, 72]. Amongst these phosphatases, PP2A is arguably the most 
studied tumor supressing phosphatase and has been proposed to be a potential therapeutic target 
to treat cancer [75, 76].  
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1.2.3.1 The phosphatase PP2A 
 
In mammalian cells, the enzyme PP2A is present as a heterotrimer comprised of scaffold, 
regulatory and catalytic subunits, each of which exist in various isoforms depending on the 
taxonomy. In the human genome, PP2A can be assembled by a combination of 2 catalytic 
subunits (C-subunits), 2 scaffold subunits (A-subunits) and 12 regulatory subunits (B-subunits) 
[77, 78]. The PP2A holoenzyme is held together by the scaffold subunits, and substrate de-
phopshorylation is catalyzed through the C (catalytic) subunit [79] (Figure 1.4).  
 
 
Figure 1.4. All subunits and corresponding isoforms of the protein phosphatase 2 A (PP2A).  
A represents the scaffold, C the catalytic and B the regulatory subunits. Figure adapted from reference [79]. 
 
The regulatory subunits (B subunits) play a crucial roles in substrate specificity [80]. Enzymatic 
activity and in vivo targets thus depend on the assembly of the protein phosphatase trimer, which 
leads to a variety of complexly-regulated functions. PP2A has been found to regulate several 
signaling cascades involved in cell cycle regulation and proliferation. PP2A-dependent signaling 
cascades affect MAPK [81], the growth controlling mTOR (mechanistic target of rapmycin) 
pathway [82-84], and the Wnt signaling pathways, which regulate proliferation and cell polarity 
[85, 86]. PP2A has been found to be the key regulator of cell cycle progression and mitosis, 
making it the master regulator of the cell cycle [37]. Most of the molecular functions 
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corresponding to cell cycle progression are negatively regulated by PP2A and, accordingly, 
increased activity has been associated with cell cycle arrest, resulting in reduced proliferation. 
The negative regulation of the proliferative and growth machinery makes PP2A an important 
tumor suppressor [87]. In line with these findings, PP2A is underrepresented, or partially 
deactivated, in various cancers. These include prostate cancer, lung cancer, and leukemia [88-
90]. Intriguingly, cell cycle regulation does not seem to be the only mechanism by which PP2A 
affects tumor growth, as recent studies show strong evidence for PP2A involvement in cellular 
nutrient supply wagons [91, 92]. Scientists have linked this finding to PP2A activation and found 
associated inhibition of tumor growth [93]. From this standpoint on, activation of PP2A has 
emerged as a potential treatment for cancer [94]. Suggested approaches to activate PP2A include 
the inhibition of PP2A-specific inhibitor proteins, such as Set and CIP2A and small molecules 
such as sphingolipids [95-97]. The mechanisms by which PP2A activation could be achieved and 
how PP2A activation leads to reduced tumor growth, however, are not yet fully understood. New 
molecular machineries by which PP2A influences tumors are still emerging. In-depth 
investigation of PP2A-activating compounds, associated signaling events, and phenotypes could 
be strategic approaches to unravel the potential of PP2A as an anti-oncogenic target.  
 
1.2.4 Small molecule regulators of kinases and phosphatases 
 
As discussed in the earlier chapters, phosphorylation is highly involved in the formation of 
cancer. The proteins that administer the abundance of phosphorylation on other regulatory 
proteins are kinases and phosphatases. Dysregulation of both classes of enzymes is found in 
cancers, and targeted adjustment of their activities through chemicals has been used to inhibit 
tumor growth [98]. At present, a large number of kinase inhibitors targeting altered signaling 
pathways in cancer cells are on the market. Kinases typically are tumor inducers due to their 
positive regulation of cell growth, leading most chemotherapeutic drugs to be designed as kinase 
inhibitors [99]. Notable examples are inhibitors of Raf proteins, an important family of kinases 
that act as molecular switches to regulate cell signaling, primarily through the stimulation of the 
MAPK pathway [100]. Raf inhibition subsequently blocks downstream effectors that control key 
cellular processes such as actin cytoskeletal integrity, cell proliferation and differentiation, and 
apoptosis. Furthermore, numerous kinase inhibitors targeting the cell growth inducer mTOR 
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[101, 102], the mTOR activator kinases of the PI3K class [103], or the receptor tyrosine kinases 
(RTKs) [104] are in clinical use to combat cancer. As there are a large number of kinases present 
in the human genome, the specificity of kinase inhibitors is important, so as not to cause side 
effects. At present, most clinically-used kinase inhibitors are of high specificity and are often 
applied only to a specific cancer genotype, for example, those that harbor somatic mutations on 
genes, such as BRAF [105]. The main problem encountered when treating cancer cells by 
specifically inhibiting kinases is that the stall of the tumor proceeds slower than cells can 
establish resistance mechanisms, causing prolonged life of patients but not a complete cure [106, 
107]. A better understanding of signalling events may lead to the development of some potential 
inhibitors that target resistant cancers, but no definite cure can be achieved using such medicines 
[108]. As occurrences of resistance and the transient effects of kinase inhibitors accumulate, 
more suggestions to treat cancer from different angles are being discussed [109]. Enzymes such 
as phosphatases are of increasing interest for the development of chemotherapeutics due to their 
pleiotropic effect on the cell cycle [110, 111]. Given that phosphatases of the PP2A class are 
categorized as tumor suppressors, their inhibition by agents like Calyculin A and Okadaic acid, is 
highly carcinogenic. This suggests that conversely, PP2A-activating chemicals could inhibit 
tumor growth [112, 113]. Within the last decade, ceramides, a class of naturally occurring 
sphingolipids, were discovered to activate PP2A and to drastically diminish cell proliferation 
[75]. Since then, synthetic analogues of ceramides have been found to reduce cancer growth. A 
noteworthy example is FTY720, a synthetic sphingolipid which activates PP2A and, in turn, 
causes cancer cells to die through cell cycle arrest and nutrient deprivation [114, 115]. 
Nonetheless, the development of PP2A-activating small molecules is still in its early stages, as 
only a few compounds with PP2A-activating properties are known, making a complete 
understanding of these medicines crucial for further advancements.  
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1.2.4.1 Vemurafenib (PLX4032) 
 
Vemurafenib, or PLX4032, is an FDA-approved kinase inhibitor used to treat metastatic 
melanoma harboring the BRAF V600E somatic mutation, which causes consecutive activation of 
the MAPK pathway [116]. Vemurafenib specifically inhibits the kinase activity of the BRAF 
V600E gene through ATP-competitive binding, a mechanism by which the kinase is deprived of 
the transferable phosphor group provided by ATP, making it kinase-dead [117]. Vemurafenib 
efficiently inhibits the kinase activity of BRAF V600E at nanomolar concentrations, while the 
inhibition of wild-type BRAF kinase occurs only at higher dosages, a phenomenon that 
originates from the BRAF gene to form active kinase dimers [118]. RAS-dependent dimerization 
of the wild-type (wt) BRAF kinase is required for its activity, while the mutated BRAF V600E is 
kinase-active in the monomeric conformation, making Vemurafenib a highly specific inhibitor of 
the BRAF V600E monomer. Vemurafenib and related kinase inhibitors, including Dabrafenib, 
favor wt BRAF to form dimers, resulting in paradoxical activation of MAPK in wt BRAF cells 
[119-121]. Inhibition of wt BRAF through dimer-inducing compounds is only observed with 
excessive dosages of the kinase inhibitor, limiting its use for the treatment of cancers harboring 
the BRAF V600E mutation [122] (Figure 1.5). Such dosages, however, are not applicable for 
treatment and, therefore, Vemurafenib is used only to treat the BRAF V600E melanoma 
genotype. Thus, treatments with Vemurafenib require genomic sequencing prior to treatment 
[123]. In turn, dimer dependency of the wt BRAF gene causes melanomas not harboring the 
BRAF V600E mutation to worsen when treated with Vemurafenib, a phenomenon referred to as 
paradoxical activation [124]. These occurrences are of high clinical significance, as several 
melanomas and other types of cancers, including colon cancer, often harbor somatic KRAS 
mutations (G13D or V14D), which lead to BRAF/MEK/ERK activation, but that cannot be 
treated with Vemurafenib [125]. Furthermore, the off target effects of Vemurafenib has been 
found to lead to the accumulation of side effects and the cause of cancers, including cystic 
lesions and basal cell carcinomas [126]. Interestingly, the efficacy of BRAF V600E inhibition 
leads to several primary and secondary resistances that are not yet fully understood. Primary 
resistance refers to the lack of response to Vemurafenib in cancers with elevated epidermal 
growth factor (EGFR) signaling, as has been observed in metastatic colon rectal cancer, 
requiring discontinuation of treatment [127]. Furthermore, Vemurafenib treatments remain 
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efficient only up to one year from the first dosage, due to acquired resistance that can result from 
re-activated MAP kinases [128]. Several underlying mechanisms, such as the overexpression of 
various RAF isoforms [129, 130] or feedback phosphorylation events that lead to internal MAPK 
activation [131], have been studied, but the underlying signaling events leading to these types of 
resistance require further investigations. 
 
Figure 1.5. Activation of the RAF kinases in dependence of inhibitor concentration.  
Wild-type RAF proteins exist largely in an auto-inhibited state. In the context of activated RAS, RAF inhibitors stimulate MEK 
activation at sub-saturating inhibitor concentrations by relieving auto-phosphorylation (P) of wild-type RAF, promoting RAF 
dimerization and association with RAS. Saturating inhibitor concentrations prevent MEK phosphorylation by blocking all RAF 
catalysis.  
Figure adapted from reference [132].  
 
The impact of cell type, genotype and time of treatment on the efficiency by which MAPK 
inhibitors, such as Vemurafenib, inhibit the growth of tumors raises strong interest in the 
generation of a complete picture of the phosphorylation-dependent signaling that spreads from 
BRAF kinases. In line with the interest in phospho-dependent signaling that is extensively 
discussed in this thesis, the study of global phosphorylation events triggered by Vemurafenib in 
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different cancer genotypes is studied with the aim of gaining additional knowledge on potential 
resistance mechanisms and of generating a more complete picture of MAPK signaling.  
1.2.4.2 Sphingolipids and SH-BC-893 
 
Sphingolipids are lipid-like molecules that are present in mammalian cells, as well as in single 
cellular microorganisms, such as yeast [133, 134]. Noteworthy sphingolipids with proven 
biological activity are: phytosphingosine, which is widely expressed in yeast; ceramide, with 
variable fatty acid chain lengths; as well as sphingomyelin and glucosylceramide (Figure 1.6). 
 
Figure 1.6. Most important sphingolipids.  
From left to right: Sphingolipid structures, corresponding names, placement within the metabolic pathway of sphingolipids. 
Figure adapted from reference [135]. 
 
In vivo synthesis of sphingolipids is evolutionary conserved and the expression of various 
sphingosine metabolites is known to regulate membrane homeostasis and a variety of 
intracellular signaling events that balance physiological cues and stresses [136]. It has been 
found that membrane homeostasis is mediated through the regulation of proteins involved in 
endocytosis and intracellular trafficking [137]. Ceramides, a subclass of sphingolipids, have been 
 
18 
named tumor suppressor lipids due to their impact on cell proliferation, death, migration, and 
senescence, making them of special interest as medicines [138-141]. Furthermore, researchers 
found that sphingolipid treatment elicits PP2A activation in vivo and in vitro through an 
unknown biochemical mechanism [75, 142], and may be associated with nutrient suppression 
and subsequent death of cancer cells [143]. Activation of PP2A causes deprivation of cells from 
extracellular nutrients through blockage of endocytosis and lysosomal fusion, mechanisms 
known to be sphingolipid-dependent [144, 145]. Importantly, such nutrient deprivation is 
specifically deadly to cancerous tissues, which depend on extracellular amino acids and glucose 
due to altered self-supply mechanisms, while healthy cells are able to adapt to starvation [146]. 
Commonly known as the Warburg effect, tumor cells require high amounts of extracellular 
nutrients because of impaired metabolic pathways and, thus, are sensitive to suppressed nutrient 
influx. C2-ceramide and a structurally related FDA-approved compound FTY720 (Fingolimod), 
which is used to treat multiple sclerosis by targeting sphingosine 1 phosphate receptors (S1P), 
have been shown to limit nutrient access to cells by activating PP2A, causing death of tumor 
cells [147, 148]. As these findings made sphingolipids potential candidates for a universal 
treatment of cancer, synthetic analogues of such compounds with optimized chemical properties 
were recently synthesized by researchers at the University of Montreal. Taking the presently-
studied and FDA-approved multiple sclerosis drug FTY720, which harbors anti-oncogenic 
properties, as a starting point, Chen et al. (2015) designed compounds that have higher potency 
to disrupt nutrient access than FTY720 [149]. Compound SH-BC-893, the most potent constrain 
of a series of FTY720-like molecules, has proven to specifically starve cancer cells, similar to 
C2-ceramide and FTY720 [150]. Importantly, SH-BC-893 does not induce bradycardia, which is 
a side effect that occurs at high doses of FTY720, and does not affect the survival of mice [149]. 
As of now, phenotypes observed upon treatment with synthetic (FTY720 and SHBC893) and 
natural sphingolipids (C2-ceramide and phytosphingosine) are the internalization of nutrient 
transporters, including the amino acid transporter 4F2HC, possibly through activated endocytosis 
[93, 151]. Kim et al. (2016) show that these starvation phenotypes caused by SH-BC-893 and 
ceramide are consistently reversed using PP2A inhibitors, such as the non-specific Calyculin A, 
suggesting PP2A as a direct or indirect target of compound SH-BC-893 and ceramides. As PP2A 
is one of the major phosphatases in the cell, it is of high clinical and scientific interest to unravel 
the intracellular signaling by which sphingolipid-activated protein phosphatase induces death of 
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cancer cells. 
 
1.3 Phosphoproteomics to understand intracellular signaling 
 
The signaling machineries that comprise thousands of phosphorylation sites are highly complex 
and require high throughput technologies to be analyzed on a system-wide level [152]. At 
present, there are a few high and low throughput techniques that allow the assessment of the 
abundance of phosphorylation sites on proteins. The most commonly known technique is the 
antibody based western blot profiling of phosphorylation sites [153]. In this low throughput 
technique, protein extracts from cells that are either stimulated or unstimulated are separated by 
sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and are subsequently 
transferred to a nitrocellulose membrane. Incubation of this membrane with antibodies that were 
raised against specific phosphorylation sites on the protein of interest allow chemoluminescence-
based detection and approximate quantification of protein phosphorylation [154]. This approach 
is not applicable to the study of signaling systems since only one or a handful of phosphorylation 
sites can be profiled at a time. In addition, each analysis requires time-consuming optimization of 
experimental procedures. At present, systems-wide analysis of the phosphoproteome is achieved 
using mass spectrometry-based proteomics [155]. Mass spectrometry-based proteomics is a 
branch of proteomics in which the analysis of proteins and their modifications is achieved using 
mass spectrometry. In brief, mass spectrometry-based proteomics can be compared with 
genomics, as both fields make use of technology that is capable of screening the whole cellular 
system at once. The difference is that genomics profiles the genome (DNA and RNA), while, in 
proteomics, the proteome (proteins and their modifications) is investigated in whole [156]. With 
the use of specialized mass spectrometry, which will be discussed in greater detail in the next 
section, protein systems including the phosphorylated proteome, can be profiled within days of 
sample preparation. The field of systems biology has greatly benefited from the use of mass 
spectrometry-based proteomics and has substantially advanced the knowledge of signaling 
machineries through systems wide investigation of post translational modifications [157, 158]. 
Therefore, the use of mass spectrometry is the preferred methodology to profile the effects of 
stimulations on biological systems in a systems wide manner. Nonetheless, the complexity of 
these systems brings analytical challenges that need to be addressed in order to disentangle the 
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vast amount of information gained from high throughput mass spectrometry-based proteomics. 
The theory of mass spectrometry based proteomics and challenges arising from the profiling of 
signaling networks are described in the following section.   
 
1.4 Mass spectrometry-based proteomics 
 
Proteomics is the study of the entire variety of proteins in a biological system, termed the 
proteome, and, over the last two decades, has become an emerging technology in pharmaceutical 
sciences and molecular biology [159]. In contrast to genomics, in which the entire genome is 
studied, proteomics focuses on the set of proteins that is produced from the genome under certain 
conditions [160]. Contrary to genetic material, which is more or less constant over time and in a 
variety of environmental conditions, proteins are highly dynamic in terms of abundance, cellular 
localization, and post-translational modification, including protein phosphorylation [161]. These 
factors greatly increase the level of complexity of proteomic analyses and require analytical 
strategies to study parts of the proteome that are of main interest to the researcher. Proteomics 
can be understood as the science of proteins that investigates their biochemical reactions in a 
biological context and, accordingly, is applicable to studies of changes arising from diseases, 
stresses or chemicals. The development of mass spectrometry (MS) techniques that allow 
ionization and sequencing of peptides and proteins has allowed the performance of system-wide 
analyses of almost the entire array of proteins and their post-translational modifications [162, 
163]. As of now, proteomics has become a widely used technique for the development of 
diagnostics, drugs and chemotherapeutics, as well as concepts in basic sciences [164-166]. 
Analytical strategies to extract and enrich the proteome of interest, as well as mass spectrometry-
based analysis, form the base of proteomics and require optimized workflows to generate reliable 
and robust data. Different workflows that study proteins at different molecular stages have been 
developed, the one used throughout this thesis is termed shotgun proteomics. In shotgun 
proteomics, all proteins in a sample are enzymatically digested into peptides and are analyzed by 
mass spectrometry [167]. Generic sample preparation techniques to extract and analyze the 
proteome have been developed during the last two decades of shotgun proteomics research and 
those used in this thesis are summarized in Figure 1.7. The key elements are sample collection 
and the preparation of protein extracts from biological samples (1). Protein digestion into 
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peptides and optional enrichment of peptides harboring post-translational modifications (2). 
Peptide analysis by liquid chromatography (LC) coupled to MS, often abbreviated as LC-MS and 
pre-fractionation methods can be applied to reduce sample complexity and increase the coverage 
of the proteome (3). Bio-informatics analysis follows to extract information about protein 
identification and quantification (4). 
 
Figure 1.7. Schematic illustration of the shotgun proteomics workflow.  
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1.4.1 Sample preparation 
 
Samples for proteomic analyses can be provided in the form of tissues or cells that have been 
subjected to a stimulation such as drug treatment or temperature shocks. In this thesis, yeast or 
mammalian cells were used to study changes in the phosphoproteome through stable isotope 
labeling of amino acids in cell culture (SILAC). Stable isotope labeling of amino acids is a 
technique in which cells are grown in the presence of isotopically labeled amino acids that 
incorporate into the proteome and, thus, greatly enhance the relative quantification of peptides 
and proteins by mass spectrometry. Of importance to sample preparation when using SILAC is 
the growth of cells in appropriate media for at least 7 cell doublings prior to stimulation and 
mass spectrometry-based analysis [168]. Technical details about the metabolic labeling 
technique used in this study will be explained in the section “Protein quantification”. Cells 
typically grow suspended in media or adhered to petri dishes that are filled with growth media, 
culture collection can be achieved through centrifugation of cell solutions or through scraping 
cells off of the growing surfaces. After cell collection, cells are washed with isotonic buffers, 
such as phosphate buffered saline (PBS), to remove any extracellular proteins that could 
contaminate the mass spectrometry-based analysis. Due to the dynamic nature of proteins and the 
biochemical system of a cell, specific care is necessary when handling biological samples during 
these steps. Biological material are kept at low temperatures to minimize biochemical reactions 
that are unrelated to the stimulation; furthermore, the time of any sample preparation are kept to 
a minimum to avoid peptide/phosphopeptide degradation through hydrolysis [169].   
 
1.4.2 Extraction, quantification and digestion of proteins 
 
Protein extraction from cells or tissues is generally performed using lysis buffers that contain 
detergents, glass beads or similar reagents that break the cell walls [170-172]. Extraction of 
proteins from cells, is achieved by mixing collected cells with a lysis buffer. Lysis buffers should 
contain detergents that lyse the cellular membrane and solubilize proteins, be of physiological 
pH (7-8) and should contain inhibitors of enzymes, such as proteases and phosphatases, which 
can induce changes in proteome dynamics after sample collection. Detergents, the most 
important ingredient of lysis buffers, also have a denaturing effect and can thus inactivate protein 
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functions, a process that preserves the dynamic state of the proteome at the time of cell lysis. 
Denaturing of proteins further linearizes the protein structure, which, in turn, facilitates 
proteolytic digestion into peptides [173]. A commonly-used detergent applicable to mass 
spectrometry-based proteomics is sodium deoxycholate (SDC) in the class of ionic detergents. 
Urea is often used to replace SDC due to its chaotropic properties that promote protein 
denaturation, solubilisation and cell lysis. Non-ionic detergents are not applicable to mass 
spectrometry, as these cannot be removed from samples through reverse phase purification prior 
to mass spectrometry analysis. Importantly, removal of detergents prior to mass spectrometry 
analysis is necessary, as detergents are of high ionization efficiency and are well-retained on 
reverse phase stationary chromatography phases, resulting in detector saturating signals that 
mask peptides and changes in the chromatographic properties of separation columns [174]. In 
addition to detergents, further aid to extract and solubilize proteins can be achieved with acoustic 
sonication of samples following cell lysis [168, 175].  
 
Once protein extraction from cells through lysis buffers and sonication is achieved, insoluble 
debris-containing lipid membranes are separated from the protein-containing solution using 
centrifugation. Determining the concentration of proteins is a crucial step on which all 
subsequent calculations of the amounts of proteolytic enzyme used, and the peptides loaded onto 
separation phases and the LC-MS system, are based. In order to have a standardized method, the 
commercially-available pierce BCA kit was used throughout all proteomic analyses in this thesis 
[176].   
 
Following protein quantification, the remaining sample is subjected to proteolytic digestion. 
Numerous enzymes are used for proteolytic digestion to generate a full array of possible peptides 
for mass spectrometry analysis. The most commonly used enzymes are trypsin, followed by Lys-
C, chymotrypsine, Glu-C and pepsin [177]. More than 80% of all mass spectrometry-based 
analyses are carried out using trypsin to generate peptides, mainly due to the improved 
sequencing properties of tryptic peptides, arising from cleavage at the basic amino acids Lysine 
(Lys) and Arginine (Arg) [178]. Peptides containing a basic C-term comprising of either Lys or 
Arg and a basic N-terminus amine are most likely to be doubly charged during MS analysis and 
generate fragment ions from both the N- and C-termini of the peptide, greatly enhancing the 
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sequencing capabilities of mass spectrometers [179]. Details of these effects on peptide 
sequencing will be discussed later on in the section “Peptide sequencing”. Trypsin allows the 
identification of most proteins and post-translational modification sites within the proteome and 
was thus used in this thesis to profile the phosphoproteome of cells subjected to different 
stimulations. Proteolytic digestion using trypsin is sensitive to excess detergents/chaotropes and 
physiological pH, requiring careful choice of lysis buffers. In a shotgun proteomics workflow, as 
was used throughout this thesis, tryptic digestion of proteins is performed in SDC or urea-
containing lysis buffers and twelve hours of reaction time.  
 
For the majority of analytical chromatography techniques and mass spectrometry-based analysis, 
it is of great importance that samples are free of contaminants, such as salts or detergents, which 
are present in lysis buffers.  For this, solid phase extraction (SPE) of peptides from proteolytic 
digests is required. SPE is a simple technique based on chromatographic separation that is used 
to separate hydrophilic salts or other small, charged molecules from the more hydrophobic 
peptides [180]. Accordingly, hydrophobic stationary phases, commercially available in the form 
of cartridges, are commonly used to extract peptides from more complex matrices. In brief, 
solvents can be run through cartridges using a pressure gradient generated by a vacuum pump, 
and application of peptide samples and washes to remove hydrophilic compounds is achieved 
using aqueous solvents with low pH (~2). Elution of peptides into clean tubes is subsequently 
performed with aqueous solutions containing up to 50% of organic solvents such as methanol or 
acetonitrile [181]. The evaporation of solvents with vacuum systems is further used to generate 
lyophilized peptide samples that are ready to use in LC-MS or further sample preparation. In 
cases where scientists are interested in a specific part of the proteome, such as the 
phosphoproteome, enrichment of phosphorylated peptides is a must, due to the low abundance of 
phosphorylation, which makes up only around 1% of the protein material [182]. A noteworthy 
comment to the reader is that the enrichment of PTM’s on the peptide level is preferred, as 
enrichment of proteins harboring the PTM’s of interest would result in the generation of mostly 
unmodified peptides upon digestion of the enriched proteins.  
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1.4.3 Large scale phosphopeptide enrichment 
 
Serine, threonine and tyrosine protein phosphorylations are the most commonly found 
phosphorylation sites and are the only ones investigated in this thesis. The negative charge of the 
phosphate group allows for specific enrichment of phosphopeptides using affinity 
chromatography media. As of now, several materials have been found to bind phosphorylated 
peptides and proteins with high affinity, including the metal oxide titanium dioxide and 
positively-charged metals such as Fe(3+), Ga(3+), Al(3+), Zr(4+) and Ti(4+) [183]. Titanium 
dioxide is easy to handle as it is commercial available as nanoparticles, while metal species have 
to be immobilized on stationary chromatography phases that contain chelating groups, such as 
nitriloacetic acid (NTA) [184]. Specific enrichment of phosphopeptides likely occurs due to the 
electrostatic interactions of positively charged metals and negatively charged phosphate groups, 
as unwanted enrichment of very acidic peptides is often observed in phosphopeptide samples 
[185]. The exact mechanisms by which the above-mentioned stationary phases enrich phosphate-
containing peptides and why they perform much better than other commonly used anion 
exchange materials are not fully elucidated but likely rely on the formation of metal chelate 
complexes [186]. In addition to the enrichment of phosphopeptides based on physical/chemical 
properties, antibodies to enrich for selected phosphopeptides, such as the low-abundant tyrosine 
phosphorylation sites, have been developed [187] and are frequently used to study phospho 
tyrosine signalling [188, 189]. This thesis, however, aims to monitor time-dependent dynamics 
of the general population of phosphorylation sites and, thus, the more complicated and less 
reproducible use of antibodies has been avoided. Furthermore, studying the spread of 
phosphosignaling over time requires the analysis of numerous samples (time points) in parallel, 
making the implication of high throughput techniques mandatory. Workflows capable of 
processing phosphopeptide enrichments of numerous samples need to be reproducible, 
applicable to parallelisation and simple. The aforementioned immobilized metal affinity 
chromatography (IMAC) has been found to be a good means to enrich a general population of 
phosphopeptides similar to titanium dioxide nano-particles [190]. However, handling the IMAC 
stationary phases requires careful adjustment of salt and pH conditions, which are not needed 
when operating titanium dioxide nanoparticles.  
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As stated earlier, all of the following high throughput studies are aimed at the analysis of system-
wide perturbations of the phosphoproteome, making the use of titanium dioxide nanoparticles 
logical. Accordingly, all phosphopeptide enrichments prepared in the scope of this thesis use 
titanium dioxide beads. As up to 14 samples needed to be processed for a single experiment, an 
experimental design allowing for parallel enrichment had to be developed. Commonly-used 
methods were assessed and adjusted to properly match the aim of parallelized phosphopeptide 
enrichment, and the use of spin tip columns was determined to be the most suitable [191]. In-
house spin tips for parallel enrichment of phosphoproteomes were prepared as described in the 
following paragraph, and are based on publicatons by Liu et al.  (2016) and Kanshin et al. (2012 
& 2013) [185, 191, 192]. The main advantage of spin tip columns over high performance liquid 
chromatography systems (HPLC) is that they can be used in centrifuges and allow parallel 
processing of samples. Preparation of spin tip columns is shown in Figure 1.8. 
 
Figure 1.8. Preparation of spin tip columns.  
A-G) depicts the workflow to insert extraction disks into 200uL pipette tips. A) 1mL pipette tips have to be cut by 5mm to 
enlarge orifice. B) Cut 1mL tips are used to take up extraction disk. C-G) Insertion of extraction disk from the 1mL tip to the 
200uL tip with the help of a capillary.  
 
Spin tip columns are made from pipette tips filled with small polymer-based frits to allow 
loading of stationary phases, such as titanium dioxide nanoparticles. In this workflow, these frits 
are made of a hydrophobic material, such as C18-coated extraction disks, which retain 
A
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phosphopeptides after elution from titanium dioxide [193]. Purified phosphopeptides can then be 
recovered from the same spin tip after desalting and elution with a hydrophobic liquid phase (a 
strong organic solvent containing acetonitrile or methanol). Titration of the frit capacity is done 
prior to each analysis in order to assure no loss of phosphopeptides. Insertion of these frits into 
each spin column requires manual precision work and is depicted in Figure 1.8 A-G. Following 
the insertion of these frits, titanium dioxide is loaded onto the spin tip by placing each tip, to 
which a frit has been added into an Eppendorf tube, as depicted in Figure 1.9 H. Equal amounts 
of titanium dioxide are loaded by pipetting the metal oxide homogenate into the spin columns 
(Figure 1.9 steps J&K). Elution of the solvent through the column is achieved through 
centrifugal force, deployed during centrifugation. Preparation of sufficient amounts of 
phosphopeptide enrichment tips can be done within a few hours and allows the processing of up 
to 24 samples (depending on the number of positions in the rotor) in parallel. 
 
Figure 1.9. Loading of spin tip with titanium dioxide beads for phosphopeptide enrichment.  
H) Placment of the spin tip containing one extraction disc into 1.7mL Eppendorf tubes. J-K) Pipetting of titanium dioxide 
homogenate into the spin tip.  
 
Following the preparation of spin tip columns, conditioning of the stationary phase with the 
mobile phase used throughout the enrichment procedure is necessary, as for most 
chromatographic applications. Generally, the mobile phase contains 50% acetonitrile, 2% formic 
acid (FA), and lactic acid, which prevents the binding of nonspecific, negatively charged 
peptides [194]. After phosphopeptide binding and several wash steps, elution of phosphorylated 
peptides is achieved with an aqueous solution of neutral pH containing excess free phosphate 
molecules that simply replace the phosphopeptides on the metal oxide phase. These 
H J K
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phosphopeptides are subsequently retained by the hydrophobic frit at the bottom end of the spin 
column, which allows for desalting and recovery of the phosphoproteome.  Enriching 
phosphopeptides on micro-scale columns requires consistent amounts of material loaded onto the 
stationary phase in order to not overload the metal oxide material, which could result in the loss 
of low affinity binders such as mono-phosphorylated peptides or phosphopeptides of basic 
nature. Considering that around 1% of the protein material is phosphorylated, 5mg of protein 
would result in an amount of phosphopeptides that is equivalent to 50µg of protein material, 
sufficient for further sample preparation prior to mass spectrometry analysis. All amounts of 
peptides are referred to as equivalents to protein material, as the quantification of such small 
amounts of peptides prior to LC-MS analysis would result in the loss of a large proportion of the 
sample and, therefore, is not feasible. Empiric experience has shown that the injection of roughly 
1µg of peptides (equivalent to 1µg of proteins) is best for mass spectrometry-based analysis of 
highly complex samples. Accordingly, 2-5mg of starting material is the standard amount of 
protein that is used for the affinity enrichment of phosphopeptides throughout the studies 
presented later on. Excess amounts of phosphopeptides had to be generated as the enriched 
phosphoproteome samples still are of extremely high complexity and need further fractionation 
to increase the depth of analysis. 
 
1.4.4 Chromatographic separation of peptides  
 
Chromatographic separation of chemical species is a technique discovered in the late nineteenth 
century when Schoenbein and Goppelsroeder experimented with the separation of dye mixtures 
into their pure forms on filter papers [195]. In chromatography, mixtures are dissolved in a fluid 
phase (mobile phase) and are separated by being flushed over columns of a solid phase 
(stationary phase). Unique physical properties of different chemical species lead to different 
travel times over the stationary phase, resulting in separation of the components of a mixture 
[196]. Such separation can be used to identify or purify one or more chemical species for 
analytical or practical purposes. Chromatography has much advanced since its first application to 
separate dyes from plants [197], and, at present, is widely used to aid the identification and 
quantification of trace materials in various samples such as soils, blood or food [198, 199] and 
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the purification of larger quantities of molecules, such as insulin, which is used to treat diabetes 
[200].  
In a shotgun proteomics workflow, chromatography is used for the separation of the vast number 
of peptides present in the proteome digest and has been found to be of great help in 
decomplexifying samples [201]. Decomplexification of samples, in other words, the presence of 
less chemical species at the time the sample enters a detector, allows for better analytical 
performance of mass spectrometers that are highly limited in the number of analytes (peptides) 
they can analyze at a given time [202]. Different types of stationary and mobile phases can be 
used to separate peptides or proteins by different types of chemical properties. In laboratory 
practice, two types of chromatography have emerged for peptide separation – reverse phase 
chromatography and ion exchange chromatography. In reverse phase chromatography, peptides 
are separated based on hydrophobicity [203, 204] while, in ion exchange chromatography, 
separation occurs based on the peptide charge state [205, 206]. As both physicochemical 
properties are of very different nature, the two separation technologies can be considered 
orthogonal and thus, are applicable to combination [207]. In a shotgun proteomics workflow, ion 
exchange chromatography is often performed using cation exchange materials to fractionate 
peptide samples into several fractions prior to their injection onto a reverse phase liquid 
chromatography system which operates in hyphenation to a mass spectrometer [208]. This exact 
setup is used in all studies of this thesis and its application is expanded upon in the following 
paragraphs.  
 
 
1.4.4.1 Offline strong cationic fractionation 
 
For shotgun based proteomics, where up to hundreds of thousands of different peptides are 
generated, efforts must be made to reduce sample complexity. Indeed, the identification of low 
abundance peptides or proteins is amongst the biggest challenges in proteomics research, making 
the sensitivity and speed by which mass spectrometers sequence peptides the major limitation 
[167]. Nonetheless, advances in peptide identification through the use of chromatographic 
separation, which de-complexifies samples prior to LC-MS analysis improve the depth of the 
proteome [201]. This so-called offline fractionation of samples increases the number of low 
abundant peptides identified in highly complex peptide mixtures while drastically increasing the 
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time of analysis. Accordingly, offline pre-fractionation is of high demand in studies that aim for 
the systems-wide analysis of proteomes [208].  
 
As described by Lenz and Urlaub (2014), offline fractionation is nothing more than 
chromatographic separation of all peptides present in a sample and successive collection of 
sample fractions that each contain their unique pool of peptides. The analysis of a smaller pool of 
peptides per LC-MS run grants more time to the mass spectrometer to sequence low abundant 
peptides and results in higher sensitivity [209]. In this thesis, cation exchange chromatography 
was used for the separation of peptide and phosphopeptide samples prior to LC-MS analysis. To 
allow for maximum sample throughput, parallelisation of fractionation was achieved by using 
spin tip columns, similar to the ones used for the enrichment of phosphopeptides. Spin tips were 
packed with strong cation exchange (SCX) material and peptides were bound to the stationary 
phase under acidic conditions. This SCX material contains highly acidic sulfonyl groups, which 
are deprotonated even under acidic conditions (pH>0) and allow for electrostatic binding of 
positively charged peptides [210]. Separate fractions are generated through step-wise elution of 
peptides with buffers of increasing ionic strength, resulting in the elution of negatively charged 
peptides prior to neutral and more positively charged species. Buffers are applied onto the 
stationary phase and are flushed through the column during centrifugation, making each fraction 
the result of a single centrifugation step. Individual fractions are collected and dried under a 
vacuum. Importantly, phosphopeptides are especially well suited for separation by SCX due to 
the negative charge added by each phospho group, resulting in a larger variability of charges 
amongst the pool of tryptic peptides compared to a set of unmodified peptides [211]. In practice, 
the resolution of spin tip columns is sufficient enough to generate more than 6 fractions for each 
peptide sample, permitting the analysis of a large dynamic range of peptides [212].  
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1.4.4.2 Reverse phase chromatography prior to mass spectrometry analysis 
 
Reverse phase (RP) chromatography coupled with mass spectrometry is widely established for 
the identification and quantification of peptide species. The terminology ‘reverse phase’ implies 
that peptides are separated based on hydrophobicity using a hydrophobic stationary phase. The 
mobile phases used are binary mixtures of water and organic solvent, each containing small 
amounts of organic acid to protonate peptides [213, 214]. Combining reverse phase separation 
and mass spectrometry maximizes the number of peptides that can be identified by minimizing 
the number of species the mass spectrometer has to sequence at a given time. Separation of 
peptides prior to analysis by MS is performed to 1) not oversaturate the detector and 2) provide 
more time to accumulate and sequence a given peptide [214]. Accordingly, the quality of reverse 
phase separation is of high importance. Physicochemical parameters that influence separation 
performance are longitudinal diffusion of particles, mass transfer kinetics between the stationary 
and mobile phases, as well as pathways molecules can follow within the column [215]. As 
chromatographic separation can be imagined as multiple extractions, the performance of 
chromatographic columns is measured in plate heights, describing the number of theoretical 
extractions occurring during the length (or height) of a column. Smaller plate heights imply 
better separation and strongly depend on the flow rate of the mobile phase, which directly 
influences longitudinal diffusion and mass transfer kinetics. Channeling of molecules through the 
column packing, a factor that negatively influences plate height, is determined only by the 
properties of the packing material, such as its porosity and particle size [198]. The relationship of 
plate height and flow rate is well described by the van Deemter equation and is of importance for 
practical optimization of chromatography parameters (Figure 1.10) [216].  
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Figure 1.10. Van Deemter curve.  
1. Flow channel distribution coefficient. 2. Longitudinal diffusion coefficient. 3. Mass transfer component. 4. Resulting 
theoretical Van Deemter curve. Figure adapted from reference [217].  
 
Accordingly, the use of smaller particles and optimized flow rates is beneficial, but results in 
increased backpressure, requiring compatible high performance liquid chromatography (HPLC) 
systems [218]. As reverse phase stationary and mobile phases are widely used for peptide 
analysis, high quality chromatography systems are cost effective to operate and easy to 
implement. Furthermore, reverse phase chromatography is perfectly suited for mass 
spectrometry, as volatile mobile phases cause minimal interferences with the mass spectrometer 
[213, 214]. Noteworthy, however, is the strong correlation between peptide length (mass) and 
hydrophobicity, making the mass spectrometer (separator and detector) and reverse phase 
chromatography not be perfectly orthogonal, resulting in co-elution of peptides with similar 
masses [219]. Nonetheless, reverse phase LC is universally used for peptide separation prior to 
mass spectrometry analysis and has proven to generate high quality separation of analytes. To 
guarantee high performance chromatography under constant flow, nano-HPLC systems that 
operate at nano-liter flow rates are used. Low flow rates increase sensitivity and minimize the 
limit of detection/quantification of peptides, by increasing the proportion of eluting molecules 
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that can be ionized [220]. Details about the ionization of analytes for mass spectrometry and the 
corresponding liquid-gas interface are discussed later on, in the section ‘Ionisation’.  
 
Reverse phase columns suited for LC-MS can be prepared in house by packing capillaries of 
lengths between 15 and 20cm with octadecyl carbon chain (C18)-coated silica particles [221]. 
Piston pump HPLC systems used to operate these columns are best to generate reliable flow rates 
and stable operation of mass spectrometers [222]. In laboratory practice, peptides are dissolved 
in water under acidic conditions, injected onto the column and are successively eluted with a 
gradient of increased organic mobile phase. During the course of multiple injections of samples 
from cohering experiments, variations in elution profiles and retention times of peptides 
constantly have to be evaluated with peptide standards to assure maximum performing liquid 
chromatography [223]. Due to the high sample complexity, injection times of shotgun 
proteomics samples generally vary between 70 and 250 minutes, depending on the depth of 
peptide coverage demanded. Gradient times of around 120 minutes are found to provide optimal 
balance between average peak width of a peptide elution peak, number of co-eluting peptides 
and feasible analysis time, resulting in acceptable coverage of the proteome [224]. Altogether, 
optimized RP chromatography parameters and a stably operating system are of key importance 
for a successful large-scale shotgun proteomics experiment [225].   
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1.4.5 Mass spectrometry 
 
Mass spectrometry analysis is the determination of mass to charge ratios (m/z) of gas phase ions 
[226]. Any aperture capable of measuring mass to charge ratios is comprised of a sample inlet, 
an interface at which gas phase ions form, the mass analyzer, in which ions are separated 
depending on m/z, and a detector that detects gas phase ions [227]. Mass spectrometric data are 
processed with the aid of a computer and sophisticated analysis software. Data are typically 
visualized in the form of mass spectra. A general scheme describing mass spectrometry analysis 
is presented in Figure 1.11. 
 
 
Figure 1.11. General scheme of a mass analyzer.  
Figure adapted from reference [227].  
 
Mass spectrometry was born in the late nineteenth century when, in 1899, Wilhelm Wien 
constructed a device that separated  anode  rays based on their mass to charge ratio [228]. Judith 
Jarvis Thompson and Francis Aston successively improved mass spectrometers and built the 
fundamentals of today’s mass analysis [226, 229]. The following sections describe the general 
principles of mass spectrometry, including brief historical reviews, and mainly exemplify the 
newest mass spectrometry technology used for proteomics analyses.    
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1.4.5.1 Ionisation techniques 
 
In mass spectrometry, the mass to charge ratio of gas phase ions is measured. Molecules are 
charged and dispersed into the gas phase in the ion source of a mass spectrometer, where gas 
phase ionization occurs. Three major ionization techniques have emerged during the 
development of modern mass spectrometry, atmospheric pressure chemical ionization (APCI), 
electrospray ionization (ESI) and matrix-assisted laser desorption ionization (MALDI). ESI and 
MALDI are soft ionization techniques [230], whilst ionization in APCI sources occurs during 
harsher conditions, leading to higher chances for fragmentation of labile molecules [231]. Soft 
ionization is preferred for the analysis of labile molecules and complex mixtures, as in source 
fragment ions, interfere with sample components. Furthermore, peptide and protein sequencing 
are based on controlled fragmentation, prohibiting the use of harsh ionization conditions, in most 
cases. MALDI and ESI, the most frequently used ionization techniques in proteomics, both have 
unique areas of application. MALDI is used for the analysis of mostly crystallized stationary 
samples with a light-absorbing matrix, while ESI is best suited to generate ions at the liquid gas 
phase interface, as present in liquid chromatography mass spectrometry (LC-MS) [230]. During 
this study, ESI has been used exclusively and is described in detail below. 
 
Electrospray generates gas phase ions after electrisation of the eluting liquid stream from the 
chromatographic column. At the end of a chromatographic column, a voltage varying between 
500 and  4500 V, depending on the diameter and composition of the eluting liquid stream, is 
applied and induces the formation of ions [232]. At the liquid to gas transition zone, the 
formation of a fine spray with cone geometry represents the presence of charged droplets, as 
described by Goeffrey Taylor [233]. If flow rates greater than 5uL/minute are used for 
chromatography, a nebulizing gas can feed into the solvent flow to aid the formation of the 
electrospray. While the electrospray mist travels towards the mass spectrometer, charge 
concentration gradually increases inside the liquid droplets due to solvent evaporation. Native 
gas phase ions have been suggested to then form due to sequential fission of droplets, caused 
either by successive evaporation of the solvent, as proposed by Dole [163], or the explosion of 
highly charged droplets due to the increasing electric field, as suggested by Thomson and Irbarne 
[234, 235]. In both cases, naked charged ions are formed at atmospheric pressure and, as a result 
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of their electric potential, are accelerated to the mass analyzer. A graphical illustration of these 
processes occurring during electrospray ionization is given in Figure 1.12 [198].    
 
Figure 1.12. HPLC-MS interface for ESI.  
1. HPLC column; 2. Nebulizing gas; 3. High voltage; 4. Charged droplet (drawn too large); 5. Evaporation; 6. Coulomb 
explosion; 7. Drying gas; 8. Skimmer; 9. Quadrupole. Figure adapted from reference [217]. 
 
Most commonly used for the analysis of peptides is electrospray ionization in positive mode, 
where a positive voltage that is applied at the liquid phase causes the formation of protons [236]. 
Protons then protonate eluting molecules at basic sites, resulting in charged species that can be 
described with the general formula [M+nH]n+. As anticipated from this formula, ions formed in 
an electrospray source can be multiply charged, depending on the number of basic sites present 
on the analyte. This allows for the analysis of large molecules at low mass to charge ratios in 
mass spectrometers with limited m/z scan ranges. Proteomics analyses have greatly benefited 
from the generation of multiply charged ions by electrospray ionization and are of utmost 
importance for peptide sequencing in tandem with mass spectrometry analyses [237, 238].  
 
1.4.5.2 Tandem mass analysis (MS/MS) 
 
Tandem mass analysis is a technique used to resolve the molecular structure of analytes. In 
tandem mass analysis, mass spectra of ions and their fragmentation products are sequentially 
acquired. This can take place in several hyphenated mass analysers, or, for the case of ion 
trapping devices, in a single mass analyzer [239]. Most frequently, a mass spectrum of non-
fragmented ions, the parent ion spectrum, is acquired first. The ion of interest is subsequently 
selected, fragmented and analyzed in a second mass spectrum, generating a spectrum of product 
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ions [240]. The subsequent acquisition of parent and product ion spectra is referred to as MS/MS 
acquisition. Acquisition of n time fragmentation of fragments is referred to as MSn and can be 
executed in ion trap devices.  MSn   is used in rare cases when detailed structural information is 
required or background contamination needs to be filtered out for increased quantification 
quality [241]. MS/MS acquisition is primarily used for peptide analysis. It is performed by first 
scanning all co-eluting ions in a full MS (MS1) scan, the selecting ion species of interest and 
fragmenting them into product ions, from which the peptide sequence can be determined. The 
product ion spectrum is referred to as the MS2 or the MS/MS spectrum [242]. Ions can be 
selected in a data-dependent (DDA) or data-independent (DIA) format. In DDA, ion species of 
interest are selected for MS/MS acquisition from the MS1 scan. In between the acquisition of 
MS1 spectra, a pre-defined number of the most abundant ions in the MS1 spectra that show 
peptide characteristics are selected for fragmentation [243]. This type of data collection is termed 
“Top-n”, as n peaks are selected for fragmentation prior to the next full MS measurement. Time-
constricted exclusion lists of already fragmented ions are further generated to limit re-
fragmentation of ions. In contrary to DDA, DIA of parent ions is performed by step-wise 
fragmentation of all ions eluting at a given time and is commonly used if highly reproducible 
data are required [244]. Each of these methods, DDA and DIA accommodate their unique 
advantages, whilst DDA is the most frequently used data acquisition method for discovery 
proteomics studies. Peptide and phosphopeptide data in this thesis have all been collected using 
data-dependent acquisition, mostly because the Orbitrap mass analyzers used throughout all 
experiments appear to be best suited for DDA. 
 
1.4.5.2 Ion fragmentation 
 
Peptide sequence information can be obtained through ancient methods, such as the Edman 
degradation, which is very time consuming, or within milliseconds from product ion spectra. To 
gain structural information about the amino acid sequence of a peptide using tandem mass 
spectrometry, controlled dissociation of peptides must occur at the peptide bonds to be able to 
read off the peptide sequence from the fragment ions in the MS/MS spectrum. The two most 
frequently used fragmentation methodologies are collision-induced dissociation (CID) and 
higher energy collisional dissociation (HCD). In both cases, fragmentation occurs due to 
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collision of ions with a carrier gas at low pressure [245, 246]. While CID fragmentation is based 
on ion trap instruments, HCD-induced fragmentation is performed in specifically designed trap 
cells that allow for later identification of ions in high resolution Orbitrap mass analyzers. It has 
been observed that HCD fragmentation generates better defined product ion spectra, especially in 
the case of peptides harboring labile modifications, such as phosphorylation. While HCD had a 
slow start due to longer fragmentation times, it has emerged as the primary method of 
fragmentation for Orbitrap-based peptide analysis [247].  
 
1.4.5.3 Peptide sequencing  
 
Peptide sequence information is retrieved from the mass to charge values of fragment ions 
resulting from peptide backbone fragmentation. Dissociation of covalent bonds through 
collisions with gas molecules can occur at amide bonds, as depicted in Figure 1.13 [248]. Peptide 
sequences are depicted from the N-terminal, on the left hand side, to the C-terminal, on the right 
hand side. Fragment ions that are generated correspond to either the C-terminal end of the 
peptide, termed as x, y and z ions, or the N-terminal end, termed as a, b and c ions [249]. Ions are 
numerated based on their distance, measured in numbers of amino acids, from either the C-
terminus or N-terminus for the respective ion species. Identification and assignment of these ion 
species in a mass spectra is the primary information needed to obtain the peptide sequence [250]. 
 
 
 
Figure 1.13. Peptide fragment ion nomenclature.  
Figure adapted from reference [248]. 
 
Upon HCD and CID collision, acylium ions (b) and ammonium ions (y) are the mostly 
frequently observed ion species. Many other ions species, including neutral losses and 
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fragmentation of amino acids themselves, can be observed, depending on the collision energy 
used [251]. Thus, collisional energy has to be optimized for every mass spectrometer to obtain 
the highest proportion of peptide backbone fragmentation. As the exact mass of the parent 
(precursor) ion is known for a given MS/MS ion spectrum, mass resolution for tandem mass 
analysis is of less importance as for the acquisition of MS1 spectra. Fragmentation spectra, 
therefore, are acquired in most types of mass analysers including the Orbitrap, Ion trap and time 
of flight (TOF) mass analyzer. 
 
1.4.5.4 Localizing and identifying phosphosites 
 
Phosphate residues add +80Da to the total mass of the corresponding non-phosphorylated 
peptide, making the determination of the number of phosphorylation sites on a peptide fairly 
easy through collation of parent ion masses with theoretical peptide masses from in silico 
digestions of appropriate proteomes [252]. Phosphopeptides are sequenced in the same way non-
modified peptides are sequenced, mostly by HCD and CID fragmentation [253]. A typical 
phosphopeptide product ion spectra is depicted in Figure 1.14 [254]. The localization of 
phosphopeptides on the peptide backbone requires the presence of fragment ions containing 
phosphate groups. Unfortunately, the labile phosphor ester bond tends to fragment during gas 
phase reactions, resulting in neutral loss of phosphate, suppressing the abundance of phosphate-
containing product ions [255]. Several approaches have been suggested to improve 
phosphopeptide localization confidence, including the creation of spectral databases and a 
combination of different fragmentation techniques [247, 256-258].  
 
 
Figure 1.14. Example of a phosphopeptide product ion spectra.  
Spectra depicts fragments that correspond to the phosphorylated ions. Figure adapted from reference [254]. 
IEG[pT][pY]GVVYK  
 
40 
 
At present, however, the acquisition of phosphoprotoemics data does not differ much from that 
of other proteomics data, mostly because the gain in spectral information from improved 
fragmentation methods would result in a decrease in the number of identified peptides, due to 
longer acquisition times [259]. Still, up to 50,000 phosphopeptides have been mapped in the 
scope of large-scale phosphoproteomics experiments conducted with conventional HCD 
fragmentation, showing that the quality of phosphoproteomics data acquisition has reached that 
of regular proteomics studies [260].  
 
1.4.5.5 Mass analysers 
 
Mass analyzers are the modules of a mass spectrometer that are capable of assigning charged 
ions to their mass to charge value [261]. Several types of mass analyzers have been developed, of 
which the most frequently used for proteomics analysis are the Quadrupole (Q) and Linear Ion 
Trap (LIT), the Time of Flight (TOF) analyzer, Fourier-Transform Ion Cyclotron Resonance 
(FT-ICR)-based instruments and the Orbitrap [262]. The most important parameters defining the 
characteristics of mass analyzers are resolution, sensitivity, mass to charge range, mass range, 
dynamic range and scanning speed. Resolution (R) is defined as the ratio of the measured mass 
(m) and the peak width (Δm)  at 50% of the maximum peak height and can be written as m/Δm 
[263]. Higher resolution allows for better resolving power of adjacent peaks at a given mass, 
making the resolution capabilities of a mass analyzer a primary characteristic of high importance 
for the definition of molecular species. Also, the trend curve by which resolution decreases with 
increasing mass is an important factor to consider if the analysis of high m/z species is 
anticipated [264, 265]. Sensitivity is the amount of ions detectable whereas mass to charge range 
is the range over which m/z values can be reported [263]. Mass range is simply the range of 
masses of molecular species detectable. Dynamic range is the ratio of the smallest to the largest 
detectable signal [263]. Scanning speed, which is one of the more important parameter for the 
analysis of proteomics samples, is the number of scans the analyzer can acquire in a given time 
and is usually reported as a frequency in Hz [266]. 
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For the analysis of complex peptide samples, high resolution to accurately define ion species, a 
large dynamic range to detect low and highly abundant peptides simultaneously and a high 
scanning speed to analyze as many peptides per time window as possible are the main factors 
that determine the suitability of a given mass analyzer [262, 267]. Orbitrap mass analysers and 
linear ion traps, which can be coupled with Orbitraps through Quadrupoles, have been used 
throughout this thesis and are described in more detail in the following sections.  
 
1.4.5.5.1 Quadrupole 
 
The Quadrupole is an ion filtering device that comprises of a square array of four conduction 
rods and is placed between an ion source and an ion detector [268]. Ions are separated based on 
their m/z-dependent, stable trajectories through oscillating electric fields. Oscillating electric 
fields are generated by concomitantly applying radio frequency (RF) and direct current (DC) 
potentials to opposing pairs of rods. The resulting potentials are –(U+V0cos(Ωt)) and +( 
U+V0cos(Ωt)), where U is the DC, and V0cos(Ωt) is the RF component, as illustrated in Figure 
1.15 [269].  
 
 
Figure 1.15. Schematic presentation of a Quadrupole mass filter.  
Figure adapted from reference [269]. 
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The corresponding electric fields influence the trajectories of ions that travel through the 
quadrupole, letting only ions with a specific m/z value pass through the quadrupole. Ions that are 
not traveling on stable trajectories are neutralized on the conduction rods, leaving only those that 
pass the ion filter to reach the detector. Variation of the electric potentials allows for scanning of 
ions with different m/z values. The m/z selectivity can be controlled by adjusting the DC/RF 
ratio, but is limited to resolutions of around ~3000, defining Quadrupoles as low resolution 
instruments [270]. An advantage of these instruments is that the duty cycle is nearly 100%, as no 
delay or dead times occur when scanning through the same or different m/z ranges. This allows 
for high scan rates at minimal loss of ions, making Quadrupoles the basis of very sensitive and 
fast mass analyzers [271]. Accordingly, Quadrupoles are well suited for the analysis of samples 
with low complexity, and as ion transmission tubes that are capable of guiding specific subsets of 
ions through the mass spectrometer. The latter finds unprecedented use in tandem mass analysis, 
where only ions with selected m/z are intended to be fragmented and analyzed in an MS/MS 
spectrum [272]. For the latter purpose, Quadrupoles are combined with other mass analyzers 
including Orbitraps and Ion traps [273, 274].  
 
1.4.5.5.2 Linear Ion Trap (LIT) 
 
Linear ion traps are devices capable of trapping, accumulating and sequentially releasing ions to 
a detector. Quadrupole rods focus the ions radially while a static electric potential confines ions 
axially, allowing for injection and accumulation of ions [275]. Ions can be sequentially ejected 
from the trap by varying the RF frequency [276]. Furthermore, ion traps are capable of 
fragmenting ions of desired m/z values by ejecting all but the desired ions and subsequently 
increasing their kinetic energy. The kinetic energy of ions within the trap is increased through the 
application of a resonance voltage, inducing strong radial oscillation of ions. The higher kinetic 
energy of ions then results in fragmentation due to collisions with carrier gas molecules inside 
the ion traps [277]. The most frequently used gas is nitrogen. A fragment ion spectrum (MS/MS) 
can then be acquired by successive ejection of ions and detection by high voltage dynodes. While 
a single linear ion trap is capable of performing MSn experiments in which ion species can be 
sequentially selected and fragmented, their use in proteomics is often coupled to high resolution 
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mass analysers that allow for parallel acquisition of high resolution MS1 spectra and low 
resolution MS/MS spectra [278].  
 
1.4.5.5.3 Orbitrap 
 
The Orbitrap mass analyzer is the latest addition to the set of high performance mass analyzers 
and has been commercially available since 2005. It has been developed with the motivation to 
build a high performance mass analyzer that is more accurate than ion traps, more sensitive than 
time-of-flight instruments and faster and more compact compared to conventional FT-ICR 
instruments [273]. Orbitraps are ion trapping devices in which ions oscillate around an inner 
electrode within an electric field generated by two symmetrical outer electrodes. The discovery 
that trapped ions can orbit around linear inner electrodes on stable trajectories dates back to 
1923, when KH Kingdon first described a cylindrical aperture with a centered wire, capable of 
trapping ions [279]. RH Perry et al. (1981) picked up on Kingdon’s studies and developed 
devices that can successfully trap laser-generated ions [280, 281]. The breakthrough was 
achieved later by Makarov et al. (2000), who described Orbitrap cells with spindle shaped inner 
electrodes and symmetrical outer electrodes, as depicted in Figure 1.16 [282]. This cell was 
shown to allow for successful trapping of ESI-generated ions that were injected from a bend 
Quadrupole trap [283]. Makarov further described the generation of m/z resolved spectra by fast 
Fourier transformation. Mass to charge resolved spectra can be acquired in Orbitrap cells, as ions 
with the same m/z isochronally oscillate along the curved inner electrode. This results in the 
separation of ions with similar m/z, allowing for the detection of an image current on the outer 
electrodes, which can be transformed into a mass spectrum through Fourier transformation [284]. 
This allows for fast acquisition of high resolution mass spectra with high mass accuracy, good 
sensitivity and dynamic range. However, as for all trapping devices, the number of ions that can 
be injected into the trap is limited. Therefore, careful control of the size of ion packages injected 
into the Orbitrap analyser is necessary and can be achieved with the curved RF-only Quadrupole 
trap, named C-trap [285].        
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Figure 1.16. Schematic presentation of a bent linear ion trap (C-trap) hyphenated to an Orbitrap mass analyzer.  
Figure adapted from reference [273]. 
 
As the Orbitrap mass analyzer is dependent on the injection of ions, the duty cycle of these 
instruments is determined by the time necessary to trap and inject ions and the time it takes to 
acquire a spectrum. It is of importance to know that higher resolution mass spectra require longer 
acquisition times because spatial separation of ions with similar m/z is time dependent [285]. 
This characteristic has been a major limitation of early Orbitrap instruments used for discovery 
proteomics and metabolomics, as highly complex mixtures require long duty cycles. However, 
recent developments have enabled Orbitrap-based instruments to acquire mass spectra at up to 23 
Hz and faster at resolutions ranging from 15,000 to 60,000 (at m/z = 200) [286]. Two Orbitrap 
instruments, the Thermo Fisher Orbitrap Q-Exactive and the Thermo Fisher Orbitrap Fusion, 
were exclusively used for proteomics analysis in this thesis and are described in more detail 
below.    
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1.4.5.5.4 Thermo Fisher Q-Exactive 
 
The Q-Exactive is a benchtop mass spectrometer with a standalone Orbitrap mass analyzer. It is 
available with a standard or ultra-high field Orbitrap. The newer version of the instrument, with a 
ultra-high field Orbitrap, is referred to as Q-Exactive HF. The Q-Exactive series of Orbitrap 
instruments can be coupled to ion sources compatible with Nano and micro flow liquid 
chromatography systems. Ions are funneled in an S-lens and are guided through a Quadrupole 
mass filter into a higher energy collision induced dissociation (HCD) cell, where peptides can be 
fragmented. Injection into the Orbitrap is carried out from the C-trap [286]. An illustration of the 
geometry of the Q-Exactive mass spectrometer is shown in Figure 1.17 a.  
 
Hybridisation of a Quadrupole and an Orbitrap enables tandem mass analysis, where either all 
co-eluting ions pass the Quadrupole prior to the acquisition of a MS1 spectrum or a specific ion 
with a set m/z is filtered by the Quadrupole, fragmented in the HCD cell and subsequently 
analyzed in an Orbitrap MS/MS scan. This setup allows for the generation of high resolution 
MS1 spectra and lower resolution MS/MS spectra, both from the Orbitrap cell. The scanning 
speed has been maximised by allocating most of the duty cycle time to the accumulation and 
fragmentation of ions parallel to the acquisition of mass spectra. As depicted in Figure 1.17 b, 
the Orbitrap mass analyser is almost constantly acquiring mass spectra, with very short transition 
times needed for  injecting ions [287]. Full MS (MS1) spectra, which typically are measured at 
high resolution, require much longer analysis times compared to MS/MS data generation, 
making the acquisition of 10-20 MS/MS spectra per full MS scan necessary to maximise the 
number of peptides identifiable from complex mixtures. In a regular peptide sequencing 
experiment, the Q-Exactive instruments achieve up to 12 Hz at resolving powers of 17,500 
(corresponding to a peak at m/z = 400) for MS/MS and around 1Hz at resolving powers of 
70,000 for MS1 spectra [288]. The improved Q-Exactive-HF is able to acquire peptide 
sequencing data at up to 23Hz at resolving powers of 15,000, allowing for the identification of 
4400 proteins from cell digests within one hour of analysis time [287].  
 
 
46 
 
Figure 1.17. The Orbitrap Q-Exactive. 
a) Geometry of the Orbitrap Q-Exactive. b) Diagram of parallel data acquisition. Figure adapted  from reference [273]. 
 
While Q-Exactive instruments are generally designed for peptide analysis, small intact proteins 
can be analyzed as well [289]. This type of Orbitrap instrumentation is also frequently used in 
metabolomics research [290]. In the scope of this thesis, the Orbitrap Q-Exactive and Q-
Exactive-HF have been used for the analysis of phosphoprotoemics and proteomics samples. 
Data acquisition methods were based on the above-described methodologies.   
 
1.4.5.5.5 Thermo Fisher LTQ Orbitrap Fusion 
 
The Orbitrap Fusion instrument is one of the most recent generations of Orbitrap-based hybrid 
mass spectrometers. The Orbitrap Fusion combines a Quadrupole mass filter, an Orbitrap and a 
Linear Ion Trap, enabling fully parallelized data acquisition [291]. As depicted in Figure 1.18 a, 
the Orbitrap Fusion contains the Quadrupole mass filter before the C-trap, which is orthogonally 
coupled with the Orbitrap mass analyzer, similar to the arrangement in the Q-Exactive 
instruments. In line with the C-trap, an HCD fragmentation-compatible ion routing multipole is 
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coupled to a LIT cell. Precursor selection can be performed in either the Quadrupole mass filter 
or at any MSn level in the Ion Trap. Fragmentation can be done using CID in the Ion Trap, HCD, 
or with electron transfer dissociation (ETD), a technique mostly applied for the fragmentation of 
larger, highly charged molecules, such as proteins [292]. The instrument’s geometry allows for 
highly diverse types of MS data acquisition that go far beyond regular shotgun proteomics 
applications. Of benefit for shotgun proteomics is the greatly improved duty cycle rate at which 
peptides can be sequenced, as HCD-type fragments can be measured in the ion trap parallel to 
the acquisition of high resolution MS1 scans. This type of parallelized data acquisition, as 
depicted in Figure 1.18 b, becomes most handy when time-consuming high-resolution spectra 
(R>120.000 @ 200m/z) are intended to be acquired.  
 
 
Figure 1.18. The LTQ Orbitrap Fusion 
a) Geometry of the LTQ Orbitrap Fusion. b) Diagram of parallel data acquisition. Figure adapted  from reference [273]. 
 
Despite the outstanding flexibility of the Orbitrap Fusion mass spectrometer, practice has shown 
that both the Orbitrap Fusion and the Orbitrap Q-Exactive perform equally well for regular 
shotgun proteomics approaches [288, 291]. Nonetheless, the Orbitrap Fusion is of great benefit 
for experimental designs, where specific quantification strategies, such as tandem mass tag 
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(TMT) labeling [293] or neutron encoded stable isotope labeling, are in use [294]. As mostly 
standard MS1 quantification methodologies were applied in the studies published as part of this 
work, the Orbitrap Fusion and the Orbitrap Q-Exactive have been used in a similar fashion and 
were considered to collect data of equal quality. 
 
 
1.4.5.6 Quantification of proteins and peptides 
 
Accurate and precise quantification of proteins and peptides has become of major importance for 
the understanding of complex biological systems. Small changes in the abundance of proteins or 
post-translational peptide modifications can cause drastic changes in cell and tissue dynamics. At 
present, the largest number of quantifiable proteins is achieved using shotgun proteomics 
approaches [295]. Thus, peptide abundance is the currency of protein and peptide quantification, 
requiring their accurate determination. The study of biological systems is mostly achieved by 
comparison of stimulated and non-stimulated systems where, in the best case, many stimulations 
can be compared in a single mass LC-MS run.  
 
Quantification methodologies are grouped into four different classes: metabolic labeling, 
chemical labeling, spiked in peptides and label-free approaches [296]. Corresponding workflows 
are depicted in Figure 1.19. As highlighted in this illustration, samples are combined at different 
points within the sample processing workflow, leaving room to introduce technical errors where 
samples from different conditions are not yet combined. Accordingly, each labeling strategy 
bears its own advantages and disadvantages, requiring their careful evaluation before designing a 
proteomics experiment. Due to the importance and complementarity of each labeling technique, 
detailed descriptions of these strategies are elucidated below. 
 
Label-free quantification is the measurement of peptide abundances measured by a mass 
spectrometer within an LC run [297]. In shotgun proteomics, measurements can be recorded in 
spectral counts, e.g. the number of times a given peptide has been observed, or in the form of 
MS1 intensities of peptide parent ions. The corresponding values are then used to compare 
relative protein and peptide abundances across different experiments. The disadvantage of label 
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free quantification is low sample throughput and the absence of internal standards, resulting in 
less accurate and reproducible quantification.  
 
 
 
Figure 1.19. Overview of labeling technologies in mass spectrometry.  
Figure adapted from reference [296]. 
 
To permit higher throughput of proteomics samples, techniques enabling multiplexed analysis of 
up to ten stimulations within a given LC-MS run have been developed.  At present, the 
methodology granting the highest sample throughput is tandem mass tag (TMT) labeling, where 
peptides are chemically labeled with up to ten different isobaric mass tags [298]. Once peptides 
functionalized with a tandem mass tag are fragmented, the isobaric tags dissociate into reporter 
ions with distinct masses. Relative abundances of these reporter ions can be read out from 
MS/MS spectra with allocated software, providing relative peptide abundances for each of the 
investigated conditions. The disadvantages are signal dilution for highly multiplexed 
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experiments, ratio suppression due to increased background signals in the low m/z range where 
TMT-reporter ion intensities are measured [299], as well as high operational costs.  
 
One more affordable technique to chemically label peptides is the insertion of isotopically-
labeled dimethyl groups at basic amine residues on peptides [300]. This technique, termed 
dimethyl labeling, allows for the comparison of up to three conditions within one LC-MS 
injection, and significantly improves the quantification accuracy of peptides and proteins in 
comparison to label-free quantification. Peptides are labeled with either unlabeled (+28Da), 
deuterated (+32Da) or deuterated and 13C labeled (+36) methyl groups in an amine reductive 
reaction [300]. MS1 intensities of co-eluting isotopic clusters from the same peptide species are 
reported and used for relative quantification of peptides and proteins. Chemical modification of 
peptides, however, results in lower identification rates and does not account for sample handling 
errors introduced prior to peptide digestions. The latter reduces the accuracy of quantification, as 
errors arising from sample processing contribute to the variation in measured peptide intensities, 
as illustrated in Figure 1.19 [296]. However, sample processing-based errors can be ruled out by 
metabolically labeling proteomes, as described below.  
 
Stable isotope labeling of amino acids in cell culture (SILAC) is a labeling technology developed 
by Mathias Mann and is extensively used for the analysis of proteomics samples [168]. In 
SILAC, the isotopically-labeled amino acids Arginine (Arg or R) and Lysine (Lys or K) are fed 
to either cells or animals such as mice or flies, resulting in metabolic incorporation of isotopes 
into the proteome after several cell divisions [301]. Once complete incorporation of amino acids 
into the proteome has been achieved, up to three experimental conditions can be compared in one 
mass spectrometry experiment. Each condition is allocated to one isotopic channel, labeled with 
either 0Lys, 0Arg (Light), 4Lys, 6Arg (Medium) or 8Lys, 10Arg (Heavy) [302]. As for dimethyl 
labeling and label-free quantification, SILAC quantification is based on precursor ion intensities 
reported in the MS1 spectra [303]. SILAC is especially well-suited for the analysis of post-
translational modifications, as this method allows for the accurate quantification of single 
peptides while not perturbing sequence information through chemical additions to the peptides. 
Finally, sample errors are minimized, as samples can be combined immediately after the 
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stimulation of cell cultures (Refer to Figure 1.19). However, human tissue extracts cannot be 
labeled with SILAC and require the use of different labeling strategies.  
  
1.4.5.7 Bioinformatics analysis  
 
Numerous software is available to analyze mass spectrometry-based proteomics data. The one 
mostly used in the scope of this thesis is MaxQuant and the implemented search engine 
Andromeda, which are freeware software developed by Jürgen Cox et al. within the workgroup 
of Matthias Mann at the Max Planck Institute for Biochemistry in Munich, Germany [303, 304]. 
MaxQuant has been specifically designed to quantify metabolically-labeled peptides and proteins 
and can be used for the majority of quantification methods [305]. The search engine Andromeda 
performs peptide spectral matching (PSM) of peptides with variable post-translational 
modifications and is extremely user-friendly [304].  
 
Similar to the majority of peptide search engines, PSM in MaxQuant is performed with the help 
of proteome databases that are provided in the fasta format [306]. Databases can be downloaded 
from websites such as Uniprot.org, where genomic information that are translated into proteomes 
is made available for various taxonomies [307]. Once raw files and proteomics databases are 
linked to the search engine, peptides are in silico digested with the protease specified. Masses of 
the theoretical (tryptic) peptides can then be collated to parent ion peaks from the raw LC-MS 
files to reduce the peptide database created from in silico digestion of the proteome. This reduced 
peptide database is then matched with observed MS/MS spectra from raw proteomics files, and 
peptide identifications are scored based on binomial distribution probabilities [304]. In order to 
guarantee high confidence of matched peptide sequences, a false database is created by reverting 
or randomizing the original peptide database used [308]. Peptides are then matched to this false 
database and are assigned scores. These matches are referred to as false positives. False positive 
scores are further used to determine a score cut-off at which a minimum of 1% of peptides are 
false positives, assuring that, theoretically, 99% of all peptides with scores higher than the cut-
off score are true positive identifications [309]. This approach has proven to be well-suited for 
large-scale proteomics data where not all peptides are anticipated to be detected. In addition to 
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PSM, peptides and proteins can optionally be quantified. Quantification of SILAC shotgun 
proteomics data by MaxQuant is briefly elucidated in the following paragraph.  
 
MS1 intensities of SILAC isotope clusters are extracted from raw files based on the specific mass 
shifts observed from Light, Medium or Heavy Lysine and Arginine residues in each tryptic 
peptide.  Intensities of SILAC pairs/triplets are extracted over the elution profile of a peptide and 
are plotted against each other, regressed with a linear model and the slope of the regression line 
is reported as the fold change. It is noteworthy that MaxQuant also realigns isotope-induced 
retention time shifts, which are mostly observed on amino acids labeled with deuterium, as is the 
case for 4Lys. Protein fold changes are reported as the median of all peptide fold changes. A 
more detailed description of the quantification procedures can be found in the supplementary 
material of the publication by Cox et al. (2009) [310].  
 
At present, numerous other peptide search and quantification software are available that can be 
used in a very similar fashion to MaxQuant. The most frequently used are Peaks [311], Mascot 
[312] and OpenMS [313]. However, with the aim to make the data analysis reproducible, only 
data from MaxQuant are discussed and depicted in the studies of this thesis. The programming 
language R (http://www.R-project.org/) has almost exclusively been implemented in 
bioinformatics workflows to analyze and visualize MaxQuant outputs.  
 
1.5 Time-resolved phosphoproteomics 
 
Knowledge about signalling cascades builds the foundation of many disease treatments. Most 
cellular biology studies aiming to understand signaling pathways are based on already known 
interactions, not allowing for unbiased assessment of systems-wide cellular responses. The era of 
mass spectrometry-based proteomics has allowed researchers to address this issue with large-
scale studies monitoring post-translational modifications in an unbiased manner. 
Phosphoproteomics has emerged as a powerful tool to understand phosphorylation pathways 
linked to specific kinases [314, 315], to unravel signaling cascades associated with extracellular 
stresses [316] and has been used to identify molecular events linked to cancer [317]. In addition 
to these few highlighted examples, phosphoproteomics has been the foundation of numerous 
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studies aiding our current knowledge about intracellular signaling. Few studies, however, have 
focused on monitoring the phosphoproteome in a time-dependent manner, even though the depth 
of information gained from phosphoproteome screenings at single time points have a limited 
scope. Those that have attempted to study the temporally-resolved proteome remarked that 
temporal resolution of signaling events benefits the definition of signaling cascades. One of the 
most interesting studies prior to the debut of this thesis was a publication by Jesper V. Olsen et 
al. (2006), who demonstrated insights into EGF signaling dynamics using five timepoints at 0, 1, 
5, 10 and 20 minutes post-stimulation with epidermal growth factor [318]. This dynamics study 
found kinetic trends to correlate with functionally related phosphorylation events and, based on 
the large number of identified phosphorylation sites, re-defined the EGF signaling pathway. In a 
similar approach, Thiago Verano-Brag et al. investigated the Angiotensin-dependent 
phosphoproteome in a time-dependent manner. Based on this experimental approach, a clear 
signaling network of Angiotensin was defined and its anti-oncogenic activities were found to 
correlate with phosphorylation-dependent delocalization of the forkhead box protein O1 
(FOXO1) [319]. Another publication by Rochelle D’Suza et al. used temporally-resolved 
phosphoproteomics to dissect the early signaling events triggered by the transforming growth 
factor-β (TGF- β) and showed that rapid changes in phosphorylation occur primarily on 
transcription-independent molecular machineries [320].  
 
Altogether, the aforementioned studies consistently highlight that dynamic profiling of the 
phosphoproteome bears the potential to more precisely define the current knowledge on 
signaling cascades through continuous observation of molecular mechanisms. Nonetheless, these 
previous studies faced limitations due to the low number of timepoints monitored, allowing for 
only hypothetical correlations between phosphoproteome dynamics and signaling networks. A 
lack in the number of phosphorylation sites monitored over time further restricted systems-wide 
assessments of signaling events.  
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1.6 Biochemical approaches to assess the functionality of protein phosphorylation 
 
Phosphoproteomics screens provide massive amounts of data that depict stimulation-specific 
changes. Hundreds and even thousands of phosphorylation sites with altered abundances can 
arise from changing environmental conditions of cell cultures, making the interpretation of 
systems-wide-acquired data a challenge. Whilst statistical and bio-informatics analyses allow for 
the assessment of perturbed molecular mechanisms, no exact information about the functionality 
of phosphorylation sites in biochemical pathways can be extracted from proteomics data. 
Additional techniques are required to clearly understand some of the interesting signaling events 
monitored during phosphoproteomics screens. These techniques include point-directed 
mutagenesis of phosphorylated amino acids into their inactive equivalents to perform functional 
assays and the use of immunofluorescence to link observed changes in the phosphoproteome to 
molecular mechanisms. These techniques however, are, by no means, applicable to a large-scale 
assessment of phosphosites, making the choice of investigated phosphorylation events often 
biased towards the interests of researchers or journal editors. Nonetheless, functional assessment 
of phosphorylation sites is crucial for the understanding of signaling networks and their 
relevance in biochemical processes. 
 
1.6.1 Site-directed mutagenesis 
 
Site-directed mutagenesis is a molecular biology technique used to study the effect of one or 
several proteogenic amino acid substitutions on cell biology. This technique is frequently used to 
assess the functionality of phosphorylation of the amino acids Ser, Thr, and Tyr, through 
substitution with non-phosphorylatable amino acids, such as alanine, or with phosphorylation-
mimicking amino acids such as Aspartic acid and Glutamic acid. Aspartic and Glutamic acid 
have been found to mimic the chemical properties of a phosphorylation group [321], while 
alanine has the opposite effect as it does not contain a phosphorylatable residue [322]. Carrying 
out mutagenesis to mimic either of the phosphorylation states of an amino acid helps to 
understand the effects of changes is phosphorylation abundances, as measured in 
phosphoproteomics screens. Point mutations are generated with genomic techniques in which 
DNA plasmids of the protein of interest are produced with or without the mutations. Protocols 
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explaining the exact procedures to synthesize plasmids with the help of polymerases can be 
found in references [323-325]. After genetic cloning, the corresponding proteins can be 
expressed either in the cellular system being studied or in bacterial cells for later purification of 
proteins. In vivo expression of mutated proteins in the investigated cell cultures is often 
performed to test for phosphorylation-dependent changes, including the appearance of 
phenotypes, the viability of cell cultures, and many more. On the other hand, expression of 
mutated proteins in bacterial cultures is used to generate larger amounts of the proteins for their 
purification, which are required for in vitro functional assays. One prominent application where 
purified proteins are needed is the investigation of kinase substrate relationships with radioactive 
phosphor probes. This technique, commonly known as “in-vitro kinase assay”, determines the 
affinity of a kinase to a specific phosphorylation site and requires the expression and purification 
of kinase and the substrate of interest [326, 327]. Point mutations in the phosphorylation sites on 
substrates are necessary to prove that no other phosphorylation site on the substrate is 
phosphorylated by the kinase, as radioactive detection of phosphorous cannot resolve for the 
exact amino acid residue that is phosphorylated. Both in vivo and in vitro assays are widely 
applied to pinpoint the functionalities of specific phosphorylation sites discovered in large-scale 
phosphoproteomics studies.  
 
1.6.2 Immunofluorescence 
 
Immunofluorescence is a technique applied to microbiological samples that uses the specificity 
of antibodies to their antigens to assign fluorescent dyes to proteins of interest [328]. 
Fluorescence can be visualized with a fluorescence-sensitive microscope. Immunofluorescence is 
widely used to assess changes in cellular morphology and specific molecular processes, such as 
actin polymerization, upon stimulation or the expression of exogenously expressed 
proteins[329].    
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1.7 Research outline 
 
This thesis is aimed at the development of mass spectrometry-based techniques to characterize 
the temporal diffusion of phosphorylation-mediated intracellular signaling and to study the 
biological effects of signaling using functional assays. Primarily, the phosphoproteomics screens 
conducted in this thesis focus on: 
 
1. The development of mass spectrometry-based techniques to monitor the 
phosphoproteome with high temporal precision upon extracellular stimulation. 
2. Defining the BRAF-RAS-MEK-ERK signaling cascade and attributed cellular events in 
colon cancer. 
3. Characterizing the effect of the kinase inhibitor Vemurafenib (PLX4032) on the 
phosphoproteome of colon rectal cancers. 
4. Gathering comprehensive information about mechanistic details by which the anti-
oncogenic sphingolipids SH-BC-893 and C2-ceramide starve cancer cells to death 
through activation of protein phosphatase 2 A (PP2A). 
 
Unraveling phosphorylation signaling cascades has mostly been approached through the 
observation of changes in the phosphoproteome at a given time post-stimulation. However, 
assessment of the dynamics of the molecular mechanisms is only possible when also observing 
what happens from the beginning of a stimulation until the observed response. Accordingly, the 
main focus of this thesis is dedicated to the development of a workflow that uses mass 
spectrometry-based proteomics techniques to monitor phosphorylation signaling at high temporal 
resolution and subsequently, the application of such a workflow to understand cell signaling and 
mechanisms by which small molecule drugs target cancerous cells.  
 
To begin with, the model organism yeast was subjected to temperature shocks, leading to a high 
degree of anticipated dynamic changes in phosphorylation signaling. This experimental setup 
was motivated by its simplicity, as temperature shock can be timed easily and yeast cells are 
relatively simple to handle. Also, excessive changes in the phosphoproteome are expected and 
there has been a long-lasting interest in characterizing temperature stress response in yeast. 
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Accordingly, this approach appeared to be well-suited to conduct a systems biology study and, at 
the same time, to develop a technically challenging workflow with a simple model organism. 
Intriguingly, this approach enabled precise dynamic profiling of more than 3000 phosphorylation 
sites, of which around 600 sites drastically changed in abundance with time. Furthermore, we 
observed an intense variability in different phosphorylation kinetics and were able to define 
kinase targets based on kinetic information. 
 
Upon successful development of a workflow that allows for temporal deconvolution of 
intracellular signaling, we applied this technique to gain further insights into cancer treatment 
with kinase inhibitors. We focussed on two genotypes of colon cancer that paradoxically respond 
to treatment with the kinase inhibitor Vemurafenib (PLX4032). While treatment of KRAS G13D 
mutated cancer with Vemurafenib results in activation and thus, growth of cancer cells, colon 
cancer cells harboring the BRAF V600E mutation respond well to the drug that efficiently 
inactivates the BRAF kinase activity. While this phenomenon has been well studied from a 
mechanistic point of view, we intended to unravel the underlying signaling events with the aid of 
temporally-resolved phosphoprotoemics. The resulting study presents a remarkably deep 
profiling of the phosphoproteome and offers extensive knowledge on MAPK pathway signaling. 
Furthermore, we unraveled novel targets of the kinase ERK and connected actin polymerization 
to the activation of the transcription factors MKL1/2. 
   
The third study was motivated by the recent discovery of a potential protein phosphatase 2 A 
(PP2A)-activating anti-oncogenic sphingolipid, named SH-BC-893. This molecule, developed in 
the workgroup of Dr. Stephen Hanessian at the University of Montreal and characterized by the 
cancer biology laboratories of Dr. Aimee Edinger at University of California in Irvine, required 
further investigation regarding its PP2A-activating properties. Scientists in the Edinger 
laboratory discovered that SH-BC-893 starves cancer cells to death through the activation of 
protein phosphatase 2 A. However, the underlying signaling events that lead to starvation had to 
be resolved in order to refine the mechanistic details of its tumor-inhibiting properties. It has 
been reported that starvation of cells occurs after the formation of vacuoles and the 
internalization of nutrient transporters. Both phenotypes can be reversed with PP2A inhibitors 
such as LB-100, while, interestingly, the natural analogue of SH-BC-893, C2-ceramide, keeps its 
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tumor-killing activity without inducing vacuolation. Accordingly, we set out to compare the 
effects of SH-BC-893 on the phosphoproteome to the PP2A inhibitor LB-100 and C2-ceramide 
in a phosphoproteomics screen to decipher the impact of each of the molecules on signaling 
dynamics. These experiments enabled us to conclude that guanylyl exchange factors (GTPases) 
are major drivers of PP2A-directed cell starvation and that SH-BC-893 activates a specific subset 
of the heterotrimeric protein phosphatase 2 A.  
 
In conclusion, this thesis presents the development of a phosphoprotoemics workflow capable of 
monitoring phosphorylation dynamics at minute-scale temporal resolution using metabolic 
labeling techniques. Refined data analysis workflows have been developed and have helped us to 
gain a deeper understanding of the dynamics of cellular signaling, as well as the effects that anti-
oncogenic drugs exert on mammalian cancer cells. 
 
1.8 Thesis overview 
 
The first chapter of my doctoral thesis represents the literature review of cell biology relevant for 
the thematic of the conducted studies. A detailed description of the analytical techniques, 
focused on mass spectrometry-based proteomics, is also presented. This introductory chapter 
covers the most relevant literature and has been composed in accordance with the contents of this 
thesis.  
 
The second chapter presents my first article describing the “Phosphoproteome dynamics of 
Saccharomyces Cerevisiae under heat shock and cold stress”, published in Molecular Systems 
Biology [330]. This publication focuses on the development of phosphoprotemics techniques to 
reproducibly monitor the phosphoproteome in cells with high temporal precision using metabolic 
labeling techniques. Experiments were carried out on the model organism yeast that were 
subjected to either heat or cold stress. The dynamics of the phosphoprotome were successively 
monitored from 0 until 28 minutes post-stimulation, resulting in interesting insights into cellular 
signaling.   
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In the third chapter, my second publication, entitled “Time-Resolved phosphoproteome analysis 
of paradoxical RAF activation reveals novel targets of ERK”, published in Molecular and 
Cellular Proteomics, is presented [331]. In this scientific work, we applied the techniques 
developed as part of the first publication to study the dissipation of phosphorylation-mediated 
signaling in colon cancer cells treated with the FDA-approved kinase inhibitor Vemurafenib 
(PLX4032).  
 
Chapter four represents the third and last article of my thesis that is submitted to Molecular and 
Cellular Proteomics. This study, entitled “Dynamic phosphoproteomics uncovers signaling 
pathways modulated by anti-oncogenic sphingolipid analogs” builds on using temporally-
resolving phosphoproteomics to characterize the effects of the novel anti-oncogenic inhibitor 
SH-BC-893 on phosphorylation signaling. In more detail, SH-BC-893 stimulation was compared 
to a specific inhibitor of protein phosphatase 2 A (PP2A), LB-100 and one of its natural 
analogues, C2-ceramide, to unravel its PP2A-activating and cancer-killing properties.    
 
Chapter five highlights the main findings from all three articles and contains a critical discussion 
of the results from each article. Furthermore, future perspectives and suggestions are stated. 
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2.1 Abstract 
 
The ability of cells and organisms to survive and function through changes of temperature 
evolved from their specific adaptations to non-optimal growth conditions. Responses to elevated 
temperatures have been studied in yeast and other model organisms using transcriptome 
profiling, and provided valuable biological insights on molecular mechanisms involved in stress 
tolerance and adaptation to adverse environment. In contrast, little is known about rapid 
signaling events associated with changes in temperature. To gain a better understanding of global 
changes in protein phosphorylation in response to heat and cold, we developed a high temporal 
resolution phosphoproteomics protocol to study cell signaling in Saccharomyces cerevisiae.  The 
method allowed for quantitative analysis of phosphodynamics on 2,777 phosphosites from 1,228 
proteins. The correlation of kinetic profiles between kinases and their substrates provided a 
predictive tool to identify new putative substrates for kinases such as Cdc28 and PKA. Cell cycle 
analyses revealed that the increased phosphorylation of Cdc28 at its inhibitory site Y19 during 
heat shock is an adaptive response that delays cell cycle progression under stress conditions. The 
cellular responses to heat and cold were associated with extensive changes in phosphorylation on 
proteins implicated in transcription, protein folding and degradation, cell cycle regulation and 
morphogenesis. 
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2.2 Introduction 
 
Single cell organisms such as yeast are regularly exposed to environmental changes that required 
the development of adaptation mechanisms for survival in sub-optimal growth conditions. 
Variation in temperature is a common stress experienced by yeast cells, a condition for which 
evolutionary changes favored organisms that developed appropriate responses to heat shock and 
cold stress. For example, S. cerevisiae have evolved protective transcriptional programs in 
response to elevated temperature (> 37 ̊C) that result in physiological changes affecting 
carbohydrate flux, cytoskeleton dynamics and protein folding [1, 2]. The molecular basis of the 
response to different stresses including heat shock has been well documented in S. cerevisiae, 
and genome-wide transcriptional profiling studies identified important regulators of 
environmental stress response (ESR) [3, 4]. A large proportion of induced ESR genes target 
different cellular processes, including carbohydrate metabolism, protein folding and degradation, 
autophagy, cytoskeletal reorganization and DNA damage repair. In contrast, ESR genes with 
repressed expression are involved in protein synthesis, ribosome synthesis and processing, RNA 
polymerase-dependent transcription and protein translation.  
Short-term exposure to moderate heat shock has been reported to induce a complx cellular 
response culminating in a transient cell cycle arrest at G1/S transition in both yeast and 
mammalian cells [5]. This response appears to be associated with the activity threshold of cyclin-
dependent kinases [5], and overexpression of G1 cyclins in yeast has been shown to overcome 
the transient arrest induced by heat shock [6]. Moreover, Ste20, Cla4, and Skm1, all members of 
the p21-activated kinase (PAK) family, are also activated upon changes in temperature, and play 
important roles in the regulation of osmosensing, filamentous growth and septin ring assembly 
[7-10]. Interestingly, decreased levels of the molecular chaperone Hsp90 or its kinase-specific 
chaperone Cdc37 are known to affect Cdc28 and Cla4 stability [11], a condition that favors a 
subset of cells to switch to a filamentous form in response to hostile environment [12]. 
While a large body of literature exists on the molecular basis of heat shock in yeast, mechanisms 
associated with the response to cold stress are still poorly understood [13]. Experimental 
evidences suggest that changes in membrane fluidity functions as a cold sensor to trigger 
subsequent signal transduction [14]. Exposure to low temperature induces the accumulation of 
trehalose, glycerol, and heat shock proteins to protect yeast cells against freeze injury [15]. Both 
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heat shock and cold stress appear to be regulated by classical stress pathways involving the high-
osmolarity glycerol mitogen activated protein kinase Hog1, and the transcriptional factors Msn2 
and Msn4 [16]. Aside from the classical stress pathways in which Hog1 is playing a central role, 
little is known about the signaling events resulting from changes in temperature.  
To gain further insights on the dynamic changes in protein phosphorylation associated with heat 
shock and cold stress, we performed a large-scale phosphoproteomics study on S. cerevisiae.  
Yeast represents one of the most intensively studied eukaryotic cell model organism with a 
relatively simple genome consisting of approximately 6,500 genes. The introduction of sensitive 
mass spectrometry (MS) instrumentation and affinity media for phosphopeptide enrichment have 
paved the way to comprehensive phosphoproteome analysis that significantly expanded the 
repertoire of protein phosphorylation identified in yeast and other model organisms. Several 
large-scale quantitative phosphoproteomics studies conducted on yeast cells have already 
described changes in protein phosphorylation in response to different stimuli including 
pheromone [17], DNA damage [18], fatty acid and peroxisome induction [19], and kinase 
inhibition [20]. Other large-scale studies using stable isotope labeling in cell culture (SILAC) 
highlighted the regulation of protein phosphorylation in yeast during the cell cycle [21], and as a 
function of ploidy [22]. While MS-based phosphoproteomics enables the profiling of thousands 
of phosphopeptides from microgram amounts of sample, the identification of the phosphosites 
that are specific to the stimulus remains a challenge, due to prevalence of promiscuous 
phosphorylation events arising from random encounters of kinases with abundant neighboring 
proteins [23]. The identification of differentially regulated phosphoproteins by conventional data 
analysis approaches typically rely on fold change (FC) in phosphopeptide abundances taken at 
different time points shortly after the onset of the stimulus. However, dynamic changes in protein 
phosphorylation are difficult to establish based on FC measurements obtained from a limited 
number of time points. We reasoned that the acquisition of high resolution kinetic profiles could 
provide valuable information on phosphoproteome dynamics to further understand how temporal 
changes in kinase and phosphatase activities are reflected on downstream substrates in response 
to environmental stress.  
Accordingly, we performed quantitative phosphoproteomics analyses using SILAC [24] and 
profiled changes in protein phosphorylation for the first 28 min upon temperature stress with a 
temporal resolution of 2 min.  The ability to determine kinetic changes in protein 
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phosphorylation with high resolution enabled the identification of 5,554 high quality profiles (≥ 
10 measurements out of 15), including dynamic phosphorylation profiles of low amplitude that 
typically elude conventional phosphoproteomics approaches based on FC alone. We identified 
391 phosphosites that showed distinct changes in phosphorylation upon either heat shock or cold 
stress. Detailed clustering analyses of dynamic profiles distinguished different types of patterns 
such as monotonous and adaptation-like responses. Also, we observed that kinases shared similar 
kinetic profiles with known substrates, a correlation that facilitated the identification of other 
putative substrates. Phosphosites exhibited notable differences of dynamic patterns in response to 
cold and heat, underlining the complexity of signaling rewiring essential for cell adaptation and 
survival.  The ability to profile phosphoproteome dynamics and identify stimulus-specific 
phosphosites may provide additional insights on the regulation of protein phosphorylation in a 
wide variety of cellular processes. 
2.3 Materials and methods 
 
2.3.1 Cell culture 
 
Yeast strain S288C (LYS1Δ::kanMX; ARG4Δ::kanMX - a generous gift of Ole Jensen, 
University of Southern Denmark) was grown in Synthetic Dextrose (0.17% yeast nitrogen base 
without amino acids, 0.5% ammonium sulfate, 2% glucose, and appropriate amino acids) 
supplemented with either light (Lys0/Arg0), medium (Lys4/Arg6) or heavy (Lys8/Arg10) lysine 
(30 mg/L) and arginine (20 mg/L) (Cambridge Isotope Laboratories). The temperature was 
monitored throughout all experiments. The temperature of all SILAC cultures was 30oC (+/-1oC) 
prior to heat or cold shock. Temperature stress experiments were achieved by adding 280 ml of 
fresh media at 30oC (control, light), 0oC (cold stress, medium) and 60oC (heat shock, heavy) to 
175 ml of cell cultures maintained at 30oC to bring the final temperature at 30, 18 and 42oC, 
respectively. Flasks with cultures were immediately placed into temperature-controlled water 
bathes. Aliquots of 42 ml from each culture were collected every 2 min and combined in 700 ml 
of cold 95% ethanol (-80oC).  
Yeast cells with an analog-sensitive mutant (cdc28-as1) were grown in the same media until 
OD600=0.7. Inhibition was performed by adding the pharmacological inhibitor 1NM-PP1 to a 
final concentration of 10 µM whereas control cells were treated with vehicle (DMSO). After 15 
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min, TCA was added to final concentration 10% and cells were collected by centrifugation 
(2,000 x g, 10 min) and washed with ice-cold PBS. Proteins were extracted and digested as 
described below. 
 
2.3.2 Yeast mutant construction 
 
To construct the cdc28-as1 strain used for SILAC analysis, mutations resulting in the F88G 
change were introduced at the CDC28 locus in strain YAL6B. The strain was transformed with a 
F88G–encoding PCR product amplified from plasmid p575, which carries the 
CDC28::Tadh1::HIS3MX6 selection cassette [25]. The presence of the F88G mutation (and 
absence of secondary mutations) was confirmed by sequencing the entire CDC28 open reading 
frame on chromosome 2 in strain D4485. To construct the cdc28-af mutant strain, plasmid p1288 
was digested with PvuII, SalI and XhoI to release its cdc28-T18A-Y19F::Tadh1::HIS3MX6 insert 
and transformed in strain YAL6B. Proper integration of cdc28-af mutations at the genomic locus 
was confirmed by selection on SC-HIS medium, PCR amplicon size analysis, and sequencing the 
entire CDC28 open reading frame in strain D4591. 
 
2.3.3 Protein extraction and enzymatic digestion 
 
Cells were pelleted by centrifugation (2,000 x g, 10 min) and ethanol was discarded. Cell pellets 
were washed twice with 35 ml of cold (0oC) PBS and lysed by bead beating for 10 min in lysis 
buffer (8 M urea, 50 mM Tris pH 8.0, supplemented with HALT phosphatase inhibitor cocktail, 
Pierce). Samples were centrifuged at 40,000 x g for 10 min, and the supernatants were 
transferred into clean tubes prior to determination of protein concentrations by BCA assay 
(Thermo Fisher Scientific). Disulfide bridges were reduced by adding dithiothreitol to a final 
concentration of 5 mM and samples were incubated at 56 °C for 30 minutes. Reduced cysteines 
were alkylated by adding iodoacetamide to 15 mM and incubating for 30 minutes in the dark at 
room temperature. Alkylation was quenched with 5 mM dithiothreitol for 15 minutes. Samples 
were diluted 6-fold with 20 mM TRIS, pH 8 containing 1 mM CaCl2 prior to overnight digestion 
at 37oC with trypsin (Sigma-Aldrich) using an enzyme to substrate ratio of 1:50 (w/w). Tryptic 
digests were acidified with 1% formic acid (FA), centrifuged (20,000 x g 10 min) and desalted 
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on Oasis HLB cartridges (Waters). Peptide eluates were snap-frozen in liquid nitrogen, 
lyophilized in a speedvac centrifuge and stored at -80oC. 
 
2.3.4 Phosphopeptide isolation and fractionation 
 
Tryptic digests were subjected to the TiO2 enrichment as described previously [26]. Sample 
loading, washing, and elution steps were performed using custom spin columns [27, 28] made 
from 200 µl pipette tip containing a SDB-XC membrane (3M) frit and filled with TiO2 beads. 
We equilibrate TiO2 material in 250 mM lactic acid in 70% ACN 3% TFA, the same buffer was 
used for sample loading. Phosphopeptides were displaced from TiO2 with 500 mM phosphate 
buffer at pH=7. Peptides were desalted in 50 µl of 1% FA and subsequently eluted from spin 
columns using 50 µl of 50% acetonitrile (ACN) 0.5% FA. Eluates were dried in a speedvac and 
stored at -80oC. To increase phosphoproteome coverage prior to MS analysis, phosphopeptides 
were fractionated offline by SCX chromatography. Peptides were solubilized in 100 µl of 
loading buffer (0.2% FA 10% ACN) and loaded onto StageTips containing 15 mg of Poly-
sulfoethyl-A SCX phase (5 µm 300A, Canada Life Science). Columns were washed with 50 µl 
of loading buffer and peptides were eluted in 6 separate 100 µl salt steps of 15, 25, 50, 80, 150 
and 1000 mM NaCl. Fractions were collected, dried in a speedvac, resuspended in 15 µl of 4% 
FA prior to MS analysis. 
 
2.3.5 Offline PGC fractionation of nonphosphorylated peptides 
 
Peptides not retained on TiO2 resin (nonphosphorylated peptides) we diluted with water to 
reduce ACN concentration to 2% and subsequently desalted on Oasis HLB cartridges. Eluates 
were dried on a speedvac. Approximately 100 ug of peptides were fractionated offline on a PGC 
column (Hypercarb™ Porous Graphitic Carbon, 50 x 21 mm) using a 80 min ACN gradient 
from 0 to 80% in 10 mM ammonium formate, pH=10 with a constant flow rate of 200 uL/min. 
Fractions were collected every 2 min and lyophilized on a speedvac. Peptides were resuspended 
in 50 uL of 4% FA and 10 uL were used for LC-MS/MS analyses. 
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2.3.6 Mass spectrometry 
 
Enriched phosphopeptide extracts were analyzed by LC-MS/MS using a Proxeon nanoflow 
HPLC system coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific). Each 
sample was loaded on a reverse-phase precolumn (5 mm length, 360 µm i.d.) and separated on a 
reverse-phase analytical column (18 cm length, 150 µm i.d.) (Jupiter C18, 3µm, 300 Å, 
Phenomenex). Both columns were packed manually. LC separations were performed at a flow 
rate of 0.6 µL/min using a linear gradient of 5-40 % aqueous ACN (0.2% FA) in 150 minutes. 
MS spectra were acquired with a resolution of 70,000 using a lock mass (m/z: 445.120025) 
followed by up to 10 MS/MS data dependent scans on the most intense ions using high energy 
dissociation (HCD). AGC target values for MS and MS/MS scans were set to 1e6 (max fill time 
500 ms) and 1e6 (max fill time 120 ms), respectively. The precursor isolation window was set to 
m/z 2 with a HCD normalized collision energy of 25. The dynamic exclusion window was set to 
30s. 
 
 
2.3.7 Data processing and analysis 
 
MS data were analyzed using MaxQuant [29, 30] software version 1.3.0.3 and searched against 
the SwissProt subset of the S. cerevisiae uniprot database (http://www.uniprot.org/) containing 
6,630 entries. A list of 248 common laboratory contaminants included in MaxQuant was also 
added to the database as well as reversed versions of all sequences. The enzyme specificity was 
set to trypsin with a maximum number of missed cleavages set to 2. The precursor mass 
tolerance was set to 20 ppm for the first search (used for non-linear mass re-calibration [31] and 
then to 6 ppm for the main search. Phosphorylation of serine, threonine and tyrosine residues 
was searched as variable modification; carbamidomethylation of cysteines was searched as a 
fixed modification. The false discovery rate (FDR) for peptide, protein, and site identification 
was set to 1%, the minimum peptide length was set to 6, and the ‘peptide requantification’ 
function was enabled. The option match between runs (1 min time tolerance) was enabled to 
correlate identification and quantitation results across different runs. MaxQuant parameters.txt 
and experimentalDesign.txt files used in this study are listed in Supplementary Table S2-9. The 
 85 
 
mass spectrometry data from this publication have been submitted to the Peptide Atlas database 
(http://www.peptideatlas.org/) and assigned the identifier PASS00536.  
 
In addition to an FDR of 1% set for peptide, protein and phosphosite identification levels, we 
used additional criteria to increase data quality. First we considered only peptides for which 
abundance ratios (FC=Stimulus/Control) were measured in at least 10 out of 15 time points. 
Then we set a cut-off for average phosphosite localization confidence across experiments (time 
points) to 0.75. Final selection of dynamic profiles was achieved by fitting all temporal curves to 
a polynomial model and filtering out fits those with a regression coefficient R2<0.9. 
(Supplementary Figure S2.3 and Supplementary Table S2-2). Based on these criteria we obtained 
5554 high confidence profiles, of which 2777 represented dynamic phosphosite profiles 
(Supplementary Table S2-1).  
 
2.3.8 Clustering of kinetic profiles, NetworKIN, GO and PPI network analysis 
 
We used fuzzy C-means algorithm to cluster all dynamic profiles [32]. Analysis and 
visualization were performed in the R environment (http://www.r-project.org/) with the Mfuzz 
package[33]. Optimal setting of the “fuzzifier” parameter was 1.235 as estimated with the 
“mestimate” function. In order to find the optimal number of clusters, we performed Repeated 
soft clustering for cluster numbers ranging from 6 to 30 were performed to calculate the 
minimum centroid distance (minimum distance between two cluster centers produced by c-
means clustering)[34].  Prediction of kinase-substrate relationships were achieve using 
KinomeXplorer with default thresholding criteria [35] (http://networkin.info/). Gene ontology 
enrichment analyses were performed against whole S. cerevisiae proteome as background using 
DAVID bioinformatics resources for proteins containing dynamic phosphosites. [36, 37] A 
protein-protein interaction network was built in STRING for all proteins containing dynamic 
phosphosites [38]. All interaction predictions were based on experimental evidences with the 
minimal confidence score of 0.9 (considered as a “highest confidence” filter in STRING). 
Results were visualized in Cytoscape network visualization and analysis [39-41].  
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2.3.9 Yeast cell cycle analyses 
 
Synchronization of cells in G1 was carried out using α-factor treatment (50 ng/ml for 120 min). 
Cells were released from the arrest by filtration and resuspension in fresh medium at the 
indicated temperatures. Samples were taken at 15 min intervals and processed to monitor bud 
formation and mitotic spindle morphology by indirect immunofluorescence, as previously 
described [42]. Spindle images were acquired on a DeltaVision microscope using the softWoRx 
software (Applied Precision). Conditions for serial dilution assays are as described previously 
[42]. 
2.4 Results 
 
2.4.1 High temporal resolution of the S. cerevisiae phosphoproteome dynamics in response to 
heat and cold  
 
We designed an experimental workflow to measure phosphoproteome dynamics with 2 min 
temporal resolution, and monitor changes associated with heat shock and cold stress in S. 
cerevisiae. Briefly, cells were grown at 30oC in media containing light (0Lys, 0Arg), medium 
(4Lys, 6Arg) or heavy (8Lys, 10Arg) isotopic forms of lysine and arginine. Cell cultures were 
mixed with either cold or hot fresh media and maintained in a thermostated water bath to induce 
a rapid shift of temperature to 18 oC (cold stress), 42 oC (heat shock) or 30 oC (control) (Figure 
2.1A). Aliquots from each culture were collected every 2 min and pooled together in cold (-
80oC) ethanol to prevent protein degradation and changes in phosphorylation. After 
centrifugation, cells were lysed by bead beating in urea buffer, and proteins were digested into 
peptides with trypsin. Phosphopeptides were enriched on TiO2 affinity resin, and fractionated 
offline into 6 SCX salt fractions prior to LC-MS/MS analysis. Phosphopeptide identification and 
quantification was performed using MaxQuant [29, 30] and further analyses were achieved using 
R (http://www.r-project.org/), Perl (www.perl.org) and bioinformatics tools such as 
KinomeXplorer [35] and STRING [38] (Figure 2.1B and Materials and Methods). We identified 
a total of 9,357 unique phosphosites on 2,344 proteins, of which approximately 70% were 
localized with high confidence (6,553 phosphosites). The abundance of phosphopeptides was 
profiled across time, and only those quantified in at least 10 out of 15 time points were retained 
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for further analysis. Accordingly, we identified 5,554 high quality profiles corresponding to 
2,777 phosphosites (1,228 proteins) (Supplementary Figure S2.1 and Supplementary Table S2-
1). A pairwise comparison of phosphopeptide abundance across time points is provided as 
Supplementary data (Supplementary Figure S2.2). 
 
Figure 2.1. Experimental design and data analysis workflow.  
A) Temperature shifts are initiated by adding either hot (60°C) or cold (0°C) media to cell cultures. The temperature of cultures is 
maintained in thermostated water bathes throughout the duration of the experiments. Samples are collected every 2 min by 
mixing yeast cultures in cold ethanol to immediately preserve protein phosphorylation. Yeast cells are centrifuged and lysed 
under denaturing conditions, and extracted proteins are digested with trypsin. Phosphopeptides are purified on TiO2 beads and 
fractionated offline on SCX spin columns prior to LC-MS/MS analyses. B) Phosphopeptide identification and quantitation is 
performed using MaxQuant, and only kinetic profiles containing at least 10 time measurements were selected for further analysis. 
Polynomial fitting was used to define regulated phosphosites. Sites with R2 > 0.9 were selected and used for fuzzy c-means 
clustering and subsequent analyses. 
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To determine the overall changes in phosphoproteome in response to heat shock or cold stress, 
we used fold change (FC) ratio of peptide abundance between conditions as a proxy for 
biological variability induced by the stimulus (Figure 2.2A). Global effects of the treatment (heat 
or cold) on the phosphoproteome was evaluated from the width of the log2 FC distribution of all 
phosphopeptides for a given time point. The width of this distribution is represented as the 
interquartile range (IQR). If the treatment produces global changes in phosphorylation this will 
be reflected by a widening of the FC distribution. We plotted the interquartile ranges (IQR) for 
log2(FC) distributions of phosphopeptides to monitor the global changes of the phosphoproteome 
upon heat and cold stress (Figure 2.2B). The IQR values of nonphosphorylated peptides retained 
on TiO2 in a nonspecific manner are also shown for comparison. At the onset, (T=0 min), no 
significant differences were observed in IQR values for all three conditions, and coefficient of 
variation for abundance measurements were within +/- 0.29 for all quantified peptides. A 
progressive increase in FC ratio of phosphopeptides was observed during the first 10 min upon 
heat shock and cold stress while the abundance of non phosphorylated peptides remained 
relatively constant over the entire time period of the experiment. It is noteworthy that changes in 
phosphorylation were markedly different between stimuli, suggesting that exposure to elevated 
temperature has more pronounced effects on the phosphoproteome of S. cerevisiae with FC 
ratios typically 4 times higher on average for heat shock compared to cold stress. Protein 
phosphorylation reached a plateau around 20 min upon stimulation, possibly reflecting a gradual 
adaptation of yeast cells to the environmental condition.  
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Figure 2.2. Proteome-wide effects of temperature.  
A) Width of FC distribution is used to define biological variability associated with a particular stimulus. No significant changes 
in the abundance of nonphosphorylated peptides were observed during the experiment, and the corresponding coefficient of 
variation was used to determine technical variability (sample processing and LC-MS/MS analysis). The FC distribution of 
phosphopeptides corresponds to the sum of technical variability and stimulus-associated changes. B) Phosphopeptides exhibited a 
progressive increase in IQR with time, reflecting the global effects of temperature on the phosphoproteome. Notably, heat shock 
produced more pronounced effects compared to cold stress. The distribution of FC for nonphosphorylated peptides remained 
largely unaffected. C) Proteins that displayed changes in phosphorylation upon temperature shifts were used to build interaction 
network using the STRING database (http://string-db.org/), and selecting high stringency (score > 0.7) interactions inferred from 
experimental data. Node degree is the number of interacting partners in the network. These analyses revealed that responses to 
heat shock and cold stress are complex and involved the activation of many kinases and phosphatases that affect downstream 
substrates with wide range of cellular functions, including cell cycle regulation and cell morphogenesis. 
 
In order to define biologically regulated phosphosites in the dataset, we first performed fitting of 
all kinetic profiles with a polynomial model, selecting only those with R2 > 0.9 (Figure 2.1B and 
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Supplementary Figure S2.3). This analysis does not depend on the absolute ratios of abundance 
measurements or fold change (FC), rather it is based on the shape and low variance (i.e. low 
RSD values of SILAC measurements) of kinetic profiles. Profiles with high RSD do not 
generally provide meaningful R2 values, and are not considered for subsequent analyses. It is 
noteworthy that FC values do not reflect actual stoichiometry of phosphorylation. For example, a 
FC value of 10 might indicate a change in phosphorylation from 1 to 10% whereas a FC value of 
2 could correspond to full protein phosphorylation (from 50 to 100%). Since biological relevance 
of phosphosite cannot be based on FC measurements alone, profiles with low amplitude (small 
FC) could be as important as profiles with high amplitude (high FC). In this study, we assign 
significance based on the shape of kinetic profiles rather than absolute values of the 
corresponding FC values. Therefore, this approach enabled the selection of profiles of low 
amplitude that could elude conventional quantitative phosphoproteomic methods based on FC 
alone. We performed fuzzy clustering of these profiles and selected only profiles with cluster 
membership value higher than 0.7 for subsequent analyses. We identified 388 phosphosites from 
271 proteins that showed distinct changes in phosphorylation (increase or decrease) with time for 
at least one stimulus (Supplementary Table S2-2). For convenience, we hereafter defined these 
phosphosites as “dynamic” to distinguish them from remaining “static” phosphosites. Dynamic 
sites showed significant changes in phosphorylation where max |log2 FC| measurements were 
typically 2-fold higher than static sites (Supplementary Figure S2.4). To account for the 
possibility that changes in protein abundance might affect the interpretation of regulated 
phosphosites, we performed experiments on flow through fractions containing 
nonphosphorylated peptides from TiO2 enrichment experiments. Samples were desalted and 
fractionated on a PGC column into 40 fractions prior to LC-MS/MS analyses. These experiments 
enabled the quantitation of ~85% of all dynamic phosphoproteins reported in Supplementary 
Table S2-2. We observed that only 2 proteins showed FC values higher than 2 over the entire 
time period of the experiment. Accordingly, Hsp42 (log2FC: 2.06) and Zeo1 (log2FC: 1.33) were 
excluded from the list of dynamic phosphoproteins. The list of quantified proteins and their 
corresponding changes in protein abundance is reported in Supplementary Table S2-3. 
To find relationships among dynamic phosphoproteins that contained at least one dynamic 
phosphosite, we integrated our identification into protein-protein interaction (PPI) network 
(Figure 2.2C), and performed GO enrichment analysis [36] (Supplementary Figure S2.5 and 
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Supplementary Table S2-4). Cell response to changes in temperature appears to be complex, and 
comprised a network of interacting proteins involved in cytokinesis, cell morphogenesis and cell 
cycle regulation. Changes in phosphorylation are consistent with a kinase-phosphatase network 
associated with the response to temperature stress, and we observed that about 15% (20/129) of 
all kinases and 7% (2/30) of all phosphatases also comprised dynamic sites (Figure 2.2C and 
Supplementary Table S2-6).  Several of these kinases including Rck2 and Hog1 are also 
regulated upon environmental stress including osmotic shock [43].     
 
2.4.2 Temporal phosphorylation profiles identify potential kinase substrates in response to heat 
shock and cold stress 
 
To gain further insights on kinetic profiles shared among dynamic phosphosites, we analyzed our 
dataset using fuzzy c-means clustering, and selected only clusters with membership >0.7 (Figure 
2.1B, and Figure 2.3A). These analyses enabled the separation of 388 dynamic phosphosites 
from 271 proteins into 15 different clusters with unimodal distributions showing monotonous 
(clusters 5, 6 and 9-12) and adaptation-like (clusters 1-4, 7, 8 and 13, 14) profiles 
(Supplementary Table S2-2). With the exception of clusters 9-12, the temporal variation in FC 
(increase or decrease) of several profiles reached a maximum value within 20 min upon 
temperature shift. Several profiles showed changes in phosphorylation that returned to their 
original status within 30 min post stimulation. For example, this is the case for the kinase Hog1, 
and the transcriptional factors Msn2 and Msn4 that were previously reported to be regulated by 
changes in temperature [16].   It is noteworthy that phosphosites from the same protein can 
exhibit different profiles, and that individual phosphosite often showed different behaviors in 
response to heat and cold.  For example, we identified 5 dynamic sites on trehalose synthase 
complex regulatory subunit, Tsl1 (S53, S73/S77, S147 and S161), of which 2 sites (S147 and 
S161) showed opposite trends upon heat shock and cold stress. Tsl1 is a regulatory subunit of the 
trehalose synthesis protein (TSP) complex that catalyses the production of trehalose from 
glucose-6-phosphate and UDP-glucose, an activity mediated by heat shock [44]. Changes in the 
phosphorylation status of Tsl1 may regulate its association with the TSP complex under stress 
condition (Supplementary Figure S2.6). 
 
92 
 
Figure 2.3. Types of dynamic behavior and kinases involved in response to heat and cold stresses.  
A) Fuzzy c-means clustering of regulated phosphosites with different kinetic profiles. Pie charts represent the distribution of 
profiles for heat (red) and cold (blue), while circle sizes correspond to the number of high membership profiles. Clusters are 
ordered according to similarities in their dynamic behavior for either up- or downregulation. B) Putative kinases associated with 
dynamic and static phosphosites based on KinomeXplorer predictions. Substrates for each kinase group are represented by bar 
plots. A relative enrichment of cyclin-dependent and MAP kinase substrates is observed among dynamic phosphosites, while a 
higher proportion of casein kinase 1/2 substrates is found for static phosphosites. C) Distribution of kinetic patterns among 
dynamic phosphosites associated with Cdk and MAPK kinase groups. Putative Cdk and MAPK substrates were found to be 
represented mostly in cluster 5 which correspond to a sustained dephosphorylation. 
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Several kinases and phosphatases were dynamically affected by changes in temperature and 
exhibited different kinetic profiles. For example, several sites of important kinases involved in 
stress response (cluster 2: Hog1 Y176), cell cycle regulation (cluster 6: Cdc28 Y19), nutrient 
sensing (cluster 8: Gcn2 S577) or cytokinesis (cluster 9: Cdc3 S503) were grouped in different 
clusters, suggesting distinct temporal regulatory activities. Based on this observation, we 
surmised that dynamic behaviors of kinase and phosphatase groups could be correlated based on 
their temporal profiles, and that substrates may exhibit similar trends. To test this proposal, we 
first associated dynamic and static phosphosites with assigned kinase groups based on 
predictions made by KinomeXplorer [35], a platform that integrates an improved NetworKIN 
algorithm for modeling kinase signaling networks by combining linear motif analysis with 
protein-protein interactions. We found that approximately 40 % of all dynamic phosphosites are 
associated with 3 main kinase groups represented by cyclin-dependent, mitogen-activated and 
AGC family kinases, and that a higher proportion of dynamic sites compared to static sites is 
observed for the first two groups (Figure 2.3B). These kinases are known to play multiple roles 
in the regulation cellular response to environmental conditions and integration of stress signals. 
The only group of kinases significantly under represented among dynamic phosphosites is casein 
kinases (Ycks). The relative proportion of enrichment or depletion of dynamic sites from other 
kinase groups is more difficult to establish as the numbers of affected phosphosites are small (< 
10 sites).   
Next, we regrouped dynamic phosphosites associated to specific kinases with their 
corresponding clusters to determine if phosphosites that were found to be phosphorylated by the 
same putative kinases were grouped in the same cluster. These analyses revealed that dynamic 
phosphosites attributed to specific kinases could be represented by different clusters 
(Supplementary Figure S2.7). This observation is not entirely unexpected since the 
phosphorylation status of any given site may be affected by several factors including the activity 
of other kinases and phosphatases, the subcellular location of protein substrates and the creation 
of binding sites modulating the interactions with proteins containing phosphobinding domains. 
While temporal profiles associated to specific kinases appeared to be complex, we also noted 
that several dynamic sites/clusters were more frequently represented in selected kinase groups 
(Figure 2.3C). For example, cluster 6 contains the cyclin-dependent kinase Cdc28, a major 
component of the cell cycle control system. The increase phosphorylation of Cdc28 at the 
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inhibitory site Y19 [45]is also correlated with a corresponding dephosphorylation of known 
Cdc28 substrates found in cluster 5 such as phosphatase Cdc14 (S429), transcription factor 
activator of CUP1 Expression Ace2 (S253), and MAP kinase Ste20 (S547, S562) [21]. Similarly, 
the increase activity of Hog1 (Y176) is also correlated by an increase phosphorylation of known 
substrates including  the transcription factor Sko1 (T215) and Rck2 kinase (S46/S50) that were 
grouped under the same temporal profiles (cluster 2).  
The observation that changes in phosphorylation profiles of kinases are associated with those of 
known substrates suggests that dynamic patterns could be used to identify putative kinase 
substrates. To explore this possibility, we focused on profiles related with changes in Cdc28 
activity upon heat shock. First, we used STRING to identify dynamic phosphoproteins known to 
interact with Cdc28, based on interactions inferred from experimental data and assigned with the 
highest confidence (>0.9)[38]. Next, for these proteins we obtained information on sites 
phosphorylated by Cdc28 based on in vivo phosphorylation data from the PhosphoGrid database 
[46, 47]. These analyses identified 32 target phosphosites, of which 9 phosphosites were detected 
in our study as dynamic, and displayed similar patterns of dephosphorylation associated mainly 
with cluster 5 (Figure 2.4 and Supplementary Figure S2.8). It is noteworthy, that protein tyrosine 
phosphatase Mih1 (S82) which targets Y19 residue on Cdc28, showed a similar 
dephosphorylation profile. In addition to Cdc14 (S429), Ace2 (S253, S428), Ste20 (S547, S562), 
Cdc27 (T351) and Stb1 (S72, S89) that were previously known as Cdc28 substrates, these 
analyses uncovered new putative sites on Kar9 (T598), Msa2 (T5) along with a novel site on 
Ste20 (T573). To confirm putative Cdc28 substrates we also performed large-scale 
phosphoproteomics analyses on a yeast strain where the WT Cdc28 was replaced with an analog 
sensitive mutant Cdc28-as1 expressed in the same strain background [21].  These experiments 
were carried out on six biological replicates with reverse SILAC labeling and confirmed the 
dephosphorylation of 2 out of 3 putative substrates upon Cdc28-as1 inhibition with 1NM-PP1: 
Msa2 T5 (log2FC: -4.68, -log10(pValue): 2.48) and  Ste20 T573 (log2FC: -2.38, -log10(pValue): 
3.06). Unfortunately, the Kar9 T598 was not detected in these experiments due to its low 
abundance. The complete list of quantified phosphosites obtained from the inhibition of the 
analog sensitive mutant of Cdc28 is presented in Supplementary Table S2-6. 
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Figure 2.4. Cdc28 substrates display similar dynamic behavior.  
An increased phosphorylation of Cdc28 at its inhibitory site Y19 was paralleled by a corresponding dephosphorylation on 
putative protein substrates. STRING was used to obtain high-confidence Cdc28 interactors among proteins with dynamic 
phosphosites, and known sites regulated by Cdc28 were inferred using PhosphoGRID. A total of eight dynamic phosphosites (red 
dots) with similar kinetic profiles were identified in our dataset (shaded area across averaged profile represents 95% confidence 
interval). 
 
To gain further insights on the inference of kinase-substrate relationships based on dynamic 
profiles, motif analyses and protein-protein interactions, we also compared our dynamic 
phosphosites with those identified in a separate large-scale phosphoproteomics study performed 
on 116 gene deletion mutants of the non essential kinases or phosphatases, and 8 analog-
sensitive kinase strains of some essential kinases (Supplementary Table S2-7) [20]. These 
analyses revealed that 43 % of our dynamic phosphosites from monophosphorylated peptides 
(134 phosphosites) were also found to be regulated in the system-wide perturbation of kinase and 
phosphatase study by Bodenmiller et al. (Supplementary Figure S2.9A) [20]. While 
approximately 2/3 of these sites were regulated by multiple kinases, we found that 42 
phosphosites were associated to a single kinase (Fig S9B). Closer examination of regulated 
phosphosites common to both large-scale phosphoproteomics studies indicated an enrichment of 
some kinases in specific clusters (Supplementary Figure S2.9C). For example, putative Cdc28 
substrates were identified in cluster 5 consistent with that observed previously using 
KinomeXplorer (Figure 2.3).  
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Our dataset also contained several phosphosites that showed rapid dephosphorylation upon heat 
shock followed by a recovery to basal level within 10 min (Figure 2.5). Among these are known 
examples of transient dephosphorylation of Msn2 and Msn4, two transcription factors that are 
activated upon cellular stress conditions, and rapidly undergo nuclear translocation [48]. The 
activation of Msn2/4 is associated with the rapid but transient dephosphorylation of several sites 
within the nuclear localization signal (NLS) [49].  Previous studies indicated that NLS of Msn2 
is a direct target of cAMP-dependent protein kinase (PKA) that plays important roles in nutrient 
sensing [50]. Under heat shock we identified 3 sites on Msn2 (S201, S288, S633) and 4 sites on 
Msn4 (S263, S316, S488, S558), all located within PKA recognition motif.  
 
Figure 2.5. Dynamic profiles reveal functional association between kinases and putative substrates.  
Schematic representation of cell signaling pathway associated with PKA and downstream substrates. Phosphorylation profiles are 
shown for each substrate site. The kinetic profiles of PKA (Tpk3 and Bcy1) are superimposable with those of known protein 
targets Msn2/4 and Rgt1. The correlation between temporal profiles was used to identify putative targets of PKA such as 
nucleoporin Nup60 and the transcription factor Skn7. 
 
In this study, we observed the dephosphorylation of both PKA catalytic subunit Tpk3 (S15) and 
the regulatory subunit Bcy1 (S83, S84, S145) (Figure 2.5). The phosphorylation of Bcy1 at S145 
by Tpk1-3 is required to establish a negative feedback loop in response to changes in nutrient 
concentrations [51].  Tpk3, Bcy1 and Msn2/4 all showed similar temporal phosphorylation 
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profiles, thus providing a dynamic link between these proteins. Upon heat shock, PKA is 
transiently deactivated which leads to rapid dephosphorylation of Msn2/4 favoring its nuclear 
translocation. The comparison of kinetic profiles similar to those of Msn2/4, Tpk3, and Bcy1 
(cluster 1) also identified other putative PKA substrates including the nuclear pore protein 
Nup60 (S10), the transcription factors Skn7 (S2) and Rgt1 (S284, S410), the inhibitor of 
glycogen debranching Igd1 (S83) and a protein of unknown function associated with cell cycle 
regulation YPL247C (S12) (Figure 2.5).  Rgt1 regulates the expression of HXT genes encoding 
glucose transporters, and is phosphorylated in vitro by all three isoforms of PKA at serine 
residues located within consensus sites [52]. Igd1 is also involved in glucose metabolism and 
was reported to act as an inhibitor of Gdb1p by enhancing the ability of yeast cells to store 
glucose as glycogen. The phosphorylation of Igd1 could regulate its interactions with Gdb1 [53]. 
The dephosphorylation of the nuclear response regulator and transcription factor Skn7 (S2) 
through the transient deactivation of Tpk3 might be required for optimal induction of heat-shock 
genes in response to oxidative stress [54].  
We also observed the dephosphorylation of an upstream regulator of PKA activity - the yeast 
ortholog of mammalian PKB/Akt and target of rapamycin complex 1 (TORC1) effector, Sch9 
protein kinase. Residue S726, which is located within the AGC-kinase domain, is a substrate of 
TORC1 and was dephosphosphorylated upon heat shock. Phosphorylation of this residue is lost 
upon rapamycin treatment, carbon or nitrogen starvation and is transiently reduced following 
application of osmotic, oxidative, or thermal stress [55, 56]. Consistent with this result, we also 
identified phosphorylation sites on Tco89 (S84) and Kog1 (S1045), two components of TORC1 
that were dephosphorylated upon heat shock. It is noteworthy that PKA activity is modulated by 
changes in cAMP concentrations, and we observed an increase phosphorylation of residue T617 
from adenylate cyclase Cyr1 upon heat shock. Residue T617 is located next to the Ras-
associating domain of Cyr1 and its kinetic profile showed an opposite trend to that observed for 
the catalytic subunit Tpk3 (S15). Taken together, our results suggest that the combination of 
protein-protein interactions and phosphorylation dynamics provides a valuable approach to 
identify putative kinase substrates and prioritize large-scale phosphoproteomics data for 
subsequent experiments. 
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3.4.4 Differential regulation of signaling pathways upon heat shock and cold stress 
 
We observed that a larger proportion of dynamic phosphosites were observed under heat shock 
compared to cold stress, indicating that cellular responses to these stimuli are inherently 
different.  To study the differential regulation of signaling pathways activated under these 
environmental changes, we grouped all dynamic phosphosites into four categories based on their 
response to cold and heat. Accordingly, the behaviors of dynamic phosphosites were classified as 
bidirectional, temperature-independent or heat- and cold-specific to distinguish situations where 
profiles exhibited opposite, same response or no response to either cold or heat (Figure 2.6A). 
We found that 36 % of dynamic phosphosites are modulated in a bidirectional fashion in 
response to heat and cold (Figure 2.6A). Among these sites, we noted that 69 % displayed 
opposite trends in phosphorylation upon these stimuli, and could correspond to sites important 
for the regulation of protein activity. An example of this is represented by the neutral trehalase 
Nth1, an enzyme that hydrolyzes trehalose to glucose to provide energy and assist in recovery 
from stress. Earlier reports indicated that trehalose levels rise in response to heat shock and 
confer thermotolerance in the fission yeast Schizosaccharomyces pombe [57]. Importantly, 
trehalose levels must be tightly regulated, as cells lacking Nth1 exhibit impaired recovery from 
heat shock [58]. Our data suggest that phosphorylation of Nth1 might regulate its enzymatic 
activity to control intracellular levels of trehalose. 
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Figure 2.6. Cross-talk of signaling pathways upon heat and cold stresses.  
A) Dynamic phosphosites are classified into four groups according to their response to heat (red) and cold (blue) along with 
representative examples. B) A total of 24 out of 270 dynamic proteins contained phosphosites from different groups highlighting 
a complex regulation of kinase/phosphatase network. C) Phosphorylation dynamics of septin Cdc3. Residues S503 and S509 are 
substrates of Cdc28, and their change in phosphorylation is known to regulate efficient ring disassembly (Tang & Reed, 2002). 
Dephosphorylation of both mono- and diphosphorylated forms of the corresponding peptide was observed upon heat shock, 
consistent with the inhibition of Cdc28 (see A). Dynamic changes on all phosphopeptide forms of S2 and S9 is also observed 
upon both heat shock and cold stress. D) Venn diagrams representing overlap between dynamic phosphosites associated with heat 
and cold stresses. Responses to heat and cold are partially redundant; both trigger temperature-independent and temperature-
dependent changes. 
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Our population of phosphosites contained a subset representing 16% of all dynamic sites that 
react in a similar manner to both increase and decrease of temperature (Figure 2.6A). These 
phosphosites are probably involved in general stress response whereby signaling events trigger 
similar changes in cellular activities upon detection of abnormal temperature conditions.  Among 
sites that showed a temperature-independent behavior, we noted the catalytic subunit of Cdc28, a 
master regulator of mitotic and meiotic cell cycles that has multiple roles in the regulation of cell 
cycle transcriptional programs, chromosome duplication and segregation, spindle dynamics, lipid 
biosynthesis, membrane trafficking, polarized cell growth, and morphogenesis. Inhibition of 
Cdc28 activity upon temperature stress via the phosphorylation on Y19 residue might be 
required to cause cell arrest and prevent cell proliferation until favorable cell growth conditions 
are restored [45, 59].  
The largest group (46%) of dynamic phosphosites is represented under the category heat-specific 
response, and included proteins such as transcription factor Msn2 and Hog1 kinase (Figure 
2.6A). The kinase Hog1 was previously shown to be activated upon thermal stress [60]. 
Transient changes in Hog1 activity may reflect a variation in the perceived turgor pressure upon 
thermal stress. It is noteworthy that cold stress near freezing conditions is also known to activate 
Hog1 and trigger glycerol production essential for freeze protection [16].  
The last group typifying cold-specific response is represented by 4 phosphosites from eIF4E-
associated protein Eap1, the component of the cleavage and polyadenylation factor I (CFI) 
Rna14, the transposon Ty1-PR2 Gag-Pol polyprotein YPR158W-B and the component of the 
COPII vesicle coat Sfb2 (Figure 2.6A). While Eap1 is known to bind eIF4E for protein 
translation, it may also affect the activity of GCN4 translation via a crosstalk mechanism 
involving TOR signaling [61]. The role of Eap1 phosphorylation is not known, though TOR 
activation results in the phosphorylation of the mammalian homolog eIF4E-binding protein to 
prevent its binding to eIF4E [62].  The second representative of this group is Sfb2, a component 
of the COPII coat involved in the anterograde transport of vesicles from the endoplasmic 
reticulum to the Golgi apparatus. However, the functional significance of Sfb2 phosphorylation 
on its activity remains unknown. 
Phosphoproteins can harbor several dynamic phosphosites with different behavior in response to 
heat and cold, and our dataset contained 24 out of 270 dynamic phosphoproteins with multiple 
phosphosites from different categories (Figure 2.6B). One of such proteins is Cdc3, a component 
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of the septin complex that displayed both bidirectional (S2/S9) and heat-specific (S503/S509) 
dynamics. We observed both mono and diphosphorylated peptides for Cdc3 (Figure 2.6C). The 
septins comprise a family of filament-forming proteins ubiquitous in eukaryotic species. It has 
been suggested that phosphorylation of Cdc3 by the Cdc28 kinase on S503/S509 at the end of G1 
may facilitate initiation of a new cell cycle by promoting disassembly of the obsolete septin ring 
from the previous cell cycle [63]. We observe dephosphorylation of both S503/S509 residues 
consistent with the inhibition of Cdc28 activity. While Cdc28 is inhibited under heat shock and 
cold stress, the dephosphorylation of Cdc3 appears to be heat-specific suggesting a more 
complex regulatory mechanism. Phosphorylation of S2/S9 residues follows an opposite trend in 
response to heat and cold, possibly suggesting the interaction of different kinases. NetworKIN 
predictions indicated that S2 can be phosphorylated by Rad53 while S9 is a putative substrate for 
SCH9/PKC1 kinases. Another interesting example of multisite phosphorylation is the RNA 
binding protein Pin4. This protein is involved in G2/M phase progression and is known to be 
phosphorylated in response to DNA damage [64]. We identified 8 phosphosites on Pin4 that are 
located within structural domains that likely affect its binding to RNA under thermal stress 
(Supplementary Figure S2.10). Altogether, these results indicate that phosphosites exhibit 
strikingly different behaviors in response to cold and heat, reflecting the cellular plasticity and 
signaling rewiring necessary for cell adaptation to adverse environment. Heat shock triggers a 
large number of specific phosphorylation events not observed under cold stress whereas a drop 
of temperature can trigger a signaling machinery common to heat shock to promote 
interconversion of metabolic intermediates necessary for cell survival (Figure 2.6D).   
 
2.4.5 Significance of Cdc28 tyrosine 19 phosphorylation during the heat shock response 
 
Our phosphoproteomic data indicated that several substrates of the Cdc28 kinase become 
hypophosphorylated in response to heat shock. This decrease in phosphorylation correlates well 
with the increased phosphorylation at the inhibitory site Y19 of Cdc28. In vertebrate cells, loss 
of the equivalent phosphorylation on Cdk1 induces premature mitotic entry [65], which suggests 
that Y19 phosphorylation in yeast could act by restraining cell cycle progression during the heat 
shock response. To test this possibility, we constructed a cdc28-af mutant defective for Y19 and 
T18 phosphorylation and determined its cell cycle profile after heat shock. It was necessary to 
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remove both T18 and Y19 phosphosites in Cdc28 since modification of the residue preceding the 
inhibitory tyrosine in CDKs can functionally compensate for the loss of tyrosine modification 
[65, 66]. CDC28 and cdc28-af mutant cells were synchronously released from a G1 arrest into 
prewarmed medium, and samples were collected at regular intervals to determine kinetics of 
budding and mitotic spindle formation. The release experiments were conducted at 30 °C and 39 
°C because yeast cells did not cycle effectively at 42 °C (Figure 2.7A and Supplementary Figure 
S2.11). Both CDC28 and cdc28-af mutant cells formed buds and accumulated mitotic spindles 
with similar kinetics when released from a G1 arrest at 30 °C (Fig S11). In contrast, the 
appearance of cell cycle landmarks was advanced in the cdc28-af mutant released at 39°C 
relative to its wild-type counterpart (Figure 2.7B-C). Specifically, cdc28-af cells showed an early 
accumulation of metaphase spindles at mitotic entry (60 min post-release; Figure 2.7B-C) and 
faster kinetics of mitotic exit (as evidenced by an increased abundance of cells with 
G1/interphase-type microtubules arrays at the end of the experiment; Figure 2.7B) when 
compared to CDC28 cells growing at 39 °C. These results are consistent with the known roles of 
Cdc28 in promoting bipolar spindle formation [67] and elongation [68] during mitosis. 
Altogether, our results indicate that the increased phosphorylation of Cdc28 Y19 and associated 
reduction in kinase activity observed during the heat shock response restrain cell cycle 
progression, most likely to allow time for cells to adapt to the cellular stress associated with 
increased temperatures and to promote effective cell division. 
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Figure 2.7. Cell cycle profile of cdc28-af mutants growing at elevated temperatures.  
A) Growth properties of CDC28 and cdc28-af mutant cells exposed to various temperatures. Fivefold dilutions of yeast cells 
were spotted on YPD plates and grown at 18, 30, 37 and 42°C for 2–4 days. Strains included on plates are as follows: D1 (WT), 
YALB6 (lys1Δ arg4Δ), D253 (tub2-401, a cold-sensitive strain), D4591 and D4592 (two independent clones with the lys1Δ 
arg4Δ cdc28-af genotype). B) Budding index and spindle morphology of CDC28 and cdc28-af cells after release from a G1 arrest 
into fresh medium at 39°C. Samples of cells were taken at intervals to determine the kinetics of bud appearance (top graph), and 
microtubule morphology (middle and bottom graphs) in cultures of CDC28 and cdc28-af cells released synchronously into the 
cell cycle. At least 100 cells were counted at each time point. C) Micrographs of CDC28 and cdc28-af cells showing spindle 
morphology (tubulin) and nuclear mass position (DAPI) 60 min after G1 release at 39°C. 
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2.5 Discussion 
 
All organisms have evolved adaptation mechanisms to survive adverse environmental conditions 
such as suboptimal growth temperatures. In S. cerevisiae, the response and adaptation to heat 
shock and cold stress are initiated by complex and rapid signaling pathways that affect a wide 
range of cellular processes including transcriptional programs, cell division and morphogenesis, 
protein folding and metabolic changes in nutrient flux. Previous transcriptional profiling studies 
on the heat shock response in yeast identified several differentially regulated genes involved in 
carbohydrate metabolism, protein folding and degradation, cytoskeletal reorganization, protein 
synthesis, ribosome synthesis and processing [3, 4]. While our quantitative proteomics data 
indicated that only ~2 % of proteins showed significant changes in protein abundance in the first 
30 min upon heat shock, we noted that several proteins including HSP12, HSP26, HSP30, 
HSP42, HSP78, HSP82, and HSP104 were upregulated by at least 2-fold. We also observed that 
a subset of ~0.4 % of all quantified proteins including the mitochondrial electron transporter 
Cyc1 and Cdc25 that regulates RasGTPase activity and cAMP cellular levels were 
downregulated following heat shock (Supplementary Table S2-3). We found that approximately 
half of the differentially abundant proteins from our proteomics data were also regulated in 
previous transcriptomics studies [3], and supported the activity of important regulatory 
mechanisms involved in the response to environmental stress. However, the comparison of genes 
regulated upon heat shock with dynamic phosphoproteins identified in our study revealed an 
overlap of only 6% (119/1959), suggesting that phosphorylation dynamics are not necessarily 
correlated with gene transcription and protein expression (Supplementary Table S2-8). These 
results also underline the significance of protein phosphorylation as a primary response to heat 
shock.       
In the present study, we developed a quantitative phosphoproteomics workflow that enabled the 
first large-scale profiling of early signaling events in yeast upon heat shock and cold stress.  The 
ability to monitor changes in protein phosphorylation with high temporal resolution facilitated 
the identification of regulated phosphosites based on the shape of kinetic profiles rather than 
conventional approaches that typically rely on FC measurements. This provided an inherent 
advantage in the identification of sites that displayed small but tractable changes in 
phosphorylation. A temporal resolution of 2 min was selected to minimize the occurrence of 
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minima/maxima between measurements. In a recent study on osmotic shock response in yeast, 
we monitored changes in protein phosphorylation over a one minute period with 5 sec resolution, 
and identified only monotonous profiles [69].  Changes in phosphorylation including those 
associated with adaptation response likely take place over several minutes, and 2 min resolution 
was deemed optimal to detect these changes. The clustering of kinetic profiles enabled the 
grouping of new potential interactions between kinases and putative substrates, to further 
understand the integration of signaling pathways and the response to environmental stress.         
Interestingly, we noted that an intricate network of kinases and phosphatases are rapidly 
activated upon changes in temperature. For example, deactivation of PKA subunit Tpk3 is taking 
place within 5 min upon heat shock and led to a transient dephosphorylation of several 
downstream substrates including Msn2/4 and Rgt1. The dephosphorylation of these transcription 
factors facilitates their nuclear import where they regulate the expression of genes associated to 
stress response element and different glucose transporters. Several other kinases and 
phosphatases displayed different temporal profiles as shown for Cdc28 and Mih1 which 
exhibited progressive and sustained changes in phosphorylation upon cell stimulation. The 
increased phosphorylation of Cdc28 at the inhibitory site Y19 was observed immediately upon 
changes of temperature, and was mirrored by a dephosphorylation of known protein targets 
including Cdc14, Ace2 and Ste20. Several of these substrates play key regulatory roles during 
the progression through the cell cycle. The functional significance of Cdc28 inhibition during 
heat shock was also determined using Cdc28-af mutants where elevated temperatures resulted in 
advanced cell cycle landmarks compared to its wild-type counterpart. These results suggest that 
the reduced Cdc28 activity observed during heat shock response slows down cell cycle 
progression and represents an adaptive response of yeast cells to this environmental stress. 
We also noted that other proteins involved in cell cycle regulation also displayed important 
changes in phosphorylation. For example, Cdc14 is an important phosphatase that antagonizes 
Cdc28 activity during mitotic exit, and phosphorylation of Cdc14 S429 was recently reported to 
inhibit its activity during S phase [70]. During most of the cell cycle, Cdc14 is sequestered in the 
nucleolus where it associates with the Nucleolar silencing Establishing factor and Telophase 
regulator, Net1, also referred to as Cfi1 [71, 72]. In line with this, we identified 9 phosphosites 
on Net1, of which 2 sites (S447, S497) showed kinetic profiles similar to those of Cdc28 
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substrates, consistent with a previous report indicating that dephosphorylation of both Cdc14 and 
Net1 favors their association in the nucleolus [73] . 
Cdc28 is a master regulator of mitotic and meiotic cell cycles and associates with G1 (Clns), S 
and G2/M (Clbs) phase cyclins to direct substrate specificity. Eukaryotic cells rely on positive 
feedback in genetic control networks and cell cycle checkpoints to ensure proper transition 
across cell cycle phases. The start checkpoint corresponds to a short time interval in late G1 
phase during which the yeast commits to division. In this period the G1 cyclin Cln3 associates 
with Cdc28, and activates the transcription of about 200 genes by phosphorylating promoter 
bound protein complexes such as transcription factors Sbf and Mbf1, and the transcriptional 
inhibitor Whi5 [74, 75]. We also observed that several phosphosites on Whi5 (S154, S156, S161) 
displayed kinetic profiles consistent with a decrease in Cdc28 activity, though these sites were 
not predicted by KinomeXplorer. Residues S154 and S156 are located within a nuclear export 
sequence (NES), and their dephosphorylation promote the rapid nuclear translocation of Whi5 to 
inhibit SBF [76]. Furthermore, Srl3 (S212), a Whi5 paralog, also showed a dephosphorylation 
profile at a consensus CDK site that reflected the reduced Cdc28 activity. Altogether, kinetic 
profiles obtained on Cdc28 substrates suggest that heat shock affects cell cycle regulation by 
preventing cells to enter G1/S phase and commit to division.  
Cell response to heat shock and cold stress was also reflected by an uneven distribution of 
dynamic phosphosites largely favoring the former stimulus. The observation that approximately 
20 % of all dynamic phosphosites were observed upon cold stress is consistent with lower 
enzymatic activities and metabolic rates expected in yeast at temperatures below optimal growth 
conditions.  In contrast to heat shock, we only observed a small number of kinases and 
phosphatases that exhibit a change in phosphorylation upon cold stress. Interestingly, we noted a 
1.4-fold increase phosphorylation of Cdc28 at its inhibitory site Y19 during cold stress, but failed 
to observe a corresponding decrease in phosphorylation of Cdc28 substrates. This might suggest 
that a minimum activity threshold is required to detect changes in phosphorylation, or that other 
regulatory mechanisms are involved. It is noteworthy that yeast cells can initiate different 
responses under cold shock conditions (10–18  ̊C) compared to near-freezing temperatures 
(<10  ̊C) [77]. This possibly suggests that yeast can actively grow at 18  ̊C, whereas growth is 
severely impeded at temperatures below 10  ̊C. In spite of the low number of phosphosites 
regulated by the cold response, our quantitative phosphoproteomics analyses revealed that many 
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of these sites were associated with the accumulation of carbohydrate reserves trehalose and 
glycogen. Indeed, we observed several phosphosites on Nth1 (S20, S21, S60, S66, S83), Tsl1 
(S147, S161) and GPH1 (T31) that displayed opposite trends in response to cold and heat, 
possibly suggesting that phosphorylation regulate the activity of the corresponding enzymes to 
control intracellular pools of trehalose and glycogen.  
While the present study provided valuable insights into early signaling events regulating 
biological functions in yeast under heat and cold stresses, we anticipate that improvements in 
both MS sensitivity and metabolic labeling reagents (e.g. neutron-encoded amino acids [78]) will 
further expand phosphoproteome coverage and multiplexing capability of these experiments. The 
identification of putative substrates through the correlation their kinetic profiles with those of 
their corresponding kinases open interesting avenues for the selection of phosphosites of 
functional interest. Appropriate filters are required to select dynamic phosphosites displaying 
low variance and significant temporal changes. In the present study, we used polynomial fitting 
and selected only dynamic profiles with defined distribution (N ≥ 10) and high correlation 
coefficients (R2 > 0.9). Although the stringency of these selection criteria facilitated the selection 
of stimulus-specific profiles, we noted that phosphosites of functional relevance with fewer data 
points or higher variability of abundance can be excluded due to low intensity and/or poor 
ionization efficiency. This was the case for Hsf1 (S608, S655), a heat shock transcription factor 
that exhibits temperature-dependent phosphorylation to initiate transcriptional programs 
associated with heat shock elements (HSE) [79]. Also, the phosphorylation profiles of some 
protein substrates might differ from those of their kinases due to the combined activity of other 
kinases or phosphatases for the same sites. The occurrence of complex phosphorylation profiles 
is time-dependent, and phosphoproteomics experiments taking place over extended time periods 
are more likely to exhibit convoluted kinetic patterns. For example, Sic1 (T5) is a substrate and 
inhibitor of CDC28, and showed a dephosphorylation profile consistent with the change in 
Cdc28 activity for the first 20 min upon heat shock, but its return to basal levels at 28 min 
suggests a more complex regulation.       
This contribution presents the first phosphoproteome dynamic study to investigate the response 
of yeast cells to rapid changes in temperature. Taken together, our data provide one of the most 
comprehensive phosphoproteomics study to identify differentially regulated signaling pathways 
upon heat shock and cold stress, and represent a unique resource to investigate cell biology 
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paradigms associated to the control and regulation of these environmental stresses. We also 
anticipate that the tools and approaches described in this study can be applied to other cell 
stimuli to gain further understanding of the evolution and organization of signaling machineries. 
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2.7 Supplementary material 
 
2.7.1 Supplementary figures 
 
 
Supplementary Figure 2.1. Summary of phosphopeptide identification.  
A total of 1,103,203 distinct MS/MS spectra were identified and assigned to 10,132 unique peptides from 2,344 proteins with a 
FDR < 1%. Phosphopeptides represented 73 % of all identified peptides, and 70% of all phosphosites (9,357) were assigned with 
high confidence (>0.75). A total of 5,554 dynamic profiles (≥ 10 out of 15 data points) were obtained from all high confidence 
assignments. Phosphorylation sites were distributed on Ser (83%) Thr (17%) and Tyr (0.2%) residues. 
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Supplementary Figure 2.2. Pair wise comparison of phosphopeptide abundance.  
The comparison of SILAC ratios (H/L) is shown in a pair wise fashion for all time points corresponding to heat shock treatment. 
Phosphopeptide abundances of all SCX fractions are considered for each time point. R2 values obtained are shown on the top left 
corner of each graph. 
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Supplementary Figure 2.3. Finding regulated kinetic profiles in the dataset.  
In order to define subset of biologically regulated phosphosites, we performed fitting of all kinetic profiles using a polynomial 
model and selected only those with correlation coefficients  (R2) > 0.9 (middle panel). Representative examples of phosphosites 
with R2 > 0.9 and R2 < 0.9 are displayed. 
 
Supplementary Figure 2.4. Amplitude of fold change (FC) for dynamic sites.  
A) From each profile the maximum amplitude (measured as absolute log2-transformed FC was determined over the stimulation 
period. B) Mean values of the maximum amplitude at individual time points showing that dynamic sites displayed higher fold 
change compared to static sites or non phosphorylated peptides. 
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Supplementary Figure 2.5. GO enrichment analysis for phosphoproteins showing dynamic phosphorylation upon heat shock and 
cold stress.  
Gene ontology enrichment analyses were performed using DAVID bioinformatics resources for proteins containing dynamic 
phosphorylation sites using the entire S. cerevisiae proteome as background. –Log[PValue(Benjamini)] correspond to the 
negative log10 of pValue corrected for multiple hypothesis testing using Benjamini criteria. 
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Supplementary Figure 2.6. Dynamic changes in protein phosphorylation on the trehalose -6-phosphate synthase (TPS) complex 
regulatory subunit Tsl1.  
A) Trehalose biosynthesis involves a two step process whereby glucose 6-phosphate plus UDP-glucose are converted to trehalose 
6-phosphate which is then converted to trehalose. Both steps are performed by the trehalose-6-phosphate synthase (TPS) 
complex. B) The yeast TPS complex comprises regulatory (Tsl1, Tps3) and catalytic (Tps1, Tps2) subunits. The Tps1 is 
associated with the conversion of glucose 6-phosphate into trehalose 6-phosphate while Tps2 subunit converts trehalose 6-
phosphate into trehalose.  Regulatory subunits Tps3 and Tsl1 have partially overlapping functions.  C) Phosphorylation profiles 
of sites identified for the regulatory subunits Tsl1 and Tps3 following heat shock and cold stress. 
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Supplementary Figure 2.7. Distribution of dynamic behaviors among putative substrates of different kinase groups.  
We used KinomeXplorer to predict kinase groups associated with the phosphorylation of dynamic phosphosites detected in our 
study. Each panel represent the distribution of substrates for a particular kinase group for each fuzzy cluster (see Fig. 3), colors 
indicate whether the corresponding cluster represents an increase or a decrease in phosphorylation. 
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Supplementary Figure 2.8. Dynamic behavior of Cdc28 substrates.  
An increase phosphorylation of Cdc28 at its inhibitory site Y19 was observed under in response to heat shock. STRING database 
was used to obtain high-confidence Cdc28 interactors among dynamic proteins detected in our study and PhosphoGRID database 
to infer known Cdc28-regulated phosphosites for these interactors. A total of 8 dynamic phosphosites (known substrates) were 
identified in our dataset, and all displayed similar dephosphorylation profiles (red dots). We detected similar dynamic profiles on 
phosphosites from other interactors, which were identified as putative substrates of Cdc28 (yellow dots). 
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Supplementary Figure 2.9. Overlap of dynamic phosphosites with system-wide perturbations of kinases and phosphatases in 
yeast.  
A) Comparison of dynamic phosphosites with those identified in large-scale phosphoproteomics study performed on 116 gene 
deletion mutants of the non essential kinases or phosphatases, and 8 analog-sensitive kinase strains of some essential kinases 
(Bodenmiller et al, 2010).  Approximately 45% of dynamic phosphosites from monophosphorylated peptides (134 phosphosites) 
were also regulated in gene deletion or analog sensitive mutants. B) Distribution of dynamic phosphosites and their associated 
kinases. Majority of dynamic phosphosites are affected by more than one condition and associated with multiple kinases. C) 
Hierarchical clustering of kinases and their dynamic clusters. Heat map corresponds to grouping of individual kinases based on 
the dynamic behavior of the corresponding substrates. 
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Supplementary Figure 2.10. Distribution of dynamic sites within Pin4 structure.  
I-TASSER (Roy et al, 2010) was used to predict the structure of the RNA binding protein Pin4. Dynamic profiles of phosphosites 
are shown in response to heat and cold stresses. Changes in the phosphorylation of Pin4 could mediate its binding to RNA under 
changes of temperature. 
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Supplementary Figure 2.11. Cell cycle profile of cdc28-af mutants growing at physiological temperature.  
Graphs showing the budding index and spindle morphology of CDC28 (top) and cdc28-af cells (bottom) after release from a G1-
arrest into fresh medium at 30 °C. Sample of cells were taken every 15 min to determine the budding index (lines), and 
microtubule morphology (bars) in cultures of CDC28 and cdc28-af cells progressing synchronously into the cell cycle. At least 
100 cells were counted at each time point. 
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2.7.2 Supplementary tables 
 
 
Supplementary Table S 2-1: All phosphopeptide profiles from heat and cold shock treatments 
(DVD-R). 
Supplementary Table S 2-2: Dynamically regulated phosphopeptide profiles from heat and 
cold shock treatments (DVD-R). 
Supplementary Table S 2-3: Protein identifications and quantifications from heat and cold 
shock treatments at 28 minutes. Quantification based on unmodified peptides (DVD-R). 
Supplementary Table S 2-4: Gene Ontology enrichment of proteins containing dynamic 
phosphosites (DVD-R). 
Supplementary Table S 2-5: Overview of the numbers of detected kinases and phosphoatases 
(DVD-R). 
Supplementary Table S 2-6: All phosphosite identification and quantification data from 
treatments with Cdc28 inhibitor (DVD-R). 
Supplementary Table S 2-7: Comparison of data from heat and cold treatments with 
phosphoproteomics results from Bodenmiller et al. (2010) (DVD-R). 
Supplementary Table S 2-8: Comparison of phosphoprotoemics data from heat and cold 
treatments with transcriptomics data from Gasch AP et al. (2000) (DVD-R). 
Supplementary Table S 2-9: MaxQuant parameters and experimental design templates (DVD-
R). 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
2.8 References 
 
1. Verghese, J., et al., Biology of the heat shock response and protein chaperones: budding 
yeast (Saccharomyces cerevisiae) as a model system. Microbiol Mol Biol Rev, 2012. 
76(2): p. 115-58. 
2. Morano, K.A., C.M. Grant, and W.S. Moye-Rowley, The response to heat shock and 
oxidative stress in Saccharomyces cerevisiae. Genetics, 2012. 190(4): p. 1157-95. 
3. Gasch, A.P., et al., Genomic expression programs in the response of yeast cells to 
environmental changes. Mol Biol Cell, 2000. 11(12): p. 4241-57. 
4. Gasch, A.P. and M. Werner-Washburne, The genomics of yeast responses to 
environmental stress and starvation. Funct Integr Genomics, 2002. 2(4-5): p. 181-92. 
5. Kuhl, N.M. and L. Rensing, Heat shock effects on cell cycle progression. Cell Mol Life 
Sci, 2000. 57(3): p. 450-63. 
6. Rowley, A., et al., Heat shock-mediated cell cycle blockage and G1 cyclin expression in 
the yeast Saccharomyces cerevisiae. Mol Cell Biol, 1993. 13(2): p. 1034-41. 
7. Gancedo, J.M., Control of pseudohyphae formation in Saccharomyces cerevisiae. FEMS 
Microbiol Rev, 2001. 25(1): p. 107-23. 
8. Holly, S.P. and K.J. Blumer, PAK-family kinases regulate cell and actin polarization 
throughout the cell cycle of Saccharomyces cerevisiae. J Cell Biol, 1999. 147(4): p. 845-
56. 
9. Raitt, D.C., F. Posas, and H. Saito, Yeast Cdc42 GTPase and Ste20 PAK-like kinase 
regulate Sho1-dependent activation of the Hog1 MAPK pathway. EMBO J, 2000. 19(17): 
p. 4623-31. 
10. Versele, M. and J. Thorner, Septin collar formation in budding yeast requires GTP 
binding and direct phosphorylation by the PAK, Cla4. J Cell Biol, 2004. 164(5): p. 701-
15. 
11. Farrell, A. and D.O. Morgan, Cdc37 promotes the stability of protein kinases Cdc28 and 
Cak1. Mol Cell Biol, 2000. 20(3): p. 749-54. 
12. Hsieh, Y.Y., P.H. Hung, and J.Y. Leu, Hsp90 regulates nongenetic variation in response 
to environmental stress. Mol Cell, 2013. 50(1): p. 82-92. 
13. Aguilera, J., F. Randez-Gil, and J.A. Prieto, Cold response in Saccharomyces cerevisiae: 
new functions for old mechanisms. FEMS Microbiol Rev, 2007. 31(3): p. 327-41. 
14. Los, D.A. and N. Murata, Membrane fluidity and its roles in the perception of 
environmental signals. Biochim Biophys Acta, 2004. 1666(1-2): p. 142-57. 
15. Schade, B., et al., Cold adaptation in budding yeast. Mol Biol Cell, 2004. 15(12): p. 
5492-502. 
16. Panadero, J., et al., A downshift in temperature activates the high osmolarity glycerol 
(HOG) pathway, which determines freeze tolerance in Saccharomyces cerevisiae. J Biol 
Chem, 2006. 281(8): p. 4638-45. 
17. Gruhler, A., et al., Quantitative phosphoproteomics applied to the yeast pheromone 
signaling pathway. Mol Cell Proteomics, 2005. 4(3): p. 310-27. 
18. Smolka, M.B., et al., Proteome-wide identification of in vivo targets of DNA damage 
checkpoint kinases. Proc Natl Acad Sci U S A, 2007. 104(25): p. 10364-9. 
 121 
 
19. Saleem, R.A., et al., Integrated phosphoproteomics analysis of a signaling network 
governing nutrient response and peroxisome induction. Mol Cell Proteomics, 2010. 9(9): 
p. 2076-88. 
20. Bodenmiller, B., et al., Phosphoproteomic analysis reveals interconnected system-wide 
responses to perturbations of kinases and phosphatases in yeast. Sci Signal, 2010. 
3(153): p. rs4. 
21. Holt, L.J., et al., Global analysis of Cdk1 substrate phosphorylation sites provides 
insights into evolution. Science, 2009. 325(5948): p. 1682-6. 
22. de Godoy, L.M., et al., Comprehensive mass-spectrometry-based proteome quantification 
of haploid versus diploid yeast. Nature, 2008. 455(7217): p. 1251-4. 
23. Levy, E.D., S.W. Michnick, and C.R. Landry, Protein abundance is key to distinguish 
promiscuous from functional phosphorylation based on evolutionary information. Philos 
Trans R Soc Lond B Biol Sci, 2012. 367(1602): p. 2594-606. 
24. Ong, S.E. and M. Mann, A practical recipe for stable isotope labeling by amino acids in 
cell culture (SILAC). Nat Protoc, 2006. 1(6): p. 2650-60. 
25. Ratsima, H., et al., Independent modulation of the kinase and polo-box activities of Cdc5 
protein unravels unique roles in the maintenance of genome stability. Proc Natl Acad Sci 
U S A, 2011. 108(43): p. E914-23. 
26. Kanshin, E., S.W. Michnick, and P. Thibault, Displacement of N/Q-rich peptides on TiO2 
beads enhances the depth and coverage of yeast phosphoproteome analyses. J Proteome 
Res, 2013. 12(6): p. 2905-13. 
27. Rappsilber, J., Y. Ishihama, and M. Mann, Stop and go extraction tips for matrix-assisted 
laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in 
proteomics. Anal Chem, 2003. 75(3): p. 663-70. 
28. Ishihama, Y., J. Rappsilber, and M. Mann, Modular stop and go extraction tips with 
stacked disks for parallel and multidimensional Peptide fractionation in proteomics. J 
Proteome Res, 2006. 5(4): p. 988-94. 
29. Cox, J. and M. Mann, MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol, 
2008. 26(12): p. 1367-72. 
30. Cox, J., et al., Andromeda: a peptide search engine integrated into the MaxQuant 
environment. J Proteome Res, 2011. 10(4): p. 1794-805. 
31. Cox, J., A. Michalski, and M. Mann, Software lock mass by two-dimensional 
minimization of peptide mass errors. J Am Soc Mass Spectrom, 2011. 22(8): p. 1373-80. 
32. Nock, R. and F. Nielsen, On weighting clustering. IEEE Trans Pattern Anal Mach Intell, 
2006. 28(8): p. 1223-35. 
33. Kumar, L. and E.F. M, Mfuzz: a software package for soft clustering of microarray data. 
Bioinformation, 2007. 2(1): p. 5-7. 
34. Schwammle, V. and O.N. Jensen, A simple and fast method to determine the parameters 
for fuzzy c-means cluster analysis. Bioinformatics, 2010. 26(22): p. 2841-8. 
35. Horn, H., et al., KinomeXplorer: an integrated platform for kinome biology studies. Nat 
Methods, 2014. 11(6): p. 603-4. 
36. Huang da, W., B.T. Sherman, and R.A. Lempicki, Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009. 4(1): p. 44-57. 
 
122 
37. Huang da, W., B.T. Sherman, and R.A. Lempicki, Bioinformatics enrichment tools: paths 
toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 
2009. 37(1): p. 1-13. 
38. Franceschini, A., et al., STRING v9.1: protein-protein interaction networks, with 
increased coverage and integration. Nucleic Acids Res, 2013. 41(Database issue): p. 
D808-15. 
39. Shannon, P., et al., Cytoscape: a software environment for integrated models of 
biomolecular interaction networks. Genome Res, 2003. 13(11): p. 2498-504. 
40. Cline, M.S., et al., Integration of biological networks and gene expression data using 
Cytoscape. Nat Protoc, 2007. 2(10): p. 2366-82. 
41. Smoot, M.E., et al., Cytoscape 2.8: new features for data integration and network 
visualization. Bioinformatics, 2011. 27(3): p. 431-2. 
42. Robellet, X., et al., A high-sensitivity phospho-switch triggered by Cdk1 governs 
chromosome morphogenesis during cell division. Genes Dev, 2015. 29(4): p. 426-39. 
43. Bilsland-Marchesan, E., et al., Rck2 kinase is a substrate for the osmotic stress-activated 
mitogen-activated protein kinase Hog1. Mol Cell Biol, 2000. 20(11): p. 3887-95. 
44. Ferreira, J.C., J.T. Silva, and A.D. Panek, A regulatory role for TSL1 on trehalose 
synthase activity. Biochem Mol Biol Int, 1996. 38(2): p. 259-65. 
45. Keaton, M.A., et al., Differential susceptibility of yeast S and M phase CDK complexes to 
inhibitory tyrosine phosphorylation. Curr Biol, 2007. 17(14): p. 1181-9. 
46. Stark, C., et al., PhosphoGRID: a database of experimentally verified in vivo protein 
phosphorylation sites from the budding yeast Saccharomyces cerevisiae. Database 
(Oxford), 2010. 2010: p. bap026. 
47. Sadowski, I., et al., The PhosphoGRID Saccharomyces cerevisiae protein 
phosphorylation site database: version 2.0 update. Database (Oxford), 2013. 2013: p. 
bat026. 
48. Jacquet, M., et al., Oscillatory nucleocytoplasmic shuttling of the general stress response 
transcriptional activators Msn2 and Msn4 in Saccharomyces cerevisiae. J Cell Biol, 
2003. 161(3): p. 497-505. 
49. De Wever, V., et al., A dual role for PP1 in shaping the Msn2-dependent transcriptional 
response to glucose starvation. EMBO J, 2005. 24(23): p. 4115-23. 
50. Gorner, W., et al., Acute glucose starvation activates the nuclear localization signal of a 
stress-specific yeast transcription factor. EMBO J, 2002. 21(1-2): p. 135-44. 
51. Budhwar, R., A. Lu, and J.P. Hirsch, Nutrient control of yeast PKA activity involves 
opposing effects on phosphorylation of the Bcy1 regulatory subunit. Mol Biol Cell, 2010. 
21(21): p. 3749-58. 
52. Kim, J.H. and M. Johnston, Two glucose-sensing pathways converge on Rgt1 to regulate 
expression of glucose transporter genes in Saccharomyces cerevisiae. J Biol Chem, 2006. 
281(36): p. 26144-9. 
53. Walkey, C.J., et al., The Saccharomyces cerevisiae fermentation stress response protein 
Igd1p/Yfr017p regulates glycogen levels by inhibiting the glycogen debranching enzyme. 
FEMS Yeast Res, 2011. 11(6): p. 499-508. 
54. Raitt, D.C., et al., The Skn7 response regulator of Saccharomyces cerevisiae interacts 
with Hsf1 in vivo and is required for the induction of heat shock genes by oxidative 
stress. Mol Biol Cell, 2000. 11(7): p. 2335-47. 
 123 
 
55. Urban, J., et al., Sch9 is a major target of TORC1 in Saccharomyces cerevisiae. Mol Cell, 
2007. 26(5): p. 663-74. 
56. Roelants, F.M., P.D. Torrance, and J. Thorner, Differential roles of PDK1- and PDK2-
phosphorylation sites in the yeast AGC kinases Ypk1, Pkc1 and Sch9. Microbiology, 
2004. 150(Pt 10): p. 3289-304. 
57. Ribeiro, M.J., et al., Trehalose synthesis is important for the acquisition of 
thermotolerance in Schizosaccharomyces pombe. Mol Microbiol, 1997. 25(3): p. 571-81. 
58. Lee, J., et al., MAPK Hog1 closes the S. cerevisiae glycerol channel Fps1 by 
phosphorylating and displacing its positive regulators. Genes Dev, 2013. 27(23): p. 
2590-601. 
59. Booher, R.N., R.J. Deshaies, and M.W. Kirschner, Properties of Saccharomyces 
cerevisiae wee1 and its differential regulation of p34CDC28 in response to G1 and G2 
cyclins. EMBO J, 1993. 12(9): p. 3417-26. 
60. Soufi, B., et al., Global analysis of the yeast osmotic stress response by quantitative 
proteomics. Mol Biosyst, 2009. 5(11): p. 1337-46. 
61. Matsuo, R., et al., The yeast eIF4E-associated protein Eap1p attenuates GCN4 
translation upon TOR-inactivation. FEBS Lett, 2005. 579(11): p. 2433-8. 
62. Cosentino, G.P., et al., Eap1p, a novel eukaryotic translation initiation factor 4E-
associated protein in Saccharomyces cerevisiae. Mol Cell Biol, 2000. 20(13): p. 4604-13. 
63. Tang, C.S. and S.I. Reed, Phosphorylation of the septin cdc3 in g1 by the cdc28 kinase is 
essential for efficient septin ring disassembly. Cell Cycle, 2002. 1(1): p. 42-9. 
64. Pike, B.L., et al., Mdt1, a novel Rad53 FHA1 domain-interacting protein, modulates 
DNA damage tolerance and G(2)/M cell cycle progression in Saccharomyces cerevisiae. 
Mol Cell Biol, 2004. 24(7): p. 2779-88. 
65. Krek, W. and E.A. Nigg, Mutations of p34cdc2 phosphorylation sites induce premature 
mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in 
vertebrates. EMBO J, 1991. 10(11): p. 3331-41. 
66. Sorger, P.K. and A.W. Murray, S-Phase Feedback-Control in Budding Yeast Independent 
of Tyrosine Phosphorylation of P34cdc28. Nature, 1992. 355(6358): p. 365-368. 
67. Amon, A., et al., Mechanisms that help the yeast cell cycle clock tick: G2 cyclins 
transcriptionally activate G2 cyclins and repress G1 cyclins. Cell, 1993. 74(6): p. 993-
1007. 
68. Rahal, R. and A. Amon, Mitotic CDKs control the metaphase-anaphase transition and 
trigger spindle elongation. Genes Dev, 2008. 22(11): p. 1534-1548. 
69. Kanshin, E., et al., A cell-signaling network temporally resolves specific versus 
promiscuous phosphorylation. Cell Rep, 2015. 10(7): p. 1202-14. 
70. Li, Y., F.R. Cross, and B.T. Chait, Method for identifying phosphorylated substrates of 
specific cyclin/cyclin-dependent kinase complexes. Proc Natl Acad Sci U S A, 2014. 
111(31): p. 11323-8. 
71. Straight, A.F., et al., Net1, a Sir2-associated nucleolar protein required for rDNA 
silencing and nucleolar integrity. Cell, 1999. 97(2): p. 245-56. 
72. Visintin, R., E.S. Hwang, and A. Amon, Cfi1 prevents premature exit from mitosis by 
anchoring Cdc14 phosphatase in the nucleolus. Nature, 1999. 398(6730): p. 818-23. 
73. Azzam, R., et al., Phosphorylation by cyclin B-Cdk underlies release of mitotic exit 
activator Cdc14 from the nucleolus. Science, 2004. 305(5683): p. 516-9. 
 
124 
74. Jorgensen, P. and M. Tyers, How cells coordinate growth and division. Curr Biol, 2004. 
14(23): p. R1014-27. 
75. Skotheim, J.M., et al., Positive feedback of G1 cyclins ensures coherent cell cycle entry. 
Nature, 2008. 454(7202): p. 291-6. 
76. Costanzo, M., et al., CDK activity antagonizes Whi5, an inhibitor of G1/S transcription in 
yeast. Cell, 2004. 117(7): p. 899-913. 
77. Kandror, O., et al., Yeast adapt to near-freezing temperatures by STRE/Msn2,4-
dependent induction of trehalose synthesis and certain molecular chaperones. Mol Cell, 
2004. 13(6): p. 771-81. 
78. Hebert, A.S., et al., Neutron-encoded mass signatures for multiplexed proteome 
quantification. Nat Methods, 2013. 10(4): p. 332-4. 
79. Sorger, P.K. and H.R. Pelham, Yeast heat shock factor is an essential DNA-binding 
protein that exhibits temperature-dependent phosphorylation. Cell, 1988. 54(6): p. 855-
64. 
 
 125 
 
Chapter 3  
 
Time-resolved phosphoproteome analysis of paradoxical RAF activation reveals 
novel targets of ERK 
 
Peter Kubiniok1,2,#, Hugo Lavoie1,#, Marc Therrien1,3* and Pierre Thibault1,2,4,* 
 
1 Institute for Research in Immunology and Cancer, Université de Montréal, C.P. 6128, 
Succursale centre-ville, Montréal, Québec, H3C 3J7, Canada. 
2 Department of Chemistry, Université de Montréal, C.P. 6128, Succursale centre-ville, 
Montréal, Québec, H3C 3J7, Canada. 
3 Department of Pathology and Cell Biology, Université de Montréal, C.P. 6128, Succursale 
Centre-Ville, Montréal, Québec H3C 3J7, Canada. 
4 Department of Biochemistry, Université de Montréal, C.P. 6128, Succursale centre-ville, 
Montréal, Québec, H3C 3J7, Canada. 
 
# These authors contributed equally to this work 
 
Manuscript: Published (April 2017 in Molecular and Cellular Proteomics, 16(4): 663–679) 
 
 
Authors Contribution 
All authors designed and participated in the study concept. P.K. performed all 
phosphoproteomics experiments after receiving training in cell culturing by H.L., P.K. analyzed 
phosphoproteomics data. All authors interpreted the data, H.L. and P.K. designed follow up 
experiments (In vitro kinase assays, point mutation of phosphorylation sites). P.K. and H.L. 
wrote a first draft of the manuscript which was finalized by P.T. and M.T. together. 
 
 
 
 
126 
3.1 Abstract 
 
Small molecules targeting aberrant RAF activity, like Vemurafenib (PLX4032), are highly 
effective against cancers harboring the V600E BRAF mutation, and are now approved for 
clinical use against metastatic melanoma. However, in tissues showing elevated RAS activity 
and in RAS-mutant tumors, these inhibitors stimulate RAF dimerization, resulting in inhibitor 
resistance and downstream “paradoxical” ERK activation. To understand the global signaling 
response of cancer cells to RAF inhibitors, we profiled the temporal changes of the 
phosphoproteome of two colon cancer cell lines (Colo205 and HCT116) that respond differently 
to Vemurafenib. Comprehensive data mining and filtering identified a total of 37910 
phosphorylation sites, 660 of which were dynamically modulated upon treatment with 
Vemurafenib. We established that 83% of these dynamic phosphorylation sites were modulated 
in accordance with the phospho-ERK profile of the two cell lines. Accordingly, kinase-substrate 
prediction algorithms linked most of these dynamic sites to direct ERK1/2-mediated 
phosphorylation, supporting a low off-target rate for Vemurafenib. Functional classification of 
target proteins indicated the enrichment of known (nuclear pore, transcription factors, RAS-RTK 
signaling) and novel (Rho GTPases signaling, actin cytoskeleton) ERK-controlled functions. Our 
phosphoproteomic data combined with experimental validation established novel dynamic 
connections between ERK signaling and the transcriptional regulators TEAD3 (Hippo pathway), 
MKL1 and MKL2 (Rho-SRF pathway). We also confirm that an ERK docking site found in 
MKL1 is directly antagonized by overlapping actin binding, defining a novel mechanism of 
actin-modulated phosphorylation. Altogether, time-resolved phosphoproteomics further 
documented Vemurafenib selectivity and identified novel ERK downstream substrates.  
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3.2 Introduction 
 
Increased RAS-ERK signaling is critically connected with tumour initiation and progression [1]. 
Canonical pathway activation is initiated at the plasma membrane (PM) where ligand bound to 
receptor tyrosine kinases (RTKs) transduce the signal to enzymes that activate RAS (NRAS, 
KRAS or HRAS) by favouring its GTP loading [2]. Downstream of RAS, the RAF family of 
Ser/Thr kinases comprises three different homologues, ARAF, BRAF and CRAF involved in the 
regulation of the RAS-ERK signaling cascade [1, 3]. In quiescent cells, RAF is kept inactive in 
the cytoplasm in an auto-inhibited complex with 14-3-3 proteins. GTP-bound RAS directly 
associates with the RAF RAS-binding domain (RBD), which recruits RAF to the PM and 
relieves its auto-inhibition [3, 4]. Importantly, RAF activation also relies on the formation of 
homo and heterodimers that allosterically control kinase activity [5]. Upon activation, RAF 
signals downstream to MEK1/2 (MAP2K1/2), which in turn phosphorylates ERK1/2 
(MAPK1/3) proteins leading to the phosphorylation of hundreds of cellular substrates on 
consensus PXS/TP motifs [6].  
RAS and RAF oncogenic mutations render them constitutively active resulting in aberrant 
signaling to downstream effectors. This induces a sustained activation of downstream MEK and 
ERK in a growth factor-independent fashion, a hallmark of cancer cells signaling. The most 
frequent genetic lesions in RAS genes, the mutation of G12, G13 and Q61 residues, lock RAS 
proteins in the GTP-bound active state [2]. Similarly, BRAF mutations like V600E occur in the 
kinase catalytic domain and result in a conformational change rendering BRAF constitutively 
active [7, 8]. RAS mutations are one of the leading causes of cancer irrespective of tissue type 
[9] while BRAF V600E mutations are also found across several tumour types, but are especially 
frequent in melanoma (70%) and thyroid cancers (45%)[10-12]. 
In view of the frequent association of RAF with cancer signaling, several drug discovery 
programs have aimed at blocking its kinase activity [13]. Pharmacological inhibitors targeting 
oncogenic RAF such as the FDA-approved PLX4032 (Vemurafenib, Vectibix or Erbitux) can 
abrogate the activity of V600E mutant BRAF [14-16]. However, wild type (WT) RAF tumours 
bearing RAS mutations or showing elevated RTK signaling give rise to aberrant activation of 
RAF kinases upon RAF inhibitor treatment [17-19]. This undesired effect is caused by a RAS-
dependent increase in RAF dimerization upon inhibitor binding which leads to the so-called 
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“paradoxical” activation of ERK signaling. The molecular basis of this phenomenon is the 
allosteric activation of drug-free RAF by drug-bound protomers across induced dimers [17-20]. 
Several cancer types therefore display poor response to RAF-specific inhibitors. This limits the 
use of ATP-competitive inhibitors like Vemurafenib (PLX4032) to the treatment of melanomas 
carrying the BRAF V600E mutation that have reduced RAS signaling [21]. Cancer cell lines 
(CCLs) derived from RAS- and RAF-mutant tumors thus behave in an opposite manner when 
exposed to RAF inhibitors. Although the “paradoxical” effect of RAF inhibitors is undesired in 
clinical settings, it represents a powerful tool to selectively induce pathway activation without 
the pleiotropic effects typically associated with RTK or phorbol ester stimulations. 
We recently showed that dynamic profiling of phosphoproteomes enabled the identification of 
novel downstream effectors of well-studied signaling pathways with high confidence [22, 23]. 
This type of proteomics analysis facilitated the characterization of biological responses to a 
variety of stimuli like osmotic shock and thermal stress [22-24]. Phosphoproteome dynamics 
provides valuable information on the shape and extent of a biological response to unravel novel 
and unexpected kinase-substrate interactions [22]. In the specific context of the RAS-ERK 
signaling cascade, the identity of ERK substrates and the timing of pathway activation determine 
what biological response will be elicited (proliferation, differentiation, survival) [25]. Systems 
approaches that include treatment kinetics are therefore needed to derive an exhaustive repertoire 
of ERK substrates and to temporally resolve phosphorylation events.  
While phosphoproteome analysis of RAS-ERK pathway blockade has recently been published 
[26], the proteome-wide consequences of “paradoxical” pathway activation have not yet been 
investigated. We posit that a dynamic understanding of this phenomenon could help decipher the 
complex response to RAF inhibitors and yield new insights on RAS-ERK pathway signaling. In 
the present study we report the application of high resolution temporal profiling coupled with 
metabolic labeling [27] to quantify changes in the phosphoproteome of HCT116 and Colo205 
colon cancer cells following Vemurafenib treatment. Altogether, this approach enabled the 
identification of 37,910 phosphorylation sites, of which 660 were dynamically regulated. We 
used this rich dataset to understand the complex response to RAF inhibitors and to identify 
additional signaling nodes that act downstream of ERK.  
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3.3 Materials and methods 
 
3.3.1 Alphascreen® SureFire® p-ERK 1/2 assay 
 
The pERK Alphascreen® SureFire® (Perkin-Elmer; Waltham, MA) was used following 
manufacturer’s instructions for the standard 2 plate assay protocol. For the time course 
experiments, a total of 3x104 cells were plated in 96-well plates, incubated overnight and treated 
with variable concentrations of PLX4032 for 60 minutes or 3.3 µM PLX4032. Treatments were 
performed in biological triplicates. Plates were read on an EnVision plate reader (Perkin-Elmer; 
Waltham, MA). 
 
3.3.2 Cell culturing of HCT116 and Colo205 cell lines 
 
Cell lines were grown in double SILAC SD-Media (Thermo Fisher Scientific, Rockford, IL) 
containing 10%FBS, 164 µM Lysine (K) and 95µM Arginine (R) and 4.3 µM proline (Silantes,  
Munich, Germany) with additional nutrients consistent with Bendall et al.  [28]. Cell plates were 
incubated at 37°C and 5% CO2 in Panasonic incubator. Cells were counted using a Leica 
Microscope with 10x0.25 objectives. 
Approximately 12.5x106 cells were plated in 32 125x25mm petri dishes. Incubation with the Raf 
inhibitor Vemurafenib (PLX4032) (Selleck Chemicals Houston, TX) was performed by adding 
1mL of PLX4032  or DMSO (vehicle) (Sigma Aldrich Co.) diluted in SILAC DMEM /10% FBS 
to reach a final concentration of 3.3µM in each petri dish. Cells were harvested every 5 min 
during the first hour of treatment with either PLX4032 (heavy label) or DMSO (light label). 
Cells were collected by adding 10mL of -80°C pre-cooled ethanol and final scraping. Heavy and 
Light cell pellets were combined in 10mL Falcon tubes. The workflow is shown in Figure 3.1C.  
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Figure 3.1. Experimental design and data analysis workflow for time-resolved phosphoproteome experiments.  
A) Dose-dependent modulation of phospho-ERK1/2 following vemurafenib treatment in Colo205 and HCT116. B) Time course 
analysis of 3.3 µm vemurafenib treatment in Colo205 (top) and HCT116 (bottom) cell lines. C) Workflow of time-resolved 
phosphoproteome profiling. Cells were incubated with 3.3 µm vemurafenib (Heavy) or DMSO (Light) and collected every 5 min 
by mixing in cold ethanol to immediately preserve protein phosphorylation. Cells are centrifuged and lysed under denaturing 
conditions, and extracted proteins are digested with trypsin. Phosphopeptides are purified on TiO2 beads and fractionated off line 
on SCX spin columns prior to LC-MS/MS analyses. Phosphopeptide identification and quantitation are performed using 
MaxQuant, and only kinetic profiles containing at least eight time measurements were selected for further analysis. Polynomial 
fitting was used to define regulated phosphosites, and only phosphopeptide profiles with an FDR of <1% were selected and used 
for fuzzy c-means clustering and subsequent analyses. 
 
3.3.3 Digestion and desalting of cell extracts 
 
Heavy and Light cell pellets from each of the 15 time points were combined in 10mL Falcon 
tubes, separated by centrifugation at 700 rpm (Sorvall Legend RT centrifuge) and washed with 5 
mL PBS. Cell lysis was performed by sonication for 15 seconds with Sonic dismembrator 
(Thermo Fisher Scientific; (Rockford, IL)) after adding 1 mL lysis buffer (8M Urea, 50mM 
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TRIS, pH 8, HALT phosphatase inhibitor from Thermo Fisher Scientific (Rockford, IL)). Cells 
were maintained at 0°C to prevent biological activities. Protein concentration was measured with 
Pierce BCA assay from Thermo Fisher Scientific (Rockford, IL). Protein disulfide bonds were 
reduced by incubating lysates in 5 mM Dithiothreitol (DTT, Sigma-Aldrich, St-Louis, MO) for 
30 minutes at 56°C while shaking at 1000 rpm. Alkylation of cysteine residues was achieved by 
incubating iodoacetamide (IAA, Sigma-Aldrich) at a concentration of 15mM for 30 min at RT in 
the dark. Excess of IAA was deactivated by adding DTT up to 5mM for 15 minutes at room 
temperature. 
All samples were diluted 5 times with 20 mM TRIS (Bioshop Burlington ON), 1mM CaCl, 
pH=8 and mixed with Trypsin (Sigma-Aldrich) (protein: trypsin 50:1 w:w) and incubated for 12 
hours at 37°C. Trypsin stock, containing 2µg/µL Trypsin was kept at -80 °C and thawed only 
once. Desalting was performed in 60 mg SPE reverse phase cartridges (Oasis HLB 3cc cartridge, 
60 mg, 30 µm particle size, Waters Mississauga, ON) previously conditioned with 3mL 
methanol, SPE Buffer (50% ACN, 1% FA) and finally 1% aqueous FA. Peptide samples were 
applied, desalted with 3mL 1% FA, eluted in 1mL SPE buffer and dried on a SpeedVac 
centrifuge (Thermo Fisher Scientific; Rockford, IL) at room temperature. 
 
3.3.4 Phosphopeptide enrichment 
 
Phosphopeptide enrichment was performed on 5µm titansphere bulk particles (Canadian Life 
Science, Peterborough, ON) according to recent protocols [29, 30]. This method provides the 
most efficient enrichment of phosphopeptides. 
 
3.3.5 Offline strong cation exchange chromatography 
 
To achieve high reproducibility and parallel sample fractionation, we used strong cation 
fractionation on homemade SCX spin columns packed with 18-22 mg of polysulfoethyl A (300Å 
Bulk material, Canada Life Science; Peterborough, ON). After equilibrating the SCX spin 
columns with each 100 µL of SCX Buffer A (10% ACN, 0.2%FA), Buffer B (1000 mM NaCl in 
10% ACN, 0.2%FA) and finally 200 µL SCX Buffer A, peptides were resuspended in 100µL 
Buffer A, loaded on the SCX column and eluted in six salt step fractions of 100µL each (0, 30, 
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50, 80, 120 and 500 mM NaCl) in SCX Buffer A. In subsequent analyses, the last salt step 
fraction was not injected as they contained negligible amounts of peptides. Prior to LC-MS/MS 
analyses all fractions were dried on a SpeedVac centrifuge at room temperature (Thermo Fisher 
Scientific) and resuspended in 4% FA. All centrifugation steps were performed at 4°C except 
when indicated. 
 
3.3.6 LC-MS/MS analysis 
 
All LC-MS/MS analyses were performed on a Q-Exactive plus mass spectrometer using a 
homemade capillary LC columns (18 cm length, 150 µm ID, 360 µm OD). Capillary LC 
columns were packed with C18 Jupiter 3µm particles (Phenomenex, Torrance, CA) at 1000 psi. 
Precolumns of 5 mm were packed at 100 psi using the same material. LC separations were 
performed at a flow rate of 0.6 µL/min using a linear gradient of 5-40 % aqueous ACN (0.2% 
FA) in 150 minutes. MS spectra were acquired with a resolution of 70,000 using a lock mass 
(m/z: 445.120025) followed by up to 10 MS/MS data dependent scans on the most intense ions 
using high energy dissociation (HCD). AGC target values for MS and MS/MS scans were set to 
1x106 (max fill time 100 ms) and 5e4 (max fill time 120 ms), respectively. The precursor 
isolation window was set to m/z 1.6 with a HCD normalized collision energy of 24. The dynamic 
exclusion window was set to 30s. 
 
3.3.7 Data processing and analysis 
 
Raw data analysis of SILAC experiments was performed using Maxquant software 1.3.0.5 and 
the Andromeda search engine [31]. The false discovery rate (FDR) for peptide, protein, and site 
identification was set to 1%, the minimum peptide length was set to 6, and the ‘peptide 
requantification’ function was enabled. The option match between runs (3 min time tolerance) 
was enabled to correlate identification and quantitation results across different runs. Up to 2 
missed cleavages per peptide were allowed. To adjust for any systematic quantification errors, 
SILAC ratios were normalized by time point. All additional parameters are reported in 
MaxQuant parameters.txt and experimentalDesign.txt provided in Supplementary Table S3-4. 
The Uniprot human proteome database (January 2014 containing 70584 entries) was used for all 
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searches. Protein groups were formed by MaxQuant, and all identified peptides were used to 
make pair-wise comparison between proteins in the database [31, 32]. Proteins containing an 
equal or overlapping set of peptides were merged together to form a protein group and ranked 
according to the highest number of peptides. All raw LC-MS/MS data and MaxQuant output 
files can be accessed from Peptide Atlas (http://www.peptideatlas.org/) using the identifier 
PASS00897. MaxQuant output files contain lists of all matched and unmatched spectra, all 
matched protein isoforms and peptides including scorings and more detailed information. In 
addition to an FDR of 1% set for peptide, protein and phosphosite identification levels, we used 
additional criteria to increase data quality. We selected only peptides for which abundance ratios 
(FC=PLX4032/Control) were measured in at least 8 out of 13 time points. Then we set a cut-off 
for maximum phosphosite localization confidence across experiments (time points) to 0.75 [33]. 
Next, we distinguished dynamic from static phosphosites by calculating a false discovery rate 
(FDR) based on curve fitting. This was achieved by fitting each profile to a polynomial order 
ranging from 1 to 8, and comparing the resulting profiles with those obtained from the same data 
following 5 rounds of randomization (Supplementary Figure 3.2). The coefficient of 
determination (R2) was calculated for each profile of a given order, and compared against those 
from the randomized dataset. For each polynomial order, dynamic profiles were selected based 
on R2 values below a FDR of 1%. Next, we used fuzzy C-means algorithm to cluster all dynamic 
profiles [34]. Analysis and visualization were performed in the R environment (http://www.r-
project.org/) , clusters were obtained with the Mfuzz package [35]. Optimal setting of the 
“fuzzifier” parameter was 1.235 as estimated with the “mestimate” function. In order to find the 
optimal number of clusters, we performed repeated soft clustering for cluster numbers ranging 
from 2 to 30 and calculated the minimum centroid distance (minimum distance between two 
cluster centers produced by c-means clustering) [36]. Next, we determined the membership value 
of dynamic profiles, and selected only those with values greater or equal to 0.9 for high 
membership profiles.   
Gene Ontology (GO) enrichment analyses were performed using the database DAVID version 
6.7 [37]. Protein interaction networks were defined using the STRING database [38] and 
interacting proteins were visualized with Cytoscape version 2.8.3 [39]. Kinase substrate 
interactions were predicted using NetworKIN and KinomeXplorer [40]. A protein-protein 
interaction network was built in STRING version 9.1 for all proteins containing dynamic 
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phosphosites [38]. All interaction predictions were based on experimental evidences with a 
minimal confidence score of 0.9 (considered as a “highest confidence” filter in STRING). 
Structure rendering was done using PyMol (Schrödinger).  
 
3.3.8 Protein purification and in vitro kinase assays  
 
GST-TEV fusion of human MKL1 (sequence corresponding to accession 3TPQ_M), MKL246-162 
(NP_054767.3) and TEAD31-436 (BC091488.1) were cloned between BamHI and XhoI in a 
pGEX4T1 plasmid engineered with a TEV cleavage site. The resulting plasmids were 
transformed in chimiocompetent E. coli BL21pLys and expression was induced overnight at 
18°C with 1mM IPTG in 500ml of terrific broth (TB). Cells were harvested and lysed by one 
cycle of freeze-thawing on ice in 25 ml of buffer F (10mM Tris-HCl pH7.5, 150mM NaCl, 1mM 
EDTA, 1mM PMSF) supplemented with benzonase (Sigma-Aldrich). Lysates were then 
sonicated four times 10 seconds with a sonicator probe set at 80% power and cleared by 
centrifugation at 4°C for 20 minutes at 40, 000g in a Sorvall SS-34 rotor. The supernatant was 
adjusted to 0.05%Tween20 and incubated with 150 µl Glutathione-sepharose 4B (GE 
Healthcare; Little Chalfont, UK) at 4°C for 4 hours. Glutathione-sepharose column, washed with 
20 bed-volumes of Buffer G (50mM Tris-HCl, pH7.5, 50mM NaCl, 0.1mM CaCl2, 2mM 2-
mercaptoethanol, 0.05% Tween20) and eluted at room temperature in Buffer G with 25mM of 
reduced glutathione (pH was ajusted to 7.5 before elution). Recombinant protein concentration 
was established using the Bradford assay and protein purity was confirmed by SDS-PAGE 
followed by Coomassie staining. Proteins were stored at -80°C in Buffer G supplemented with 
20% glycerol. 
Active ERK was obtained from Carna Bio (Kobe, Japan) (04-143) and purified rabbit muscle 
actin was obtained from Cytoskeleton (AKL99). Actin was resuspended at 10mg/ml in Buffer H 
(5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, 5% sucrose). G-actin was prepared by 
incubation with 50µM Latrunculin B for 1h at room temperature followed by sedimentation of F-
actin in a Sorvall Discovery M150 SE at 100 000g for 1 hour at 4°C. 
In vitro kinase assays were conducted in kinase A buffer (50mM HEPES pH 7.5, 10 mM MgCl2, 
1 mM EGTA, 0.01% Brij-35, 2mM DTT, 1mM PMSF, 1X leupeptin and pepstatin) with 30 ng 
of active ERK and 2 µg of GST fusion protein. When required, the reactions were combined 
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with TEV cleavage of GST fusions by including 3 units of acTEV (Invitrogen; Carlsbad, CA) in 
the kinase reactions. Kinase reactions were initiated by addition of ATP (50µM final) + 5µCi of 
ATP[γ-32P] (Perkin Elmer; Waltham, MA) and were incubated at 37°C for 30min. Reactions 
were stopped at 95 C in the presence of Laemmli sample buffer. Kinase reactions were loaded on 
SDS-PAGE gels, proteins were stained with Coomassie G-250 and gels were finally dried and 
exposed to X-ray films. 
For actin titration experiments, recombinant MKL1 was incubated overnight with different molar 
ratios of G-actin. The protein mixes were then subjected to kinase reaction in the presence of 
ERK2 and ATP as described above. All experiments were performed in biological triplicates and 
only the best western blots are depicted in the corresponding Figures. 
 
3.4 Results 
 
3.4.1 Dynamic changes in the phosphoproteome following Vemurafenib treatment  
 
For this study, we chose two colon cancer cell lines that display elevated ERK signaling due to 
different genetic lesions. Colo205 cells harbor a BRAF V600E mutation but are otherwise WT 
for RAS, while HCT116 cells contain a KRAS G13D mutation but are WT for RAF [41]. These 
cell lines are widely used in the cancer research community and respond differently to RAF 
inhibitors. Indeed, phospho-ERK1/2 (pERK) is inhibited in Colo205 cells following incubation 
with RAF inhibitor while it is induced in HCT116 cells [20, 42]. We profiled the change in 
ERK1/2 activation for different concentration of the RAF inhibitor Vemurafenib, and determined 
that a concentration of 3.3 µM induced an 8-fold increase of pERK in HCT116 cells (Figure 
3.1A). In contrast, the same concentration resulted in full pERK inhibition in Colo205 cells 
(Figure 3.1A). Time course measurements showed that the pERK response to Vemurafenib 
treatment was maximal after 20 min in both cell lines (Figure 3.1B).  
To evaluate the downstream effects of this response, we monitored the global change in the 
phosphoproteome of both cell lines over a period of 60 min post stimulation with a temporal 
resolution of 5 min (Figure 3.1C). We used stable isotope labeling with amino acids in cell 
culture (SILAC) [43] where control (DMSO vehicle) and stimulated cells (3.3 µM Vemurafenib) 
were cultured in dialyzed FBS for more than 10 doublings with Light and Heavy Lys and Arg 
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amino acids (see material and methods for 
additional details). Cells from each time point 
were harvested, rinsed with PBS, snap frozen in 
precooled ethanol at -80°C, and then combined in 
equal amounts. Prior to MS analyses, cell 
suspensions were washed with PBS to remove 
ethanol, lysed in urea, and proteins were reduced, 
alkylated and subsequently digested with trypsin. 
Phosphopeptides were enriched using TiO2 
microcolumns and fractionated off line into 6 
SCX salt fractions prior to LC-MS/MS analysis. 
Phosphopeptide identification and quantification 
was performed using MaxQuant and processed in 
R (http://www.r-project.org/) to cluster 
phosphopeptide profiles and determine regulated 
phosphorylation sites.  
These analyses enabled the identification of 
28,711 and 20,931 phosphopeptides (localization 
confidence ≥ 75%) for HCT116 and Colo205 
cells, respectively. In total, we identified 37,910 
unique phosphopeptides, of which 10,300 were 
quantified across more than 8 time points 
(Supplementary Figure 3.1). To profile the global 
changes in the phosphoproteome, we determined 
the fold change (FC) in phosphopeptide 
abundance for the first hour after incubation with 
Vemurafenib (Figure 3.2A). 
Figure 3.2. Phosphoproteome-wide effect of RAF inhibitors in HCT116 and Colo205 colon cancer cells.  
A) Distribution of FC for dynamic sites of a given time point is represented by the IQR and is used to determine the global 
changes in phosphorylation upon inhibitor treatment. B) Phosphopeptides exhibited a progressive increase in IQR with time, 
reflecting the global effects of vemurafenib on the phosphoproteome. Notably, incubation of HCT116 cells with vemurafenib 
produced more pronounced effects compared with those observed for Colo205 cells. The distribution of FC for non-
phosphorylated peptides remained largely unaffected for both cell types. C) 660 phosphopeptides showed time-dependent 
changes in abundance and clustered into four groups. 
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To define regulated phosphosites in the dataset, we first selected phosphopeptides quantified in 
more than 8 time points and performed fitting of all kinetic profiles with a polynomial model. 
Next, we distinguished dynamic from static phosphosites by calculating a false discovery rate 
(FDR) based on curve fitting. This was achieved by fitting each profile to a polynomial order 
ranging from 1 to 8, and comparing the resulting profiles with those obtained from the same data 
following 5 rounds of randomization (Supplementary Figure 3.2). The coefficient of 
determination (R2) was calculated for each profile of a given order, and compared against those 
from the randomized dataset. For each polynomial order, dynamic profiles were selected based 
on R2 values below a FDR of 1%, and prevented over fitting profiles to high polynomial order. 
Accordingly, these analyses identified 660 dynamic phosphopeptide profiles out of 10,300 
profiles for polynomial order ≤ 4 (Supplementary Table S3-1). These dynamic profiles formed 
four distinct clusters according to the Mfuzz algorithm [35], and were either up-regulated or 
down-regulated and showed an early or a late response (Figure 3.2C). From the 660 dynamic 
profiles, we selected only those that have membership values equal or greater than 0.9, which 
resulted in 220 “high membership” profiles (Supplementary Table S3-2).  
Dynamic data show progressive broadening of FC values observed for both cell lines with a 
gradual shift in the median distribution toward a decrease or an increase in phosphorylation for 
Colo205 and HCT116, respectively. The width of this distribution was calculated from the 
interquartile range (IQR) for the log2(FC) distribution of phosphopeptides at each time point and 
plotted over the entire cell stimulation period (Figure 3.2B). The resulting curve showed a 
progressive and linear increase in the phosphopeptides fold-change IQR with time, a trend that 
was markedly different from non-phosphorylated peptides which remained largely unaffected 
over the same time period (Figure 3.2B). Also, changes in protein phosphorylation were more 
pronounced for HCT116 compared to Colo205 as reflected from the variation of IQR with time. 
Interestingly, we observed a steady increase in IQR values during the first hour although 
phospho-ERK1/2 activation levels reached a maximum after 20 min post stimulation (Figure 
3.1B). 
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3.4.2 RAS-ERK pathway modulation accounts for most dynamic phosphoproteome changes 
induced by Vemurafenib  
 
Profiles within the “high-membership” dataset were used to contrast the response of the two cell 
lines, and to predict kinase activities following Vemurafenib inhibition. The grouping of profiles 
from both cell types identified five pairs of profiles with distinct patterns (Figure 3.3A). 
 
Figure 3.3. Phosphoproteome of HCT116 and Colo205 shows an opposite response to vemurafenib treatment.  
A) Pairwise comparison of phosphopeptide profiles for HCT116 and Colo205 cell lines highlighting the most significant trends 
observed. The majority of observed dynamic phosphorylation events follow ERK-like regulation (groups 1–3). B) Core members 
of the RAS-ERK pathway (MEK and ERK) as well as downstream effectors (ETV3) show opposite regulation in each cell line. 
Singly phosphorylated ETV3_S245 decreases in abundance upon ERK activation due to an overall hyperphosphorylation of the 
doubly phosphorylated form of ETV3_S245/S250. C) Putative kinases associated with dynamic and static phosphosites based on 
NetworKIN predictions and KinaseXplorer grouping. Substrates for each kinase group are represented by bar graphs. 
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The first group is represented by opposite temporal changes in the two cell lines, and correspond 
to 33 down-regulated phosphosites identified in Colo205, and 32 were up-regulated in HCT116 
(Figure 3.3A). The second and most populated group comprised 124 phosphopeptides up-
regulated in HCT116, and were either not identified (92) or showed a static behavior in Colo205 
(32) (Figure 3.3A). The third group corresponds to a more limited number of phosphopeptides 
that were dephosphorylated in Colo205 but were either not identified (24) or remained static in 
HCT116 (2) (Figure 3.3A). Groups 4 and 5 are discussed below. 
The first three groups shown in Figure 3.3A represent 83% of the “high-membership” sites, and 
are directly or indirectly associated with RAS-ERK pathway activation (Figure 3.3A; ERK-like 
profiles). Consistent with this proposal, phosphopeptides comprising MEK2 (MAP2K2) and 
ERK1 (MAPK3) activation sites were clustered in groups 1 and 2, respectively (Figures 3.3A 
and 3.3B). A large proportion of dynamic phosphorylation sites thus behaved in accordance to 
the RAS-ERK pathway response whereby up-regulated phosphopeptides were largely dominated 
by profiles identified in HCT116 cells (156/165), while down-regulated phosphopeptides were 
mostly found in Colo205 (59/88). Also, the majority of the 220 dynamic phosphorylation sites of 
our “high-membership” dataset comprised proline-directed phosphorylation motifs (148/220), a 
hallmark of ERK-mediated events [6]. 
However, we noted that several sites of the “high membership” dataset were not fulfilling the 
ERK consensus motif, and could represent secondary or tertiary events occurring within the 
highly inter-connected kinase-substrate network downstream of ERK. To predict which kinase-
substrate relationships were responsible for dynamic phosphorylation events in our dataset, we 
used the bioinformatic tool KinomeXplorer [40], a platform based on an improved NetworKIN 
algorithm that model kinase signaling networks by combining linear motif analysis with protein-
protein interactions. The corresponding analysis is shown in Figure 3.3C where kinase groups 
are clustered according to KinomeXplorer. This analysis confirmed that a substantial enrichment 
of dynamic phosphorylation sites are predicted to be ERK-mediated (Figure 3.3C). In addition, 
putative substrates of JNK and p38 comprised a proline-directed consensus motif, and formed  a 
subset of the dynamic sites (Figure 3.3C). This analysis also indicated that our “high-
membership” dataset contained putative PKB, GSK3, PAK, CK1 and p70S6K substrates. 
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Interestingly, two AGC kinases (PKB and p70S6K) share a RXRXXS/T consensus motif with 
known ERK downstream effectors of the RSK family (p90RSK or RPS6KA)[44]. Concurrently, 
the RSK paralogs RPS6KA1, 3 and 4 were dynamically modulated on ERK-dependent sites in 
our dataset (Supplementary Table S3-1), and therefore, several dynamic phosphorylation on 
RXRXXS/T sites are likely to be secondary events associated with RSK proteins. Supporting this 
idea, several known RSK-modulated phosphosites (PDCD4_S457, BAD_S75, TBC1D4_S588) 
were identified in our dataset (Supplementary Tables S3-1 and S3-2) [45-47].  
A small subset of 28 sites in HCT116 and 9 sites in Colo205 from our “high-membership” 
dataset did not correlate with pERK response and could potentially represent off-target events 
(Figure 3.3A; groups 4 and 5). A closer examination of these data revealed that several sites are 
located on peptides that contained multiply phosphorylated forms. The modulation of these 
phosphopeptides with a kinetic profile inconsistent with ERK activation/inhibition status are 
explained in part by the processivity of phosphotransfer whereby we observed an increase in the 
abundance of the multiphosphorylated peptides while the singly phosphorylated form decreased 
in abundance. The overall level of phosphorylation of a given peptide can therefore increase 
despite the fact that the monophosphorylated form disappeared over time. A case in point is 
ETV3 whose phosphorylation on S245 rapidly decreased while the doubly phosphorylated form 
(S245/S250) increased during the same time period in HCT116 (Figure 3.3B). It is noteworthy 
that 23 phosphopeptides from group 4 are singly-phosphorylated on a proline-directed motif, of 
which 13 contained a second putative proline-directed phosphorylation site (Supplementary 
Table S3-3). Altogether, these observations support the notion that most activity associated with 
Vemurafenib treatment corresponds to on-target effects with a limited number of secondary and 
tertiary signaling events associated with downstream ERK-modulated substrates. These 
observations are consistent with a recent phosphoproteomics study comparing RAF and MEK 
inhibitors activity [26]. 
 
3.4.3 Time-resolved phosphoproteome profiling identifies new ERK substrates  
 
Our analysis established that dynamic phosphorylation sites were mostly associated with the 
regulation of the RAS-ERK pathway. We next wanted to exploit the kinetic information in our 
dataset in order to identify novel high-affinity downstream substrates of ERK. We posit that the 
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clustering of phosphopeptides as “Early” or “Late” could reflect ERK-substrate affinities. To 
perform this analysis, we grouped all high-membership phosphorylation sites from clusters 
“Early Down” and “Early Up” in both cancer cell lines and searched for ERK1/2 physical 
interactions with cognate proteins using the STRING databases [48]. This network was 
complemented with information on known and predicted ERK substrates derived from the 
BioGRID database [49] and the NetworKIN algorithm [50] respectively. This enabled the 
identification of 22 uncharacterized interactions between ERK and putative Early substrates 
(Figure 3.4; red and yellow nodes). The similarity of these putative ERK-mediated kinetic 
profiles was displayed as the average change in phosphorylation over time (Figure 3.4, top right).  
 
Figure 3.4. ERK substrate network modulated upon vemurafenib treatment (Refer to next page for figure legend).  
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Legend of Figure 3.4: 
STRING was used to obtain high confidence ERK1/2 interactors among proteins with dynamic phosphosites. This was 
complemented with known ERK1/2-regulated sites reported in BioGRID. Dynamic phosphosites were found in known 
interacting proteins (red dots, StringDB), in predicted direct interactors (yellow dots, Networkin algorithm), or in validated ERK 
substrates (green dots, BioGRID interaction database). Nodes represented in this high confidence ERK substrate network display 
similar dynamic behaviors upon vemurafenib treatment (top right, shaded area across averaged profile represents 95% confidence 
interval). 
 
We complemented this interaction-based analysis with predictions of docking motifs to 
determine if ERK selectivity and processivity was also influenced by sequence motifs present in 
the corresponding substrates. We used ScanProsite [51] to identify KIM- (D-motif; variable 
consensus) [6] and DEF-motifs (F-X-F-P) [52] within 50 amino-acid distance of the high-
membership ERK phosphorylation sites (Figure 3.4; blue dots)( Supplementary Figure 3.3A). 
We observed an enrichment of KIM- and DEF-motif consensus sequences in our dynamic set 
compared to static phosphoproteins although only a small subset of sequences (13) comprised 
these docking sites. Furthermore, six high-membership HCT116 phosphorylation sites that 
contained a docking motif were grouped in the Early cluster (Supplementary Figure 3.3B). In 
contrast, KIM or DEF-containing proteins were distributed in both Early and Late clusters in 
Colo205 cells (Supplementary Figure 3.3B). This result is not entirely unexpected since 
dephosphorylation of ERK substrates in Colo205 does not solely rely on ERK-substrate affinity 
but also on phosphatase-substrate interactions. Interestingly, the average kinetic profiles of Early 
phosphosites with KIM or DEF motifs showed a more rapid change in phosphorylation 
compared to those that did not contain these motifs (Supplementary Figure 3.3C). Examples of 
phosphosites for substrates with and without KIM or DEF motifs are shown in Supplementary 
Figures 3.3 D and 3.3E. It is noteworthy that bioinformatic searches for sequence determinants 
other than KIM- and DEF-motifs failed to identify relevant linear motifs in our datasets that 
could play a role in ERK-substrate interactions (data not shown). 
 
3.4.4 Time-resolved phosphoproteome analysis identifies novel biological functions connected 
with RAS-ERK signaling 
 
To decipher which cellular functions were regulated upon RAS-ERK pathway modulation by 
Vemurafenib we performed standard Gene Ontology (GO) enrichment analysis of our high-
membership and dynamic datasets using DAVID [37, 53]. These analyses indicated the 
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enrichment of genes associated with “RAS/RTK signaling”, “regulation of Rho signal 
transduction”, “kinases/phosphatases” and “actin cytoskeleton organization” (Table 3.1). The 
dynamic gene set yielded similar GO term enrichment but also included the functional groups 
related to the regulation of “cell death/apoptosis”, “mRNA transport/nuclear pore” and “RNA 
splicing” (Table 3.1). Although several of these GO terms were previously shown to connect 
with the RAS-ERK pathway, such as “mRNA transport/nuclear pore” [54], our analysis 
identified other less usual connections between ERK and “actin cytoskeleton organization” and 
“regulation of Rho signal transduction”. We used GO terms enriched in our dataset (Table 3.1) 
combined with manual curation of gene lists to derive a systems level view of these novel RAS-
ERK pathway connections (Figure 3.5).  
 
Table 3.1. Gene Ontology terms (Biological Function) enriched amongst phosphorylated proteins that show time-dependent 
modulation after Vemurafenib treatment.  
Comparison of the MFuzz “high-membership” dataset (Clustering Membership ≥ 0.9, total of 220 phosphorylation profiles) and 
“dynamic” dataset (Clustering Membership ≥ 0.0, total of 660 phosphorylation profiles) is shown. 
Gene	Ontology	Term	
pValue	
Mem≥0.9	
pValue	
Mem≥0.0	
RTK-Ras	signaling	 9.82*10-3	 6.62*10-5	
Regulation	of	Rho	signal	
transduction	 9.40*10-3	 4.28*10-7	
mRNA	transport	/	Nuclear	pore	 NA	 3.94*10-3	
RNA	splicing	 NA	 1.00*10-3	
Kinases	/	phosphatases	 8.29*10-3	 7.52*10-4	
Actin	cytoskeleton	organization	 9.29*10-3	 2.33*10-8	
Regulation	of	cell	death	 NA	 7.78*10-5	
 
 
These analyses revealed that several phosphosites occurred upstream of RAF and may represent 
negative feedback loops. Among those, we identified the time-dependent modulation of S642 in 
CRAF (RAF1) C-terminal tail, a target site of activated ERK involved in desensitizing CRAF to 
additional stimuli [55]. Upstream factors of canonical RTK-RAS signaling (RTKs ERBB2 and 
EGFR and the RAS-GEF SOS1) as well as the insulin receptor (InsR) signaling pathway 
(IRS1/2, GIGYF1/2) were also phosphorylated at proline-directed sites. Similarly, scaffolding 
proteins of the RAS-ERK cascade (GRB10, PXN and CNKSR1) were dynamically 
phosphorylated in response to Vemurafenib treatment (Figure 3.5). Interestingly, several of these 
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putative feedback sites were modulated early after Vemurafenib treatment, suggesting that 
phosphorylation of these sites is concurrent with the phosphorylation of downstream ERK 
effectors.  
 
Our data also identified the modulation of bona fide signaling effectors of the RAS-ERK 
pathway such as RSK (RPS6KA1, 3 and 4) and p70-S6K (PRS6KB2) (Figure 3.5). Consistent 
with earlier reports [56], our phosphoproteomics study identified the phosphorylation by ERK of 
RPS6KA1 (S363, S732 and T573) and RPS6KB2 (S423) (Figure 3.5).  
 
Figure 3.5. Depiction of RAS-ERK signaling pathway and primary and secondary connections to substrates identified by time-
resolved phosphoproteome profiling. Primary and secondary targets dynamically modulated upon vemurafenib treatment.  
Main functional groups depicted are “RPS6 kinases,” “RTK signaling,” actin cytoskeleton organization, nuclear pore, and 
“transcription”. Key players of actin cytoskeleton regulation, including Rho GEF's and GAP's, are emphasized. The Hippo 
pathway target, YAP1, acts together with TEAD factors (here TEAD3) to control transcription at promoters containing M-CAT 
elements. TCF and MKL1/2 assemble with SRF on promoters comprising serum response elements (SREs). The MKL1/2 
regulators LMO7 and FLNA/B included putative RSK (RPS6A) phosphosites that were dynamically modulated after 
vemurafenib treatment. 
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We also noted that Vemurafenib affected potential crosstalks with other signaling pathways. For 
example, several adaptor proteins of cAMP-dependent protein kinase (PKA) (AKAP1, 2, 11, 12 
and 13) were dynamically phosphorylated on ERK target sites (Supplementary Figure 3.5) [57]. 
Another possible crosstalk identified by our analysis involved GO terms “Rho signaling” and 
“actin cytoskeleton organization”, which were amongst the main regulons modulated in response 
to Vemurafenib treatment. Several Rho GAPs (ARHGAP35, 12 and 29) and Rho GEFs 
(ARHGEF11, 12, 13 18, TRIO, TRIOBP, DOCK5 and EPS8L2) were dynamically modulated 
on ERK motifs (Figures 3.5A and B). We noted that the previously reported ERK target site 
T212 was concomitantly modulated in the Rho/Rac/CDC42 downstream effector PAK1 [58]. 
Several proteins involved in actin polymerization were also dynamically phosphorylated after 
Vemurafenib treatment (e.g. CTTN, CTTNBP2, FLNA and FLNB).  
The phosphorylation of nuclear pore complex (NPC) subunits by ERK was reported in an earlier 
phosphoproteomic study [54]. Here, we identified the dynamic phosphorylation of NUP50, 
NUP107, NUP153, NUP188 and TPR and RANBP2 (Figures 3.5-3.6 and Supplementary Table 
S3-1). These proteins participate in several sub-structures of the nuclear pore and have distinct 
functions during translocation of biomolecules across the pore. ERK-dependent phosphorylation 
of NPC proteins was shown to affect the individual properties of the subunits. For instance, 
NUP50 phosphorylation on ERK sites located within FG repeats regulates its interaction with 
importin-beta and transportin [54]. Similarly, mutation of ERK sites in TPR resulted in cell cycle 
defects associated with the failure to recruit MAD1/2 to the NPC [59].  
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Figure 3.6. Kinetic profiles of selected phosphosites upon incubation with 3.3 µm vemurafenib and in vitro kinase assays.  
Kinetic profiles are shown for selected phosphosites from RPS6 kinases, protein substrates from actin cytoskeleton organization, 
and transcription. In vitro kinase assays with radiolabeled ATP to confirm the direct phosphorylation of TEAD3_S148, 
MKL1_S33, and MKL2_S77 by recombinant active ERK2 (bottom right) are shown. In vitro phosphorylation of MKL1 using 
recombinant active ERK2 in the presence of ERK, MEK, or RAF inhibitors confirmed the site-specific phosphorylation of 
MKL1 by ERK (bottom right). 
 
ERK activation is necessary for its migration into the nucleus where it phosphorylates specific 
regulatory proteins and transcription factors (TFs) to initiate transcription of immediate-early 
genes [60-62]. Accordingly, quantitative phosphoproteomics identified several known TFs 
phosphorylated by ERK such as ETV3_S245/S250, ERF_S531, JUND_S90/S255 and 
STAT3_S727 [63, 64] as well as putative substrates such as FOXP4_S554, TP53BP1_S366 and 
TEAD3_S148 (Figures 3.5-3.6). TEAD3 participates in the Hippo tumor-suppressor pathway, 
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which controls organ size and cell death. This pathway culminates in the phosphorylation and 
inactivation of the transcriptional co-activator YAP1, which itself relies on DNA-binding 
adaptors of the TEAD family to mediate a complex transcriptional response [65]. YAP1_S61 is a 
bona fide substrate of the Hippo pathway kinase LATS1 [66], and was found upregulated only in 
Colo205 cells. In contrast, TEAD3_S148, a proline-directed site, showed an increase in 
phosphorylation upon vemurafenib treatment only in HCT116 cells. Mammalian TEAD proteins 
(TEAD1-4) share a common domain architecture consisting of a TEA DNA-binding domain and 
a YAP1-interacting region [67]. TEAD3_S148 is located in the linker region between these two 
conserved portions of the protein. In order to assess direct phosphorylation of this site by ERK, 
we performed in vitro kinase assays. While WT TEAD3 was phosphorylated in the presence of 
active ERK2, 32P incorporation was completely abrogated with TEAD3 S148A variant (Figure 
3.6). This establishes a direct connection between RAS-ERK signaling and the Hippo pathway 
transcription factor TEAD3. 
Among the transcription factors dynamically modulated upon Vemurafenib treatment, our 
attention was also attracted by the presence of megakaryoblastic leukemia 1 (MKL1) and 2 
(MKL2). These were phosphorylated on S33 and S77 respectively; two orthologous phosphosites 
that comprise an upstream KIM-motif and that were not previously characterized (Figure 3.4 and 
Figure 3.5). Although these sites were not identified as ERK substrates based on STRING 
interactions, a previous report suggested the direct phosphorylation of MKL1_S454 by ERK as 
part of a negative feedback mechanism [68]. Interestingly, our phosphoproteomic analyses 
revealed the rapid phosphorylation of MKL1_S33 and MKL2_S77 upon Vemurafenib treatment 
while MKL1_S454 remained unchanged (Figure 3.6 and Supplementary Figure 3.4). Further 
experimental validation was obtained using in vitro kinase assays. GST-MKL fusion substrates 
were incubated with active ERK in the presence of radiolabeled ATP. In vitro reactions 
confirmed that active ERK specifically phosphorylated MKL1_S33 and MKL2_S77 since 32P 
incorporation was abrogated in S33A and S77A mutant proteins (Figure 3.6).  
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3.4.5 MKL1 S33 defines a novel actin-dependent mechanism that modulates kinase-substrate 
interactions 
 
Megakaryoblastic leukemia transcription factors MKL1/2 were grouped under the GO function 
“actin cytoskeleton organization”, a term being highly enriched in our dataset. These proteins act 
as actin-dependent transcriptional coactivators of the serum-response factor (SRF), a known 
transcriptional regulatory hub acting downstream of the RAS-ERK pathway [69]. In resting cells, 
MKL1 transit between the nucleus and the cytosol, and its localization was reported to depend on 
the availability and binding of globular actin (G-actin) to RPEL motifs. In serum-starved 
conditions, MKL1 is bound to G-Actin and sequestered in the cytoplasm but is rapidly 
translocated to the nucleus in conditions that favor the polymerization of actin and the formation 
of stress fibers [70-73]. Structural analyses of MKL1-Actin interaction revealed that RPEL 
motifs and the two intervening spacers can each bind a G-actin monomer, forming a compact 
assembly of five G-actins with one MKL1 RPEL repeat [74-76] (Figure 3.7A).  
Close inspection of MKL1 crystal structures revealed that KIM residues overlap with the G-actin 
binding site found in RPEL1 (Figures 3.7A and 3.7B, green)[71, 73]. Furthermore, MKL1 S33 is 
tightly packed against the second G-actin molecule that interacts with the linker connecting 
RPEL1 and RPEL2 (Figure 3.7A, yellow).  
Based on these observations, we posit that the binding of G-actin to RPEL1 domain of MKL1 
(Green) might control the access of ERK to the conserved KIM motif, thereby affecting the 
phosphorylation of MKL1 S33 (Figure 3.7C). Also, MKL1 S33 must be released from the 
second G-actin subunit (yellow) to facilitate its phosphorylation by ERK. To validate this 
proposal, we performed in vitro kinase assays on recombinant MKL1 harboring KIM-motif 
mutants R5A/R6A and L9A/L11A or RPEL1 mutant R16A/R17A (Figure 3.7D). These analyses 
confirmed that MKL1 phosphorylation by ERK was abrogated for the R5A/R6A and L9A/L11A 
MKL1 mutants, suggesting that the KIM motif is necessary for docking onto ERK to facilitate 
MKL1 S33 phosphorylation. In contrast, the R16A/R17A double mutant known to affect MKL1 
binding to G-actin [74], did not affect ERK-dependent phosphorylation of S33 (Figure 3.7D).  
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Figure 3.7. Phosphorylation of MKL1 is modulated by globular actin binding.  
A) Structural representation of MKL1 (ribbon) with actin (surface) showing occlusion of MKL1 KIM motif and Ser-33 residue 
by G-actin. Protein Data Bank accession 3TPQ was used for structure rendering (76). B) Schematic representation of a model 
whereby actin binding to MKL1 prevents phosphorylation of MKL1 Ser-33 by ERK1/2. C) Sequence alignment of MKL1 
showing the conservation of KIM motif and Ser-33 across species. Residue Ser-33 is located between the first two RPEL repeats 
required for monomeric actin binding. The putative kinase-interaction motif (KIM) for ERK as well as the actin-binding region 
of the first RPEL motif are also highlighted. D) In vitro kinase assays of wild type and alanine mutant GST-TEV-MKL1 with 
recombinant active ERK2. Mutation of residues Arg-5 and Lys-6 or Leu-9 and Leu-11 within the KIM motif is sufficient to 
prevent phosphorylation of Ser-33 by ERK2. E) In vitro phosphorylation assay of wild type and alanine mutant MKL1 in 
presence of recombinant active ERK2 and variable amounts of actin. Phosphorylation of MKL1_S33 by ERK2 is impeded at 
elevated actin concentrations (8:1 and 16:1 molar ratios), whereas the phosphorylation of R16A/R17A mutant MKL1 is resistant 
to actin titration. 
 
To determine whether G-actin binding to MKL1 could affect its phosphorylation by ERK, we 
pre-incubated WT MKL1 overnight with various concentrations of G-actin, and performed in 
vitro ERK kinase assays (Figure 3.7E). These experiments revealed that phosphorylation of 
MKL1 was only observed at low G-actin concentration, suggesting that excess actin shielded 
MKL1 S33 and prevented its phosphorylation by ERK (Figure 3.7E, left panel). To rule out a 
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possible non-specific interaction due to protein crowding in the kinase assay, we conducted the 
same in vitro kinase assay using the MKL1 R16A/R17A double mutant (Figure 3.7E, right 
panel). In contrast to WT MKL1, the R16A/R17A double mutant was fully phosphorylated 
irrespective of G-actin concentration. These experiments support the notion that actin binding to 
MKL1 prevents S33 phosphorylation by ERK, and suggest an interplay between actin dynamics 
and MKL phosphorylation. In the course of preparing this manuscript, consistent findings were 
published by the group of Richard Treisman who validated S33 phosphorylation by ERK as well 
as the importance of the upstream KIM motif and the role of globular actin binding in blocking 
phosphorylation at this site [77]. However, we note that residue numbering differed between this 
publication (S98) and ours (S33) since different mRNA isoforms were used as references (S33 
numbering corresponds to MKL1 isoform X1 (XP_016884377)). 
 
3.5 Discussion 
 
Mass spectrometry combined with metabolic labeling (e.g. SILAC) enabled the quantification of 
phosphoproteins on a systems-wide scale. The temporal profiling of protein phosphorylation 
facilitated the identification of RAS-ERK pathway substrates and secondary events in two colon 
cancer cell lines that respond differently to the RAF inhibitor Vemurafenib. By taking advantage 
of the opposite response to RAF inhibitors, our experimental strategy provided a quantitative 
view of ERK signaling dynamics without the pleiotropic effects of growth factors, serum or 
phorbol esters that can give rise to pathway crosstalks. Our quantitative phosphoproteomic 
analyses revealed that Vemurafenib has low off-target activity on kinases other than RAF or on 
phosphatases. This observation is consistent with a recent study comparing the proteome-wide 
effects of BRAF and MEK inhibitors when used alone or in combination [26].  
The use of targeted RAF stimulation in combination with time resolved phosphoproteomics 
facilitated the deconvolution of early and late phosphorylation events, and associated 
downstream and upstream targets of ERK. Our analysis suggests that predicted direct ERK 
substrates (i.e. containing a proline-directed site) are in general rapidly phosphorylated upon 
RAF induction, as evidenced by the early phosphorylation of p90RSK proteins RPS6KA1 and 
RPS6KA3. A rapid induction was also observed for other well-known substrates such as nuclear 
pore complex subunits and transcription factors (e.g. ETV3, JUND, ERF). Rapid kinetics was 
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also observed for uncharacterized ERK downstream targets like several Rho GEFs and Rho 
GAPs. Nonetheless, bona fide ERK target sites were also associated with late events (e.g. 
STAT3, NUP188 and RPS6KA4). Therefore, substrate phosphorylation kinetics alone cannot 
distinguish direct from indirect ERK targets. Kinetic differences might however be explained by 
distinctive molecular features such as linear motifs (DEF- and KIM-motifs), three-dimensional 
structure elements, quaternary complexes formation and cellular co-localization that could 
account for changes in kinase–substrate affinities.  
In addition to ERK targets, our study provided insights into the dynamic changes in 
phosphorylation of secondary events such as the phosphorylation of several RSK substrates. 
Interestingly, several known (TBC1D4, BAD, PDCD4) and predicted (FLNA and FLNB) RSK 
target sites, were identified as late events in our dynamic phosphoproteomic dataset 
(Supplementary Table S3-1 and S3-2). This observation is consistent with the view that RSK-
dependent signaling events are subsequent to and thus downstream of ERK signaling. Although 
this will require more data, and analysis, it is likely that time-resolved phopshoproteomics will 
allow epistatic analysis of cell signaling networks. 
Dynamic phosphoproteomics identified several known (e.g. STAT3, ETV3, ERF, JUND) and 
putative ERK substrates (e.g. TEAD3, TAF6, TCF12, FOXK2, FOXP4) involved in 
transcriptional regulation. In particular, we demonstrated for the first time that the transcription 
factor TEAD3 is directly phosphorylated by ERK at S148 in the linker region between TEA 
DNA-binding domain and YAP1-interacting region [67]. Our results are thus consistent with the 
presence of crosstalk between the RAS-ERK and the Hippo pathway that would implicate TEAD 
transcription factors. The phosphorylation of TEAD3 at S148 could modulate its interaction to 
DNA and/or to YAP1 either alone or through the recruitment of other binding partners. YAP1 is 
a downstream regulatory target in the Hippo signaling pathway and its binding to TEAD 
transcription factors is required to stimulate the expression of genes involved in tissue 
homeostasis [78]. Interestingly, a recent genetic screen in BRAF-mutant tumor cells identified 
YAP1 as a survival input mediating RAF and MEK inhibitors resistance in melanoma [79]. This, 
together with other evidence [80, 81] suggests a crosstalk between the Hippo and RAS-ERK 
pathways. The role of TEAD3 phosphorylation on S148 in this crosstalk would deserve to be 
investigated. 
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Our study also identified the RPEL motif of megakaryoblastic leukemia (MKL) transcription 
factors as putative ERK substrates. Using in vitro kinase assays we demonstrated that ERK 
directly phosphorylates MKL1_S33 and MKL2_S77 in the linker region between RPEL1 and 
RPEL2 domains. The phosphorylation of this orthologous site in both proteins relies on a 
canonical ERK KIM-motif that was only recently identified [77]. Our analysis showed that this 
motif facilitates the binding of ERK to MKL1 and enhance its phosphorylation. We also 
confirmed that accessibility to this KIM motif and to S33 is modulated by G-actin binding to the 
MKL1 RPEL repeats, consistent with results described in Panayitou et al. [77]. On the basis of 
these results, we proposed a novel mode of kinase-substrate regulation whereby G-actin binding 
can mask the docking and phosphorylation of MKL1/2 by ERK. Alternatively, unbound MKL1/2 
can be more readily phosphorylated by ERK when actin dynamics is shifted to the formation of 
filaments. It will be interesting to determine if actin-dependent regulation of phosphosites applies 
more widely to other kinase-substrate pairs. Conversely, it was shown by gel filtration that S33 
phosphorylation has an impact on the stoichiometry of actin binding by MKL1 RPEL motifs 
(S98 in Panayotou et al. 2016). Indeed, the WT protein binds to three molecules of actin while 
the phosphomimetic mutant binds to two actin molecules [77]. This result implicated ERK-
dependent phosphorylation in the regulation of MKL1 nucleocytoplasmic shuttling by globular 
actin, whereby a reduction in actin binding upon S33 phosphorylation promotes nuclear import 
[77]. 
Interestingly, our analysis identified several Rho regulators presumably phosphorylated by ERK 
upon Vemurafenib treatment (ARHGAPs and ARHGEFs). It is unclear if these phosphorylation 
events in ARHGAPs and ARHGEFs affect their activity and downstream Rho activation status. 
Nevertheless, it is possible that these factors indirectly impinge on MKL1/2 activity by 
modulating the balance between globular and filamentous actin. Our analysis additionally 
identified LMO7 and FLNA as potential RSK substrates. These are two recently reported 
regulators of MKL1, further reinforcing the role of ERK in MKL1/2-dependent transcriptional 
control. LMO7 was shown to relieve actin-mediated repression of MKL while a recent study 
indicated that FLNA directly interacts with MKL1 [82, 83]. 
It is noteworthy that unlike another study conducted by Muehlich et al. [68], our data do not 
provide evidence for feedback phosphorylation sites T450 and S454 on MKL1/2 upon specific 
RAF-MEK-ERK activation. This might be explained either by the different stimulation periods 
 153 
 
(e.g. 0-60 minutes of Vemurafenib treatment vs. up to 3 h by Muehlich et al.) or by the different 
stimulus used to trigger activation of the pathway. For instance, serum stimulation used by 
Muehlich et al. triggers a pleiotropic response that includes RAS and Rho activation while 
Vemurafenib acts specifically downstream of RAS to selectively turn on the RAF-MEK-ERK 
signaling pathway. Alternatively, feedback phosphorylation of MKL1 may require elevated ERK 
activation, which might not be achieved when paradoxical activation of the pathway is induced 
by Vemurafenib.  
The novel link we and Panayiotou et al. (2016) established between ERK signaling and MKL1//2 
regulation suggest that at least two ERK outputs converge on cofactors of serum-response factor 
(SRF) (Figure 3.5). The first one targets ETS-family proteins (e.g. ETV3 and ERF, identified in 
this study), together known as ternary complex factors (TCFs) that associate with SRF-bound 
promoters and are well-known ERK substrates [84]. The second one consists of MKL1/2 
transcriptional co-activators. We thus suggest that TCFs might act in conjunction with an 
MKL1/2 axis downstream of ERK to modulate the transcription of SRF-bound elements (SREs; 
CArG) in promoters (Figure 3.5). This possible crosstalk between RAS-ERK and Rho-actin-
MKL-SRF signaling is interesting on at least two accounts. Firstly, RAF mutations (BRAF or 
CRAF) are found in Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFC) that 
belong to a group of syndromes called RASopathies but also in childhood-onset dilated 
cardiomyopathy. The clinical presentation of patients afflicted with these syndromes includes 
cardiac defects often associated with heart hypertrophy, which is also recapitulated in mouse 
models of NS [85, 86]. Myocardin family transcription factors including Myocardin itself 
(MYOCD), MKL1 and MKL2 are known to regulate a SRF-dependent transcriptional program 
involved in heart development [87-91]. It is thus possible that this RAS-ERK-MKL1/2 signaling 
axis contributes to some of the clinical manifestations observed in RASopathies. Secondly, 
several lines of evidence tie Rho signaling [92], MKL1 and SRF-dependent transcription with 
epithelial-mesenchymal transition (EMT) and metastasis [93]. The Rho-MKL1-SRF axis may 
therefore crosstalk with RAS-ERK signaling to modulate cancer cells invasiveness. 
We anticipate that the global profiling of phosphorylation dynamics in response to cell stimuli 
will provide the foundation for the deconvolution of the cellular phosphoregulatory network. 
Phosphokinetic experiments such as those described here will also provide an important resource 
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to further rationalize direct/indirect interactions and off-target effects between substrates and 
their putative kinases. 
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3.7 Supplementary material 
 
3.7.1 Supplementary figures 
 
 
Supplementary Figure 3.1. Summary of phosphopeptide identification. 
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Supplementary Figure 3.2. Selection of dynamic phosphopeptide profiles using polynomial fitting.  
Each profile was randomized 5 times and fitted with a polynomial of order 1-8. Original data were concomitantly fitted and the 
distribution for each polynomial (randomized vs. original data) was used to determine an FDR threshold. FDR of 1% was chosen 
at which a threshold of different R2 values for different polynoms are obtained. Finally, data were filtered by requiring that a 
given profile is fitted better than the R2 value of the threshold for each polynomial (order 1-5). 
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Supplementary Figure 3.3. Detection of ERK substrates that contain KIM and DEF docking sites.  
A) Relative enrichment of KIM and DEF motifs among static and dynamic phosphosites. B) Distribution of KIM and DEF motifs 
across all four dynamic cluster groups. C) Averaged kinetic profiles of “early” phosphosites with and without KIM/DEF motifs. 
Profiles are separated according to up or down regulation. Phosphorylation on phosphosites in close proximity to KIM/DEF 
motifs generally responds quicker. D) Examples of phosphosites for substrates with and without KIM or DEF motifs. Substrates 
harboring KIM or DEF motifs tend to be phosphorylated more rapidly. E) List of all phosphosites with KIM/DEF motifs. 
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Supplementary Figure 3.4. MS verification showing that MKL1_T450/S454 phosphorylation is not changing over time.  
A) Observed profile of MKL1_T450/S454 phosphorylation in HCT116. B) MaxQuant viewer showing the SILAC pair of the 
MKL1_T450/S454 peptide in the LC-chromatogram. C) Full MS spectra of the MKL1_T450/S454 SILAC pair close to the top 
of the elution peak. D) MS/MS verification of the MKL1_T450/S454 phosphopeptide. 
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Supplementary Figure 3.5. ERK activity is regulating key cellular functions.  
A) A subset of phosphosites dynamically modulated upon Vemurafenib treatment are involved in “PKA/cAMP signaling”, 
“protein phosphatase complexes”, “TOR signaling”, “microtubules”, “protein sorting”, “apoptosis” and “translation”. B) Kinetic 
profiles of representative substrates involved in “cAMP-dependent protein kinase (PKA) regulation” and in “protein phosphatase 
complexes” (STRN4). 
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3.7.2 Supplementary tables 
 
Supplementary Table S 3-1: List of all identified phosphopeptide profiles (DVD-R). 
Supplementary Table S 3-2: List of high membership dynamic phosphopeptide profiles (DVD-
R). 
Supplementary Table S 3-3: Phosphopeptides from group 4 with proline-directed 
phosphorylation motif (DVD-R). 
Supplementary Table S 3-4: Maxquant parameters and experimental design (DVD-R). 
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4.1 Abstract 
 
The anti-neoplastic sphingolipid analog SH-BC-893 starves cancer cells to death by down-
regulating cell surface nutrient transporters and blocking lysosomal trafficking events. These 
effects are mediated by the activation of protein phosphatase 2A (PP2A). To identify putative 
PP2A substrates, we used quantitative phosphoproteomics to profile the temporal changes in 
protein phosphorylation in FL5.12 cells following incubation with SH-BC-893 or the specific 
PP2A inhibitor LB-100. These analyses enabled the profiling of more than 15,000 
phosphorylation sites, of which 958 sites on 644 proteins were dynamically regulated. We 
identified 114 putative PP2A substrates including several nutrient transporter proteins, GTPase 
regulators (e.g. Agap2, Git1), and proteins associated with actin cytoskeletal remodeling (e.g. 
Vim, Pxn). To identify SH-BC-893-induced cell signaling events that disrupt lysosomal 
trafficking, we compared phosphorylation profiles in cells treated with SH-BC-893 or C2-
ceramide, a non-vacuolating sphingolipid that does not impair lysosomal fusion. These analyses 
combined with functional assays uncovered the differential regulation of Akt and Gsk3b by SH-
BC-893 (vacuolating) and C2-ceramide (non-vacuolating). Dynamic phosphoproteomics of cells 
treated with compounds affecting PP2A activity thus enabled the correlation of cell signaling 
with phenotypes to rationalize their mode of action. 
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4.2 Introduction 
 
Oncogenic mutations selected during the tumorigenic process rewire the metabolic circuitry to 
meet the increased anabolic demands of cancer cells. Because oncogenic mutations constitutively 
drive growth and proliferation, cancer cells depend on a steady influx of nutrients via cell surface 
transporters and receptors and on the lysosomal degradation of internalized macromolecules into 
subunits that can be used for biosynthesis and/or the production of ATP [1]. Because cancer cells 
are constitutively anabolic, they are unable to tolerate nutrient stress that causes quiescence and 
catabolism in normal cells.  Restricting nutrient access using sphingolipid-inspired compounds is 
an appealing therapeutic strategy to impede cancer cell proliferation and survival. Previous 
reports indicated that endogenous and synthetic sphingolipids starve many different cancer cell 
types to death by triggering the down regulation of multiple nutrient transporter proteins and/or 
blocking lysosomal fusion reactions [2-7].  
 
In mammalian cells, ceramides can function as tumor suppressors, mediating signaling events 
associated with apoptosis, autophagic responses and cell cycle arrest [8]. Several sphingolipids 
activate protein phosphatase 2A (PP2A) and negatively regulate multiple signaling pathways that 
promote nutrient transporter expression [5, 9-13]. Although the mechanism underlying 
sphingolipid regulation of PP2A activity is not entirely clear, previous reports suggest that 
ceramides can  bind to endogenous protein inhibitors of PP2A to enhance its catalytic activity 
[13].  Interestingly, while Fingolimod (FTY720, Gilenya), pyrrolidine analogs such as SH-BC-
893, and ceramide all induce nutrient transporter down-regulation downstream of PP2A 
activation, only FTY720 and SH-BC-893 produce PP2A-dependent cytoplasmic vacuolation [5]. 
Ceramide, on the other hand, produces distinct effects from FTY720 and SH-BC-893 on the 
tubular recycling endosome, although whether these effects are PP2A-dependent is less certain 
[5, 14]. These observations suggest that these structurally-related molecules differentially 
activate PP2A, resulting in distinct patterns of dephosphorylation and different endolysosomal 
trafficking phenotypes.  
 
To determine how PP2A activity induces nutrient transporter loss and cytosolic vacuolation, we 
profiled the dynamic changes in protein phosphorylation in the murine prolymphocytic cell line 
FL5.12 following incubation with SH-BC-893, the specific PP2A inhibitor LB-100, or C2-
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ceramide. Metabolic labeling and quantitative phosphoproteomics [15-17] identified kinetic 
profiles that could be correlated with putative PP2A substrates. This approach identified 15,607 
phosphorylation sites, of which 958 were dynamically regulated by the treatments. While 265 
putative PP2A sites were common to both PP2A agonists, our analyses also revealed 467 sites 
uniquely regulated by either SH-BC-893 or C2-ceramide that provided further insights into the 
SH-BC-893-specific phenotype, vacuolation.    
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4.3 Materials and methods 
 
 
4.3.1 Cell culture  
 
FL5.12 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine 
serum (FBS), 10 mM HEPES buffer, 55 µM 2-mercaptoethanol, 2 mM L-glutamine, 500 pg/mL 
murine recombinant IL-3, and antibiotics.  HeLa cells were cultured in DMEM with 4.5 g/L 
glucose and L-glutamine supplemented with 10% FBS and antibiotics. For proteomic analyses 
FL5.12 cells were grown in triple SILAC SD-Media (Thermo Fisher Scientific, Rockford, IL) 
containing 10% FBS, 500 pg/mL murine recombinant IL-3, 164 µM Lysine (K), 95 µM Arginine 
(R), 4.3 µM proline (Silantes,  Munich, Germany) with additional nutrients consistent with 
Bendall et al. [18]. Cells were incubated at 37°C and 5% CO2. Cells were counted using a Leica 
microscope with a 10 x 0.25 objective. Approximately 500 million cells per SILAC channel were 
grown in 500 mL spinner flasks. Incubation with small molecules was performed by adding 1 
mL of small molecule or DMSO (Sigma Aldrich Co.) diluted in SILAC RPMI 1640/10% FBS to 
reach the final concentration. Cells were harvested every 5 min during the first hour of treatment 
with either 5 µM SH-BC-893 (heavy label) or 50uM C2-ceramide (medium label) or 10 µM LB-
100 (medium label) or DMSO (light label). Drug concentrations used for treatments are based on 
previously published references [5, 7, 19]. Cells were collected by pipetting 75 mL (25 mL per 
SILAC channel) of culture into 425 mL of -80°C pre-cooled ethanol.   
 
4.3.2 Flow cytometry 
 
For quantification of cell surface CD98, 400,000 FL5.12 cells were stained with either PE-
conjugated rat IgG2a k isotype control (Biolegend, cat. no. 400508) or PE-conjugated rat anti-
mouse CD98 (Biolegend, cat. no. 128208) in blocking buffer (PBS with 10% FBS and 0.05% 
sodium azide) for 30 min on ice.  Cells were washed twice in ice-cold wash buffer (PBS with 2% 
FCS and 0.05% sodium azide), resuspended in wash buffer containing 1 µg/mL DAPI, and 
returned to ice.  Analysis was restricted to live cells (DAPI-negative) and data normalized to the 
untreated control after background subtraction. 
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4.3.3 Vacuolation assay 
 
 Vacuoles were quantified as in Perryman et al. [20]. Briefly, FL5.12 cells were treated as 
indicated for 3 h then pelleted by centrifuging at 2,000 rpm for 3 min in a microfuge. The cell 
pellet was resuspended in 10 µL, and 3 µL of the cell suspension was examined under a 0.13 to 
0.17 mm thick coverglass (VWR Micro cover glass, square, No.1, cat. no. 48366-045) on a 
microscope slide.  FL5.12 cells were evaluated by differential interference microscopy (DIC) 
using a 100x oil-immersion objective with a Nikon TE2000-S fluorescence microscope.  To 
calculate the vacuolation score, at least 10 different fields of view containing 5-12 cells per field 
were assessed.  Scores were assigned to individual cells as follows: 0 = no vacuoles, 1 = very 
small vacuoles, 2 = multiple well-defined vacuoles, 3 = multiple large vacuoles.  To calculate the 
vacuolation score, the following formula was used: 
 score = 3×%	cells	in	cat. 3 + 2×%	cells	in	cat. 2 + 1×%	cells	in	cat. 13  
 
4.3.4 Fluorescence microscopy 
 
To monitor F-actin, FL5.12 cells were fixed with 4% paraformaldehyde for 10 min, washed, and 
incubated in permeabilization and blocking buffer (PBS with 10% FBS, 0.3% saponin, and 
0.05% sodium azide) containing Alexa Fluor 488 conjugated phalloidin (Cell Signalling 
Technologies, 1:100 dilution).  Cells were then imaged on a Nikon Eclipse Ti spinning-disk 
confocal microscope using a 100x oil-immersion objective.  Images were analyzed using ImageJ; 
fluorescence intensity was normalized between all images and displayed using the LUT “16 
colors.”   
 
4.3.5 Immunoblotting 
 
Cells were lysed in RIPA buffer containing protease (Pierce, Cat #88265) and phosphatase 
inhibitors (Sigma, Cat #4906845001). Protein concentration was quantified using a BCA protein 
assay (Thermo Scientific, Cat #23223). Samples were prepared in NuPAGE sample buffer 
(Invitrogen, Cat #NP0007) and 50 mM DTT, run on Invitrogen NuPAGE 4-12% Bis-Tris gels 
 
172 
(Cat #NP0336BOX), and transferred to BioTrace NT nitrocellulose membranes (Pall, Cat 
#66485). After transfer, membranes were dried at room temperature for 30 min, incubated in 
blocking solution (5% bovine serum albumin, 0.05% NaN3 in TBST) for 1 h, and then incubated 
overnight at 4°C in blocking solution containing primary antibody. Blots were washed three 
times in TBST (TBS with 0.1% Tween 20), incubated at RT for 1 h in blocking solution 
containing IRDye-conjugated secondary antibodies (1:10,000), and then washed three times in 
TBST. Blots were imaged using a LI-COR Odyssey CLx imaging system. 
 
4.3.6 Digestion and desalting of cell extracts 
 
Heavy, medium and light cells from each time point were combined in 500 mL collection tubes 
(Sorvall centrifuge bottles), separated by centrifugation at 1,200 rpm (Sorvall Legend RT 
centrifuge) and washed first with 35 mL PBS, then 5 mL PBS, and finally 3 times with 1 mL 
PBS while transferring from 500 mL collection tubes to 50 mL falcon tubes to 1.7mL Eppendorf 
tubes, respectively. Cell lysis was performed by sonication for 15 seconds with a sonic 
dismembrator (Thermo Fisher Scientific; Rockford, IL) after adding 1 mL lysis buffer (8M Urea, 
50mM TRIS, pH 8, HALT phosphatase inhibitor (Thermo Fisher Scientific). Cells were 
maintained at 0°C to prevent protein degradation. Protein concentration was measured by BCA 
assay (Thermo Fisher Scientific). Protein disulfide bonds were reduced by incubating lysates in 5 
mM dithiothreitol (DTT, Sigma-Aldrich, St-Louis, MO) for 30 min at 56°C while shaking at 
1,000 rpm. Alkylation of cysteine residues was achieved by incubation with iodoacetamide 
(IAA, Sigma-Aldrich) at a concentration of 15 mM for 30 min at RT in the dark. Excess IAA 
was quenched for 15 min at RT by adding DTT to 5 mM. All samples were diluted 5 times with 
20 mM TRIS (Bioshop Burlington ON), 1 mM CaCl2, pH 8 and mixed with 2 µg/µL trypsin 
(Sigma-Aldrich) (protein: trypsin 50:1 w:w) and incubated for 12 h at 37°C. Trypsin was kept at 
-80 °C and thawed only once. Desalting was performed on 60 mg solid phase extraction (SPE) 
reverse phase cartridges (Oasis HLB 3cc cartridge, 60 mg, 30 µm particle size, Waters 
Mississauga, ON) previously conditioned with 3 mL methanol, SPE Buffer (50% acetonitrile, 
ACN, 1% formic acid, FA) and finally with 1% aqueous FA. Peptide samples were loaded, 
washed with 3 mL 1% FA, eluted in 1 mL SPE buffer and dried on a vacuum centrifuge (Thermo 
Fisher Scientific) at RT. 
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4.3.7 Phosphopeptide enrichment 
 
 Phosphopeptide enrichment was performed on 5 µm titansphere particles (Canadian Life 
Science, Peterborough, ON) according to published protocols [21, 22]. Loading of protein 
extracts on the titansphere beads, washing, and elution steps were performed using custom spin 
columns [23] made from 200 µl pipette tip containing a SDB-XC membrane (Empore, 3M) frit 
and filled with TiO2 beads. Peptides were desalted in 50 µL of 1% FA and subsequently eluted 
from spin columns using 50 µL of 50% ACN 0.5% FA.  
 
4.3.8 Offline strong cation exchange chromatography 
 
To achieve high reproducibility and parallel sample fractionation in high throughput proteomics 
experiments, we used strong cation fractionation (SCX) on homemade spin columns packed with 
18 to 22 mg (for cell lysate of 3 to 8 mg protein extract) of polysulfoethyl A 300Å particle, 
(Canada Life Science; Peterborough, ON). After equilibrating the SCX particles with each 100 
µL of SCX Buffer A (10% ACN/0.2%FA v/v), Buffer B (1 M NaCl in 10% ACN/0.2%FA v/v) 
and finally 200 µL SCX Buffer A. Peptides were resuspended in 100 µL Buffer A, loaded on the 
SCX column and eluted in six salt step fractions of 100 µL each with 0, 30, 50, 80, 120 and 500 
mM NaCl in SCX Buffer A. Prior to LC-MS/MS analyses all fractions were dried on a 
SpeedVac centrifuge at RT (Thermo Fisher Scientific) and resuspended in 4% FA. All 
centrifugation steps were performed at 4°C except where indicated. 
4.3.9 Mass spectrometry analysis  
 
LC-MS/MS analyses were performed on a Q-Exactive HF (SH-BC-893 vs. C2-ceramide 
experiments) or an Orbitrap tribrid Fusion (SH-BC-893 vs. LB-100 experiments) mass 
spectrometer using homemade capillary LC columns (18 cm length, 150 µm ID, 360 µm OD). 
Capillary LC columns were packed with C18 Jupiter 3 µm particles (Phenomenex, Torrance, 
CA) at 1,000 psi. Samples were directly injected on LC-columns and separations were performed 
at a flow rate of 0.6 µL/min using a linear gradient of 5-35 % aqueous ACN (0.2% FA) in 150 
minutes. MS spectra were acquired with a resolution of 60,000 using a lock mass (m/z: 
445.120025) followed by up to 20 MS/MS data dependent scans on the most intense ions using 
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high energy dissociation (HCD). AGC target values for MS and MS/MS scans were set to 1x106 
(max fill time 100 ms) and 5x105 (max fill time 200 ms), respectively. The precursor isolation 
window was set to m/z 1.6 with a HCD normalized collision energy of 25. The dynamic 
exclusion window was set to 20 s.  
 
4.3.10 Data processing and analysis  
 
Raw data analysis of SILAC experiments was performed using Maxquant software 1.5.3.8 and 
the Andromeda search engine [24]. The false discovery rate (FDR) for peptide, protein, and site 
identification was set to 1%, the minimum peptide length was set to 6, and the ‘peptide 
requantification’ function was enabled. The option match between runs (2 min time tolerance) 
was enabled to correlate identification and quantitation results across different runs. Up to 2 
missed cleavages per peptide were allowed. To adjust for any systematic quantification errors, 
SILAC ratios were normalized by time point. All additional parameters are reported in 
MaxQuant parameters.txt and experimentalDesign.txt provided in Supplementary Table S4-1. 
The Uniprot mouse proteome database (September 2015 containing 35,281 entries) was used for 
all searches. Protein groups were formed by MaxQuant, and all identified peptides were used to 
make pair-wise comparison between proteins in the database. Proteins containing an equal or 
overlapping set of peptides were merged together to form a protein group and ranked according 
to the highest number of peptides.  
 
All raw LC-MS/MS data and MaxQuant output files can be accessed from PeptideAtlas 
Consortium via the FileZilla partner repository which can be accessed at the following location 
ftp://PASS01168:VH7449z@ftp.peptideatlas.org/ with the following password “VH7449z” and 
identifier “PASS01168”. MaxQuant output files contain lists of all matched and unmatched 
spectra, all matched protein isoforms and peptides including scorings and more detailed 
information. In addition to an FDR of 1% set for peptide, protein and phosphosite identification 
levels, we used additional criteria to increase data quality. The Andromeda score threshold for 
the identification of phosphopeptides was set to 40 with a delta score to the second best match of 
8, as optimized by Sharma K et a. (PMID 25159151). We selected only peptides for which 
abundance ratios (FC=Drug/Control) were measured in at least 6 time points. Then we set a cut-
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off for maximum phosphosite localization confidence across experiments (time points) to 0.75. 
Next, we distinguished dynamic from static phosphosites by calculating an FDR based on curve 
fitting as recently described [17]. We further performed clustering analysis using the fuzzy 
means package [25] which is implemented to the R environment (https://cran.r-project.org/).  
 
Gene Ontology (GO) enrichment analyses were performed using the database DAVID version 
6.7 [26]. Protein interaction networks were defined using the STRING database and interacting 
proteins were visualized with Cytoscape version 2.8. A protein-protein interaction network was 
built in STRING version 9.1 for all proteins containing dynamic phosphosites. All interaction 
predictions were based on experimental evidences with a minimal confidence score of 0.7 
(considered as a “high confidence” filter in STRING). Linear motif analysis was done using 
Motif-x [27, 28]. 
 
4.4 Experimental Design and Statistical Rationale 
 
For time resolved phosphoproteomics experiments, FL5.12 cells were collected from one large 
cell culture (500mL) per SILAC channel. Time course experiments (SH-BC-893 and LB-100; 
SH-BC-893 and C2-ceramide) were conducted on different days. Sample processing for each 
time course experiment was performed in parallel and from the same batch of materials and 
chemicals to maximize reproducibility of peptide digestion, phosphopeptide enrichment and 
fractionation. All time points of each SCX fraction were consecutively loaded onto the LC-MS 
system to ensure similar peptide coverage for all time points. SCX fractions were injected with 
increasing salt concentration. All data were analyzed using the same FASTA file (Uniprot Mouse 
proteome, accessed September 2015, 35,281 entries) and MaxQuant version 1.5.8.3. 
 
Microscopy experiments (e.g., phalloidin staining in Fig. 4.7A-C, vacuolation images in Fig. 
4.1C, 4.7E, and 4.8A,C-E) were completed in 2-3 biological replicates performed on separate 
days to account for biological variation. Microscopy images representative of the >100 cells per 
condition per biological replicate were used in figures. For quantitation of cytoplasmic 
vacuolation (Fig. 4.8A,C-E), at least 400 cells per condition from three biological replicates were 
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performed and error bars show the 95% confidence interval.  Statistical significance was 
evaluated with a Student’s t test (two-tailed, paired), as described in each figure legend.   
 
For flow cytometry experiments quantifying the surface levels of CD98 (Fig. 4.1B and 4.7D), at 
least three biological replicates were performed on different days to account for biological 
variation. Surface CD98 levels are normalized to vehicle within each experiment, and the 
normalized values are averaged. Variation is shown as standard error of the mean and statistical 
significance was assessed by Student’s t test (two-tailed, paired), as described in the figure 
legends. 
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4.5 Results 
 
 
4.5.1 SH-BC-893 and C2-ceramide produce distinct, PP2A-dependent alterations in 
endolysosomal trafficking 
  
The synthetic sphingolipid SH-BC-893 is a structurally constrained analog of FTY720 (also 
known as Fingolimod) that fails to activate S1P receptors 1 or 3 yet retains anticancer properties 
[20, 29, 30]. Both SH-BC-893 and C2-ceramide (N-Acetyl-sphingosine, Figure 4.1A) suppress 
cell growth and survival in part by down-regulating nutrient transporter proteins through the 
activation of the cytosolic serine/threonine protein phosphatase PP2A [5, 7, 14, 29]. The cell 
surface antigen 4F2 heavy chain (solute carrier family 3 member 2, Slc3a2 or CD98) is a 
chaperone required for the surface expression of several associated light chains that transport 
amino-acids [31]. Incubation with either 2.5 µM SH-BC-893 or 50 µM C2-ceramide resulted in a 
40% down regulation of 4F2hc that was reversed by the selective PP2A inhibitor LB-100 (Figure 
4.1B). These observations are consistent with published studies in multiple cell types [5, 7, 14, 
20, 29]. In addition to limiting cell surface CD98 expression, SH-BC-893, but not ceramide, 
prevented the fusion of endocytic vesicles and autophagosomes with lysosomes resulting in 
enlarged multivesicular bodies, MVB [5]; LB-100 reversed this effect (Figure. 4.1C). These 
results confirm that disruptions in endolysosomal trafficking that starve cancer cells to death [5] 
are PP2A-dependent in FL5.12 cells. 
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Figure 4.1. SH-BC-893 and C2-ceramide cause PP2A-dependent disruptions in endolysosomal trafficking.  
A) Structures of the PP2A activators FTY720 (Fingolimod), C2-ceramide, SH-BC-893 and the PP2A inhibitor LB-100. B) 
Surface CD98 levels in FL5.12 cells pre-treated with LB-100 (100 µM) for 1.5 h prior to addition of DMSO vehicle, SH-BC-893 
(5 µM), or C2-ceramide (50 µM) for 1 h. Using Student’s t-test (n.s.) not significant; *,p ≤0.05;**, p≤0.01; and ***, p≤0.001  C) 
DIC microscopy of FL5.12 cells pre-treated with LB-100 (100 µM) for 1.5 h prior to addition of DMSO, vehicle, SH-BC-893 (5 
µM), or C2-ceramide (50 µM) for 2 h.   
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4.5.2 Dynamic phosphoproteomics deconvolves signaling events associated with changes in 
PP2A activity 
 
To investigate the molecular mechanisms underlying nutrient transporter loss and vacuolation, 
we profiled the temporal changes in protein phosphorylation in FL5.12 cells treated SH-BC-893, 
C2-ceramide, or LB-100 using quantitative phosphoproteomics and metabolic labeling (Figure 
4.2). Changes in the phosphoproteome associated with SH-BC-893 or LB-100 treatment were 
analyzed in triple SILAC experiments. 
 
Figure 4.2. Triple SILAC phosphoproteomics workflow.  
Light cells are treated with vehicle, medium cells were treated with C2-ceramide (50 µM) or LB-100 (10 µM), and heavy cells 
were treated with SH-BC-893 (5 µM). Cells were collected every 5 min from 0-60 min of stimulation by snap freezing in pre-
cooled ethanol. Cells were lysed in urea, digested with trypsin and phosphopeptides were enriched using titanium dioxide. Strong 
cation fractionation (SCX) was performed prior to LC-MS/MS analysis. Phosphopeptide identification and quantitation was 
performed using MaxQuant, and only kinetic profiles of sites with localisation confidence > 0.75 and measured in at least 6 time 
points were selected for further analysis. Polynomial fitting was used to define regulated phosphosites, and only phosphopeptide 
profiles with FDR < 1% were selected and used for fuzzy c-means clustering and subsequent analyses. 
 
LB-100 was selected for these studies as it is more selective towards PP2A than other 
serine/threonine protein phosphatase inhibitors such as calyculin A or okadaic acid which affect 
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both PP1 and PP2A [32, 33].  In a parallel set of experiments, C2-ceramide’s effects on the 
phosphoproteome were compared to those of SH-BC-893 using a similar strategy. Unstimulated 
cells (0Lys, 0Arg, light), and cells treated with LB-100/C2-ceramide or SH-BC-893 (4Lys, 6Arg, 
medium or 8Lys, 10Arg, heavy) were collected every 5 min for 60 min, and combined together in 
pre-cooled ethanol (-80˚C) at each time point. Cells were centrifuged, lysed, and digested with 
trypsin prior to phosphopeptide enrichment on TiO2 affinity media. The eluted phosphopeptides 
were subsequently fractionated on strong cation exchange (SCX) spin columns and analyzed by 
liquid chromatography tandem mass spectrometry (LC-MS/MS). Phosphopeptide identification 
and quantification was performed using MaxQuant [34, 35] and kinetic trends and clusters 
identified using R (http://www.r-project.org/). A total of 15,607 unique phosphopeptides were 
identified corresponding to an average phosphopeptide enrichment level of 85% for all 
experiments. SILAC experiments enabled the identification of 12,137 and 9,738 unique 
phosphopeptides on 2,949 and 2,550 proteins for LB-100/SH-BC-893 and C2-ceramide/SH-BC-
893 experiments, respectively (Supplementary Table S4-2). On average, 70% of phosphosites 
were localized with high confidence (8,559 sites for LB-100/SH-BC-893 and 6,704 sites for C2-
ceramide/SH-BC-893). Closer examination of these data revealed that 3,928 phosphosites in LB-
100/SH-BC-893 and 2,919 phosphosites in C2-ceramide/SH-BC-893 experiments were 
quantified in at least 6 time points, and were classified as high-quality kinetic profiles 
(Supplementary Figures 4.1 and 4.2 and Supplementary Table S4-3). Of the 5,029 high quality 
profiles, 1,818 were common to both experiments (Supplementary Figure 4.3). A list of 
phosphopeptides corresponding to these profiles is presented in Supplementary Table S4-3 for 
both triple SILAC experiments. As described previously, curve fitting with a polynomial model 
and a false discovery rate (FDR) of 1% distinguished dynamic from static profiles [17]. These 
analyses identified 629 and 428 dynamic profiles corresponding to regulated phosphosites in LB-
100/SH-BC-893 and C2-ceramide/SH-BC-893 experiments, respectively (Supplementary Table 
S4-4). A comparison of these regulated phosphosites revealed that only 54 phosphopeptides were 
common to all three conditions suggesting that many of the changes in cell signaling taking place 
were not regulated by all three stimuli (Supplementary Figure 4.3).  
 
Phosphorylation events that vary in opposite directions in cells treated with SH-BC-893 and LB-
100 are likely to be PP2A-dependent. The dynamic profiles showed a progressive broadening of 
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fold change (FC) values with a gradual shift in the median distribution toward a decrease or an 
increase in phosphorylation for cells treated with SH-BC-893 or LB-100, respectively. The width 
of this distribution was calculated from the inter quartile range (IQR) of the Log2 (FC) 
distribution of phosphopeptides at each time point and plotted over the entire cell stimulation 
period (Figure 4.3A). The resulting curve showed a progressive increase in the IQR, in contrast 
to the trend observed from non-phosphorylated peptides that remained unaffected with time. 
Also, the extent of changes in protein phosphorylation was more pronounced for cells treated 
with LB-100 compared to those incubated with SH-BC-893.  
 
Fuzzy clustering separated these dynamic profiles into those that displayed rapid or progressive 
increases or decreases in phosphorylation or showed an adaptation-like response (Figures 4.3B 
and C).  From the 629 dynamic profiles identified in experiments comparing SH-BC-893 and 
LB-100 treatments, 384 were regulated by SH-BC-893, and are represented in Figure 4.3B. The 
majority of profiles in SH-BC-893-treated cells showed a progressive dephosphorylation (200 of 
384 profiles), consistent with the expected agonist activity of this compound (Figure 4.3C). In 
contrast, profiles from cells treated with the PP2A inhibitor LB-100 displayed a progressive 
increase in phosphorylation with time (349 of 534 profiles). Fifty-two profiles in cells treated 
with SH-BC-893 exhibited adaptation characterized by a rapid dephosphorylation over the first 
20 min post-stimulation followed by a recovery phase that extended over the remaining time 
period (Figure 4.3C). Interestingly, phosphosites that displayed transient dephosphorylation were 
more highly conserved than static sites (p<0.001) or dynamic sites that changed unidirectionally 
(p<0.05) suggesting that the adaptation cluster may define a subset of functionally important 
phosphorylation events (Supplementary Figure 4.4).  
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Figure 4.3. Phosphoproteomics results from the comparison of treatments with LB-100 (10 µM) and SH-BC-893 (5 µM).  
A) Inter quartile range (IQR) shows the global change in phosphorylation upon treatment. Unmodified peptides (control) do not 
change over time while LB-100 and SH-BC-893 treatments show a progressive increase in IQR with time. B) Heatmap of all 390 
phosphosites regulated by SH-BC-893. Different kinetic behaviors are indicated. C) Kinetic trends extracted from LB-100 and 
SH-BC-893 treatments using fuzzy means clustering, numbers correspond to profiles observed with a particular kinetic trend. 
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To identify putative PP2A substrates, we compared phosphorylation profiles that changed in 
opposite directions when FL5.12 cells were treated with LB-100 and SH-BC-893. Out of the 629 
dynamic profiles identified in the triple SILAC experiment, 289 profiles were common to both 
treatments, and 114 of these profiles showed reciprocal (bidirectional) behavior (Figure 4.4A). 
We also noted that a subset of 175 profiles common to both LB-100 and SH-BC-893 displayed 
comparable trends that were either increasing or decreasing in phosphorylation with time, and 
were referred to as monodirectional.  Linear motif analysis of monodirectional or bidirectional 
phosphopeptides with motif-X revealed that approximately half of phosphosites that displayed 
bidirectional profiles showed a SP or a RxxS motif while monodirectional sites were mainly 
represented by proline-directed phosphorylation (PxSP and SP motifs) (Figure 4.4B). To 
decipher which phosphorylation events are associated with changes in PP2A activity, we 
selected phosphosites that exhibited reciprocal trends with SH-BC-893 and LB-100 together with 
those uniquely regulated by SH-BC-893 (209 sites), and performed Gene Ontology (GO) 
enrichment using DAVID (Figure 4.4C). Proteins associated with guanosine triphosphate 
hydrolase (GTPase) regulators and actin filament reorganization were significantly enriched; 
GTPases and actin dynamics both play critical roles in regulating intracellular trafficking.   
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Figure 4.4. Comparison of dynamic phosphorylation sites following SH-BC-893 and LB-100 treatments.  
A) Venn diagram showing that 292 phosphosites are common to both treatments while 253 and 98 phosphosites are uniquely 
regulated by LB-100 and SH-BC-893, respectively. Of the 292 common sites, 116 sites showed opposite (Bidirectional) tends 
and 176 sites are regulated in the same direction (Monodirectional). B) Phosphorylation motifs extracted from motif-x. 
Monodirectional phosphosites display PxSP and SP motifs. Bidirectional sites that show rapid changes in phosphorylation are 
present on Serine-rich peptides. C) Gene Ontology enrichment of proteins corresponding to the 214 bidirectional and 
unidirectional (for SH-BC-893) phosphosites. 
 
A literature analysis was performed to determine whether dynamic profiles had been previously 
identified as PP2A interactors [36-38]. This analysis revealed that 30 proteins (37 phosphosites) 
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identified in our screen were common with PP2A-interactors identified in other reports [36-38] 
(Figure 4.5A, Supplementary Table S4-4). Closer examination of these data indicated that 15 of 
these proteins are interconnected through a protein-protein interaction network and that 6 of 
these members (Vim, Pxn, Pak2, Gsk3β, Cfl1, Arhgef2) are known regulators of cytoskeleton 
organization (Figure 4.5B). Phosphorylation profiles of these substrates are shown in Figure 
4.5C. Previous reports have indicated that Vimentin (Vim) phosphorylation at several residues, 
including Ser42 and Ser430, is regulated by PP2A and functionally important [39, 40]; 
inactivation of vimentin leads to increased actin stress fiber assembly [41]. The cytoskeletal 
protein Paxillin (Pxn) that regulates the actin-membrane attachment showed a rapid 
dephosphorylation at site Ser83 upon the first 5 min of SH-BC-893 treatment followed by a 
recovery and a more gradual decrease in phosphorylation that extended over the entire 
stimulation period. The closely located phosphorylation sites Pxn Thr31 and Thr118 have 
previously been reported to regulate cell migration in a RhoA dependent manner [42, 43]. The 
cytoskeleton organizing kinase Pak2 showed strong dephosphorylation on Ser141. Furthermore, 
Arhgef2 Ser122 showed a rapid dephosphorylation upon SH-BC-893 treatment. This site is 
proximal to Ser143 previously described to impact F-actin based morphological changes [44]. 
The actin depolymerizing protein Cofilin1 (Cfl1) showed a progressive increase in 
phosphorylation at Ser3, a site whose phosphorylation inactivates the actin-depolymerizing 
activity of cofilin [45].  Similarly, SH-BC-893 induces phosphorylation of the glycogen synthase 
kinase 3 b (Gsk3b) on Ser9, a site that has previously been reported to regulate the 
reorganization of cytoskeleton forming microtubules [46]. With the exception of Cfl1 Ser3, all 
sites described above showed differential regulation upon SH-BC-893 and LB-100 treatments.   
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Figure 4.5. Identification of putative PP2A targets.  
A) Comparative analysis of the list of candidate PP2A substrates identified from various proteomic studies. The comparison was 
done at the protein level since not all datasets reported the position of the phosphorylated sites. B) A network of phosphorylation 
sites identified as direct PP2A targets based on comparative literature review. Color coding indicates if the proteins are involved 
in actin reorganization. C) Dynamic profiles of sites from putative PP2A targets involved in actin reorganization. 
  
 187 
 
4.5.3 Dynamic phosphoproteomics identifies distinct cell signaling events associated with C2-
ceramide and SH-BC-893  
 
While both SH-BC-893 and C2-ceramide down-regulate nutrient transporters in a PP2A-
dependent manner, only SH-BC-893 promotes cytoplasmic vacuolation (Figure 4.1). 
Quantitative phosphoproteomics experiments performed on FL5.12 cells treated with SH-BC-
893 or C2-ceramide enabled the identification of cell signaling events differentially associated 
with these compounds. Dynamic profiles again formed three distinct clusters according to fuzzy 
clustering, displaying rapid or progressive increases or decreases in phosphorylation or an 
adaptation-like response (Figure 4.6A and B). In total, we identified 428 dynamic profiles, of 
which 254 profiles were common to SH-BC-893 and C2-ceramide (Figure 4.6C). Approximately 
80% of common profiles (203 of 254 profiles) showed a mono-directional trend where 
progressive changes in protein phosphorylation were similar both in magnitude and direction for 
these two compounds consistent with the fact that these agents produce largely overlapping 
phenotypes in cells.  Interestingly, 51 of the 254 common profiles showed opposite trends, while 
126 or 48 profiles were uniquely regulated by C2-ceramide or SH-BC-893, respectively. These 
differentially regulates sites could be responsible for divergent phenotypes such as vacuolation.  
 
To correlate phosphorylation changes with the distinct vacuolation phenotypes associated with 
C2-ceramide and SH-BC-893, dynamic profiles were separated into three groups: 1) Common 
and mono-directional profiles, 2) Bi-directional profiles or dynamic profiles unique to SH-BC-
893 and 3) Dynamic profiles unique to C2-ceramide. GO term enrichment analyses were 
performed to determine if these groups were related to specific cellular compartments and 
molecular functions. Results from the corresponding analyses are displayed in the radar plots of 
Figure 4.6D. The majority of profiles identified belong to group 1 (203 shared monodirectional 
profiles) and are likely to account for phenotypes induced by both C2-ceramide and SH-BC-893 
(e.g., nutrient transporter down-regulation). These profiles correspond to substrates that are 
largely involved in the regulation GTPase activity and actin cytoskeleton organization. Profiles 
from group 2 that showed opposite trends or are specific to SH-BC-893 treatment (99 profiles) 
were associated with the GO terms: endosome, intracellular membrane bound organelle and 
plasma membrane. Amongst these we found 11 phosphorylation sites on 9 proteins involved in 
vesicle trafficking and lysosomal fusion (Supplementary Figure 4.5). This result is consistent 
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with findings that SH-BC-893 but not C2-ceramide inhibit lysosomal trafficking events [5]. 
Group 3 comprises 126 profiles that are unique to C2-ceramide treatment. Phosphorylated 
substrates associated with this group are mostly localized in the nucleus with functional GO 
terms enriched for DNA binding, Chromatin binding and “DNA-directed DNA polymerase 
activity”. A protein-protein interaction network of the corresponding phosphoproteins highlights 
several of the corresponding members and regroups proteins involved in DNA replication, DNA 
repair, nucleotide synthesis, and ribosome assembly (Supplementary Figure 4.6). 
 189 
 
 
Figure 4.6. Dynamic phosphoproteomics identifies signaling events differently regulated by C2-ceramide and SH-BC-893 
treatments.  
A) Heatmap corresponding to 380 phosphorylation sites that were dynamically phosphorylated upon C2-ceramide treatment. 
Kinetic trends are indicated. B) Dynamic profiles extracted from C2-ceramide and SH-BC-893 treatments using fuzzy means 
clustering. Numbers correspond to profiles observed for a given cluster. C) Venn diagram of dynamic phosphosites showing that 
254 phosphosites are common, 126 and 48 phosphosites are uniquely regulated by C2-ceramide and SH-BC-893, respectively. Of 
the 254 commonly regulated sites, 51 show opposite change in phosphorylation (bidirectional) and 203 are regulated in the same 
direction (monodirectional). D) Radar plot showing the enrichment of GO terms associated with specific groups highlighted in 
different colors. E) Motif-X analyses of bidirectional sites showing an over-representation of basophilic motifs. F) Network of 
putative Akt substrates and known interacting members. 
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Next, we analyzed dynamic profiles from each group with Motif-X to determine if a specific 
phosphorylation consensus sequence was over-represented in these datasets (Supplementary 
Figure 4.7A). These analyses indicated that a large proportion of dynamic profiles were 
represented by proline-directed and basophilic phosphorylation motifs. Further analyses 
performed with the kinase prediction software available from the Group-based Prediction System 
(GPS) [47] identified Akt as a putative kinase targeting dynamic basophilic motifs. Interestingly, 
bidirectional sites from group 2 comprised the largest proportion of putative Akt substrates from 
all groups (Figure 4.6E and Supplementary Figure 4.7B). Among the 21 putative Akt substrates 
from group 2, we identified 6 proteins (Vim, Slc33a1, Gsk3b, Pikfyve, Acly, Pi4kb) that are 
known to interact with each other, including 3 proteins (Gsk3b, Pikfyve, Acly) previously 
reported as Akt substrates [48-50] (Figure 4.6F). For convenience, Supplementary Figure 4.8 
presents the kinetic phosphorylation profiles of several Akt substrates. Together, these results 
suggest that a subset of bidirectional sites are putative Akt substrates associated with vesicle 
trafficking and could account for the vacuolation phenotype observed only with SH-BC-893.   
 
4.5.4 SH-BC-893 and C2-ceramide stimulate actin polymerization that is necessary for 
cytoplasmic vacuolation but not surface nutrient transporter loss 
 
To gain a systems-level view of changes in protein phosphorylation observed for C2-ceramide 
and SH-BC-893, we used GO terms enriched in our datasets (Figure 4.6D, Supplementary Table 
S4-5) combined with manual curation of gene lists to generate a pictogram of regulated 
phosphosites (Supplementary Figure 4.9).  Protein groups of interest included membrane 
transport, endocytosis/cell adhesion, actin reorganization, nutrient transport and GTPase 
regulation (GTPase activators, GAPs and guanidine nucleotide exchange factors, GEFs).  
 
Because dynamic phosphorylation sites similarly affected by SH-BC-893 and C2-ceramide were 
clustered in proteins that modulate actin dynamics (Figure 4.6D), actin polymerization was 
monitored in SH-BC-893- or C2-ceramide-treated FL5.12 cells using fluorescently-conjugated 
phalloidin. Both SH-BC-893 and C2-ceramide robustly increased F-actin formation in the cell 
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cortex and in a cytosolic, likely endosomal, compartment (Figure 4.7A). Similar effects were 
observed in murine embryonic fibroblasts (MEFs) and in HeLa cells (data not shown). 
Consistent with a role for PP2A activation in this phenotype, the PP2A inhibitors LB-100 and 
calyculinA (CalyA) blocked actin polymerization at both locations (Figure 4.7B). The actin 
polymerization inhibitor Latrunculin A (LatA) also prevented actin polymerization with SH-BC-
893 and C2-ceramide (Figure 4.7C). However, while LB-100 blocked CD98 down-regulation 
induced by SH-BC-893 or ceramide (Figure 4.1B), LatA did not suggesting that the loss of 
surface transporters depends on PP2A activation but not actin polymerization (Figure 4.7D). This 
result was unexpected, as actin polymerization is essential for nutrient permease downregulation 
by sphingolipids in yeast [51]. Interestingly, LatA reversed vacuolation by SH-BC-893 (Figure 
4.7E). The actin polymerization stimulator Jasplakinolide did not promote vacuolation on its own 
(data not shown). Together, these data suggest that both C2-ceramide and SH-BC-893 stimulate 
actin polymerization in a PP2A-dependent manner and that actin polymerization is necessary but 
not sufficient to produce cytoplasmic vacuolation.  
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Figure 4.7. C2-ceramide and SH-BC-893 promote actin polymerization.  
A) FL5.12 cells treated with SH-BC-893 (10 µM) or C2-ceramide (50 µM) for 1 h and then stained for F-actin with Alexa Fluor 
488-conjugated phalloidin.  B) Same as in A), except cells pre-treated with vehicle or PP2A inhibitors calyculinA (calyA, 5 nM) 
or LB100 (10 or 100 µM) for 1.5 h prior to SH-BC-893 addition.  C) Same as in A), except cells pre-treated with vehicle or actin 
polymerization inhibitor latrunculinA (LatA, 1 µM) for 30 min prior to SH-BC-893 (2.5 µM) or C2-ceramide (30 µM) addition.  
D) FL5.12 cells pre-treated (30 min) with LatA (1 µM) were treated with SH-BC-893 (2.5 or 5 µM) or C2-ceramide (30 or 50 
µM) for 1 h and surface CD98 quantified by flow cytometry. E) FL5.12 cells pre-treated with LatA (30 min, 1 µM) were treated 
with SH-BC-893 (5 µM) for 2 h and imaged by DIC microscopy to visualize vacuoles.  n = 2 in D).  n ≥ 30 cells per condition in 
E). In E), using two-tailed t-test to compare 893-treated cells to combination of LatA and 893, *** = p ≤ 0.001. 
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4.5.5 Ceramide inhibits SH-BC-893-induced vacuolation by inactivating Akt 
 
The finding that ceramide results in the dephosphorylation of more proteins than SH-BC-893 
suggested that, rather than failing to induce vacuolation, ceramide may dephosphorylate and 
inactivate a proteins necessary for vacuolation. In support of this model, co-addition of C2-
ceramide inhibited cytoplasmic vacuolation by SH-BC-893 in FL5.12 cells (Figure 4.8A).  
Similar results were obtained in HeLa cells and murine prostate cancer epithelial cells 
(Supplementary Figure 4.10A and not shown). As highlighted in Supplementary Figure 4.8, 
multiple Akt substrates were dephosphorylated in cells treated with C2-ceramide but not SH-BC-
893. That the effect of C2-ceramide was dominant was confirmed in Figure 4.8B and 
Supplementary Figure 4.10, B,C by monitoring the Akt-dependent phosphorylation of PRAS40 
at threonine 246 [52]. These observations suggested that C2-ceramide may block vacuolation by 
inactivating Akt.  Consistent with this model, the allosteric Akt inhibitor MK2206 reduced both 
Akt activity and vacuolation in FL5.12 cells treated with SH-BC-893 (Figures 4.8B,C); similar 
results were obtained in mPCE prostate cancer cells (Supplementary Figures 4.10C,D). The 
deletion of Rictor, an mTORC2 component necessary for Akt activation [53], also blocked 
vacuolation in the presence of SH-BC-893 again suggesting that Akt activity is essential for this 
phenotype (Figure 4.8D). Together, these data suggest that C2-ceramide does not vacuolate cells 
because Akt inactivation prevents the manifestation of this phenotype. 
 
Two Akt substrates that are dephosphorylated in the presence of C2-ceramide but not SH-BC-
893, Pikfyve and Pik4b, regulate late endocytic trafficking [54, 55]. Gsk3b also localizes to 
MVBs and lysosomes and may regulate their function [56]. Consistent with its phosphorylation 
by Akt, GSK3b Ser9 phosphorylation increases with SH-BC-893 but decreases with C2-
ceramide (Supplementary Figure 4.8). Because Ser9 phosphorylation inhibits Gsk3b activity 
[57], Gsk3b inhibition may contribute to vacuolation. To test this, SH-BC-893 or C2-ceramide 
was combined with the Gsk3b inhibitor CHIR99021 and vacuolation monitored. While 
CHIR99021 did not vacuolate on its own or induce vacuolation in C2-ceramide-treated cells, 
CHIR99021 enhanced vacuolation of FL5.12 cells by SH-BC-893 (Figure 4.8E). This effect was 
much more dramatic in HeLa cells where CHIR99021 also sensitized cells to SH-BC-893 
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induced death despite its complete lack of toxicity as a single agent (Supplementary Figures 
4.10E,F). These data suggest that SH-BC-893, but not C2-ceramide, vacuolates cells because 
Akt continues to inhibit Gsk3b. 
 
Figure 4.8. Ceramide inhibits vacuolation by reducing Akt activity.  
 
A) FL5.12 cells were treated for 3 h with SH-BC-893 (2.5 µM) and/or C2-ceramide (50 µM) as indicated and imaged by DIC 
microscopy. B) Western blot measuring the phosphorylation of the AKT substrate PRAS40 (total and phospho-Thr246) in 
FL5.12 cells treated for 30 min with SH-BC-893 (5 µM), C2-ceramide (50 µM), and/or MK2206 (1 µM) as indicated. C) FL5.12 
cells treated for 3 h with SH-BC-893 (2.5 µM) and/or AKT inhibitor MK2206 (1 µM) as indicated and visualized as in (A). D) 
Rictor WT and KO murine embryonic fibroblasts (MEFs) treated for 6 h with vehicle or SH-BC-893 (5 µM) then visualized by 
phase contrast microscopy. E) FL5.12 cells treated for 3 h with SH-BC-893 (2.5 µM) or C2-ceramide (50 µM) and the Gsk3b 
inhibitor CHIR99021 (10 µM) as indicated; visualized as in (A). In (A,C,E), ≥ 400 cells per condition were analyzed from a total 
of three independent experiments; using a two-tailed t-test to compare either SH-BC-893 or C2-ceramide to the vehicle control 
(in E) or SH-BC-893 alone to the combination of SH-BC-893 with C2-ceramide (A), MK2206 (C), or CHIR99021 (E), n.s. = not 
significant, ** = p ≤ 0.01, or *** = p ≤ 0.001. 
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4.6 Discussion 
 
 
In this study, quantitative phosphoproteomics was used to identify phosphoproteins that 
responded differentially to pharmacological compounds that modulate PP2A activity and to 
correlate the PP2A-dependent phenotypes that affect intracellular trafficking and nutrient 
transporter loss. Time-resolved phosphoproteome analyses of FL5.12 cells treated with the PP2A 
agonist SH-BC-893 or the PP2A inhibitor LB-100 enabled the identification of putative PP2A 
substrates and phosphorylation events specific to each compound. These analyses confirmed that 
SH-BC-893 affected PP2A activity as approximately 75% of phosphorylation sites (289 out of 
384 sites) were also targeted by LB-100. A more detailed analysis of the dynamic changes in 
protein phosphorylation common to LB-100 and SH-BC-893 revealed that 40% of these profiles 
displayed the expected reciprocal response and could represent putative PP2A substrates. A 
significant proportion of these targets are involved in the regulation of cell migration and actin 
cytoskeleton organization, including previously known PP2A substrates such as Vim, Pxn, Pak2, 
and Arhgef2. 
 
Gene ontology analysis of phosphoproteins that were dynamically regulated monodirectionally 
by SH-BC-893 and C2-ceramide suggested that changes in actin dynamics contribute to the 
intracellular trafficking defects observed in sphingolipid-treated cells (Figure 4.6D) and led to 
the discovery that both SH-BC-893 and C2-ceramide promote PP2A-dependent actin 
polymerization at the cell cortex and in the cytoplasm (Figures 4.7A,B). Given that actin 
polymerization plays an important role in sphingolipid-induced nutrient transporter 
internalization in yeast [51], it was surprising that actin polymerization was not necessary for 
down-regulation of nutrient transporter proteins by SH-BC-893 and C2-ceramide (Figures 
4.7C,D). Moreover, rather than contributing the shared phenotype, loss of surface nutrient 
transporters, actin polymerization was necessary for a phenotype observed uniquely in SH-BC-
893-treated cells, vacuolation (Figure 4.7E). As vacuolation contributes to the anti-neoplastic 
activity of SH-BC-893 in vitro and in vivo [5], the molecular mechanism underlying this 
phenotype is of significant interest.  
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The differential ability of SH-BC-893 and C2-ceramide to produce vacuolation (Figure 4.1C) led 
us to hypothesize that cell signaling events responsible for vacuolation would be encompassed in 
phosphosites that varied in opposite manner in SH-BC-893- and C2-ceramide-treated cells.  A 
basophilic phosphorylation motif typical of Akt substrates was enriched among these 
differentially regulated dynamic sites; multiple Akt substrates were dephosphorylated in C2-
ceramide-, but not SH-BC-893-treated, cells (Figure 4.6F and Supplementary Figure 4.8). It has 
been widely reported that ceramide reduces the phosphorylation and activity of Akt [58]. In 
contrast, Akt Ser473 phosphorylation was maintained in SH-BC-893-treated cells not just in this 
study (Supplementary Figure 4.10A,B), but also in vivo in autochthonous prostate tumors [5]. 
Differential regulation of Akt activity by SH-BC-893 and C2-ceramide might result if these 
sphingolipids activate PP2A through distinct mechanisms. Alternatively, as SH-BC-893 is water 
soluble to >60 mM while C2-ceramide is poorly soluble in aqueous solutions, these compounds 
may activate PP2A in different subcellular compartments. Membrane-localized C2-ceramide 
may activate plasma-membrane localized PP2A more effectively than SH-BC-893; Akt is 
activated by kinases found at the plasma membrane [59]. It is also possible that SH-BC-893 and 
C2-ceramide differentially regulate the phosphorylation of the PP2A regulatory subunit B56β 
(Ppp2r5b) by Clk2 thereby affecting the interaction between Akt and PP2A [60, 61]. Regardless 
of the mechanism underlying differential Akt activation by these sphingolipids, the reduction in 
vacuolation when Akt was inhibited by MK2206, Rictor deletion, or C2-ceramide demonstrate 
that Akt activity is necessary for SH-BC-893-induced vacuolation (Figures 4.8A-D and 
Supplementary Figures 4.10A-D). In summary, these phosphoproteomics studies led to the 
unexpected discovery that C2-ceramide was dominant over SH-BC-893 in vacuolation assays 
(Figure 8A and Supplementary Figure 4.10A) and the conclusion that, rather lacking an activity 
possessed by SH-BC-893, ceramide fails to vacuolate cells because it inactivates Akt.  
 
A detailed mechanistic understanding of how Akt activity supports vacuolation will require 
additional studies. However, the almost 2-fold increase or decrease in the phosphorylation of the 
Akt substrate Gsk3b phosphorylation at its inhibitory site Ser9 with SH-BC-893 or C2-ceramide, 
respectively (Supplementary Figure 4.8), and the accentuation of vacuolation by the Gsk3b 
inhibitor CHIR99021 (Figure 4.8E and Supplementary Figure 4.10E) suggest that Gsk3b may 
suppress vacuolation by positively regulating MVB function. Because CHIR99021 was not 
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sufficient to induce vacuolation in C2-ceramide treated cells (Figure 4.8E), it is likely that 
additional Akt substrates besides Gsk3b contribute to the vacuolation phenotype.  Consistent 
with published studies showing that vacuolation contributes to the anti-neoplastic effects of SH-
BC-893 [5], inhibition of Gsk3b also sensitized cells to SH-BC-893-induced death 
(Supplementary Figure 4.10F). Gsk3b inhibitors are currently being developed for treatment of 
acute myeloid leukemia and breast cancer. Considering these findings, there may be a strong 
rationale for combining Gsk3b inhibitors and SH-BC-893 in cancer treatment. In conclusion, 
global, kinetic phosphoproteomic screens utilizing PP2A-activating sphingolipids helped to 
elucidate signaling pathways necessary for cellular starvation by sphingolipids, and highlighted a 
key role for Akt and Gsk3b signaling in regulating lysosomal trafficking events. 
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4.8 Supplementary material 
 
 
4.8.1 Supplementary figures 
 
 
Supplementary Figure 4.1. Summary of statistics of triple SILAC phosphoproteomics experiment comparing LB-100 and SH-
BC-893-treated FL5.12 cells. 
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Supplementary Figure 4.2. Summary of statistics of triple SILAC phosphoproteomics experiment comparing C2-ceramide and 
SH-BC-893-treated FL5.12 cells. 
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Supplementary Figure 4.3. Comparison of compounds affecting PP2A activity revealed different protein subsets affecting cell 
signaling.  
A) Overlap of high quality kinetic profiles obtained from both triple SILAC experiments comparing either SH-BC-893 and LB-
100 or SH-BC-893 and C2-ceramide. 1860 profiles were common to both experiments. B) Overlap of dynamically regulated 
phosphosites. 
 
Supplementary Figure 4.4. Conservation rate analysis.  
Conservation of phosphorylation sites was compared based on grouping of the kinetic profiles observed for different treatments. 
Phosphorylation sites showing adaptation-like behavior upon treatment with SH-BC-893 are more conserved across species. 
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Supplementary Figure 4.5. Proteins from endosomes, late endosomes or intracellular membrane-bound organelles are 
differentially phosphorylated upon treatment with sphingolipids.  
Partial network and kinetic profiles of phosphorylation from proteins following cell treatment with SH-BC-893 and C2-ceramide. 
 
 
Supplementary Figure 4.6. Network of proteins that are uniquely phosphorylated upon C2-ceramide treatment. 
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Supplementary Figure 4.7. Consensus motif of phosphorylation sites observed in dynamic profiles from C2-ceramide and SH-
BC-893 phosphoproteomic experiments.  
A) Motif-X analyses of phosphorylation sites from three groups of dynamic profiles. B) Relative proportion of Akt sites within 
each group predicted from GPS 3.0 (http://gps.biocuckoo.org/). 
 
 
Supplementary Figure 4.8. Dynamic profiles of putative Akt substrates associated with vesicle trafficking. 
This image cannot currently be displayed.
 203 
 
 
Supplementary Figure 4.9. Pictogram of proteins that are dynamically phosphorylated upon SH-BC-893 and C2-ceramide 
treatment.  
Only proteins associated to the main GO term molecular functions (Membrane transport, GTPase and GEF regulation, Actin 
binding, Endocytosis) are shown. Color coding indicates differences and similarities observed between C2-ceramide and SH-BC-
893 treatments. 
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Supplementary Figure 4.10. Ceramide inhibits vacuolation in multiple cell lines by reducing Akt activity.  
A) HeLa cells treated for 3 h with SH-BC-893 (5 µM) and the indicated concentrations of C2-ceramide were imaged by phase 
contrast microscopy to visualize vacuoles.(B) Western blot for AKT (total and phospho-Ser473), PRAS40 (total and phospho-
Thr246) and tubulin (loading control) in HeLa cells treated for 30 min with SH-BC-893 (5 µM), C2-ceramide (50 µM), and/or 
MK2206 (1 µM). C) As in (B), except with mouse prostate cancer epithelial cells (mPCE). D) HeLa cells treated for 6 h with SH-
BC-893 (5 µM) and/or the AKT inhibitor MK2206 (1 µM) were visualized as in (A). E) HeLa cells were treated for 6 h with 
indicated concentrations of SH-BC-893 or C2-ceramide and/or CHIR99021 (10 µM) as indicated and visualized as in (A). F) As 
in E, except at 24 h. 
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4.8.2 Supplementary tables 
 
Supplementary Table S 4-1: MaxQuant search paramters (DVD-R). 
Supplementary Table S 4-2: List of all identified phosphopeptide profiles (DVD-R). 
Supplementary Table S 4-3: List of high quality phosphopeptide profiles (DVD-R). 
Supplementary Table S 4-4: List of all dynamically regulated phosphoprofiles (DVD-R). 
Supplementary Table S 4-5: Gene Ontology enrichment of phosphorylation sites from the 
comparison of C2-ceramide and SH-BC-893 based on grouping described in 4.5.4 (DVD-R). 
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Conclusion and Future Perspectives 
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5.1 Conclusion 
 
 
Protein phosphorylation is one of the most prominent post-translational modification regulating 
the functioning of cells. Protein phosphorylation is carried from one protein to another on pre-
defined routes to regulate molecular machineries. These intracellular routes, or pathways, 
transmit information that is crucial for the functioning of cells and, if deregulated, can have 
unpredictable outcomes. Understanding signaling pathways, and identifying their precise 
member proteins has been of major interest in cancer research in the past decades. Various 
techniques including mass spectrometry based phosphoproteomics and biochemical assays such 
as western blots have been used to generate maps of signaling cascades. Defining the boundaries 
of these cascades mostly relies on known phosphorylation motifs that can be used to predictively 
associate kinases to their substrates. Our persisting interest in phosphorylation pathways and the 
development of new methodologies led to the hypothesis that signaling routes could be 
disentangled based on kinetic profiling of the phosphoproteome. Accordingly, the aim of my 
thesis was to develop mass spectrometry methodologies that allow the monitoring of 
phosphoproteome kinetics post-stimulation, with vast phosphoproteome coverage. Monitoring 
phosphorylation reactions at high temporal resolution was anticipated to provide insights on 
intracellular signaling routes.  
 
Within the scope of this thesis, I developed and applied methodologies allowing to profile the 
phosphoproteome at high temporal resolution. Phosphoproteome profiling was used to generate 
datasets following perturbations of yeast and mammalian cancers cells. These data proved to be 
of high statistical reliability and allowed the characterization of distinct signaling pathways from 
untargeted stimulation (such as temperature shocks) as wells as from targeted perturbations of 
cells with anti-oncogenic drugs.  
 
In a first study, I combined triple SILAC labeling with previously-optimized phosphoproteomics 
workflows [1, 2] and followed the temperature stress response of the yeast phosphoproteome 
within the first thirty minutes of stimulation at a temporal resolution of three minutes [3]. To 
investigate the phosphoproteome with high temporal resolution, snap freezing technologies were 
implemented to preserve timepoints prior to mass spectrometry based proteomics analysis. Data 
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analysis revealed that phosphorylation was a major regulator of the temperature stress response 
as over 5% of the yeast phosphoproteome appeared to be dynamically regulated. Temporal 
profiling unraveled 15 specific kinetic trends of which many could be associated to stimulation-
specific pathways. Intriguingly, time-resolved data could be used as a predictive tool to link 
kinase activity to their substrates. The most noteworthy observation was a rapid increase in 
phosphorylation on Tyr 19 of the cell cycle-regulating kinase Cdc28 following heat shock. 
Phosphorylation of Tyr 19 on Cdc28 has been shown to inactivate the kinase activity [4], and 
consistently, known substrates of Cdc28 showed a rapid decrease in phosphorylation with similar 
dynamic characteristics. Temporal information was then used to reveal functional association 
between the protein kinase A (PKA) and putative substrates. The ability to derive enzyme-
substrate relationships from dynamic datasets was considered an important feature that could 
potentially aid to precisely define the signaling events perturbed by anti-oncogenic drugs in 
future studies.  
Hence, the developed time resolved phosphoprotoemics techniques were applied to study the 
phosphoproteome response of human colon cancer cells treated with the BRAF kinase inhibitor 
Vemurafenib in my second publication [5]. Colon cancer cells that respond paradoxically to 
treatment with Vemurafenib were investigated to understand the underlying mechanisms that 
drive the death of these cancers. The resulting dataset enabled the generation of a precise 
signaling network of the BRAF-RAS-MEK-ERK cascade. Temporal information allowed the 
distinction between early and late signaling events linking kinase substrates to later feedback 
mechanisms. Only the increased depth of phosphoproteome coverage in this dataset enabled the 
accurate definition of the MAP kinase network, which at present, is the most comprehensive one 
available [6]. Novel members of the MAPK signaling network were associated to the MAP 
kinase ERK by using in vitro kinase assays. Those confirmed the predicted kinase–substrate 
relationships. This dataset also unveiled that the anti-oncogenic drug Vemurafenib increases 
phosphorylation on the transcription factors MKL1/2 in colon cancer cells harboring somatic 
BRAF mutations. The increased phosphorylation was shown to be blocked by the binding of 
globular actin to the MKL1/2 RPEL motifs. Consistently, it was recently published that MKL1/2 
phosphorylation at these sites reduces their affinity for actin and has thus profound functional 
consequences on these transcription activators [7]. As kinetic information proved to be 
supportive to profile drug induced perturbations of the cellular signaling machinery, expanding 
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the application of temporally-resolved proteomics to study novel, anti-oncogenic compounds 
became obvious.  
In a third study I profiled the phosphoproteome response of hematopoietic mouse cells to 
treatment with the anti-oncogenic sphingolipid-derived compound SH-BC-893 and its natural 
analogue C2-ceramide. Compound SH-BC-893 causes cell starvation through induction of 
nutrient transporter loss at the cell surface and vacuolation; C2-ceramide phenocopies SH-BC-
893 except that it does not induce vacuolation. These phenotypes have previously been found to 
occur after PP2A activation with both compounds [8-10]. Interestingly, time-resolved 
phosphoproteomics, deployed to unravel the molecular events leading to starvation phenotypes 
depicted activation and deactivation of PP2A post-incubation with sphingolipids. Comparison of 
sphingolipid responses to those of the specific PP2A inhibitor, LB100, highlighted that 
sphingolipids specifically increase the affinity of PP2A to phosphogroups on GTPase- and actin-
regulating proteins. The observed targeted activation of PP2A leading to de-phosphorylation of 
these proteins suggests that GTPases and actins are key events that mediate cell starvation. Using 
fluorescence microscopy we found that actin reorganization, induced through sphingolipid 
activity, was inhibiting the cellular nutrient import machineries. Comparison of 
phosphoproteomes following C2-ceramide and SH-BC-893 treatment was further used to 
generate maps of proteins likely causing vacuolar fusion reactions. Altogether, this dataset 
depicts that specific activation of PP2A with sphingolipids results in cell starvation through 
targeted dephosphorylation of actin regulators and GTPases.   
 
Throughout the above summarized studies, temporal profiling of the phosphoproteome yielded a 
precise picture of the cellular events taking place post-stimulation. It allowed to decipher kinase 
substrate networks based on kinetic trends and enabled the definition of molecular machineries 
associated with targeted stimulation. Accordingly, this tool improved our current view on 
intracellular signaling cascades by taking snapshots of the phosphoproteome status at predefined 
time points following stimulation. The biggest asset and novelty from this approach was that up 
to fourteen timepoints were taken in intervals as small as 3 minutes. This appeared advantageous 
for the precise definition of phosphorylation kinetics, in comparison to other studies were only 
few timepoints were taken at large intervals. Only dynamic profiling of phosphorylation events 
allowed to link regulated phosphorylation sites to molecular events as those described above.  
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An additional characteristic that emerged from temporally resolved data is that statistics defining 
regulation of a phosphosite became more intuitive. While experiments based on the observation 
of a single timepoint use t-test based fold change cutoffs to define if a phosphorylation site is 
significantly changing or not, time-resolved data allowed the assessment of significance based on 
curve fitting of dynamic profiles. Using the datasets presented in this thesis, I generated 
bioinformatic workflows allowing the distinction of dynamic and static phosphorylation sites 
based on polynomial fitting and false discovery rates. This allowed the unbiased extraction of 
low and high amplitude changes while discriminating for profiles containing a large number of 
outliers.  
 
In conclusion, experimental design, analytical reproducibility and bioinformatics analysis 
provided the means to generate the high-quality datasets enabling the unraveling of key signaling 
events on a systems biology level.  
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5.2 Perspectives 
 
Time-resolved phosphoproteomics have been deployed to gain further insights into the dynamics 
of intracellular signaling pathways. It was found to be well-suited to study drug response 
signaling as well as overall perturbations of the cellular system. Future improvements could be 
made on the analytical workflow and bioinformatics analyses. Furthermore, the knowledge 
obtained from the datasets should be expanded by performing targeted follow up studies. All 
three perspectives are discussed below.   
 
5.2.1 Simplifying the analytical workflow 
 
SILAC has proven to be a reliable technique to quantify phosphosites with high precision. The 
downsides, however, are its limited multiplexing capacities as only up to three SILAC channels 
can be used per MS run, making the acquisition of kinetic data time consuming. In a triple 
SILAC experiment, each time point is one sample where a control and up to two stimulations can 
be compared. During MS analysis of these samples, quantification of low abundance peptides 
across all timepoints becomes highly unlikely, resulting in less complete kinetic information. MS 
run time and in between run reproducibility could be greatly improved by the use of labeling 
techniques with higher multiplexing capacities and would circumvent the disadvantages 
encountered from SILAC labeling. In the past years, several techniques that allow for accurate 
quantification and pooling of up to 10 stimulations have been developed. The most frequently 
used multiplexing strategy is tandem mass tagging (TMT). TMT allows the analysis of highly 
multiplexed samples by chemically labeling peptides post digestion [11, 12]. While this MS/MS 
based quantification strategy has been found to cause ratio suppression due to the quantification 
in the low mass range, novel approaches including ion mobility spectrometry or MS3 
quantification can diminish these issues, making it applicable for kinetic studies [13, 14]. The 
use of TMT for temporal profiling of the phosphoproteome would allow to obtain all time 
measurements for almost all phosphopeptides that are identified. In turn, much fewer 
observations where only few timepoints are measured would occur, allowing for even higher 
coverage of the dynamic proteome than achieved with SILAC. In addition, the MS run time 
would be drastically decreased, making the analysis of numerous stimulations more feasible. 
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While implementing a TMT workflow to follow phosphoproteome dynamics, one has to 
carefully consider that peptide labeling and pooling of timepoints is performed post digestion. 
Compared to SILAC where cells are pooled at the time each sample is collected, the later 
pooling and labeling of peptides with the TMT approach will induce a larger margin of error for 
quantification. This error would have to be assessed prior to performing any large scale 
experiment and sample handling would have to be iteratively improved.    
 
5.2.2 Improving bioinformatics analysis of phosphoproteome data 
 
Data filtering and assessment of kinetics have been optimized over the course of the three studies 
presented in the thesis. However, interpretation of data to extract biologically relevant 
information has been the most time consuming and confusing part of data analysis. The most 
frequently used tools were Gene Ontology enrichment [15, 16] to unravel molecular mechanisms 
and STRING database [17] to predict protein-protein interactions. Both tools are highly biased 
towards the already studied information and thus do not allow for breakthrough discoveries. 
Especially when novel boundaries of signaling routes are intended to be defined as anticipated 
from kinetic data, biased analysis is the least useful. Development of informatics tools that would 
find the boundaries of pathways solely based on kinetic information could be of great help. For 
example, recent work published from Pierre Thibault’s laboratory makes use of machine learning 
algorithms to find phosphorylation networks in an unbiased manner from peptide sequence 
information [18]. Similar tools using the additional kinetic information would be of high interest 
to be developed for all kinds of kinetic experiments.  
 
5.2.3 Building up on the knowledge obtained from dynamic phosphoproteome datasets 
 
Phosphoprotoemic datasets, especially those with kinetic information, harbor a vast amount of 
information that is difficult to assess and to expand. In most cases, expansion of knowledge is 
based on the very biased selection of observations that are of particular interest to the hypothesis 
or the scientist themselves. Accordingly, follow up studies on findings that could be useful for 
the general community have to be carefully selected. Unbiased follow up experiments that would 
link the big picture phosphoproteomic data to biochemical mechanisms would be preferred. 
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From all experiments conducted in this thesis, the most unsolved question that remains is the 
mechanism by which anti-oncogenic sphingolipids starve cancer cells to death. Phosphorylation 
on molecular machineries associated with GTPase regulation and actin cytoskeleton 
reorganization were found to be impaired later to sphingolipid treatment. We found these 
processes to affect nutrient access to cancer cells later to PP2A activation. However, concrete 
effects of single phosphorylation sites that were observed to change in abundance following 
treatments remain uninvestigated.  Prospective experiments should focus to characterize selected 
phosphorylation sites through expression of point mutants in cancer cells. Phosphorylation sites 
that are of high interest for further assessment include Arhgef2 Ser122 and Micall1 Ser430. As 
highlighted in chapter 4, Arhgef2 is a well-studied guanylyl exchange factor that drives 
endocytosis and actin reorganization, phenotypes that could regulate nutrient access to cancer 
cells [19-22]. Micall1 was further suggested to drive cytoplasmic vacuolation, a phenotype that 
plays a crucial role in the survival of cancer cells [23, 24]. Mutagenesis of these selected 
phosphorylation sites would prove the findings from the phosphoproteomics experiments and 
add to the knowledge about regulation of nutrient homeostasis.   
Moreover, understanding the biochemical mechanism of action of sphingolipids including the 
cancer killing drug SH-BC-893 should become a priority of future research. SH-BC-893 bears 
extremely high potential to serve the treatment of a variety of cancers as it significantly impacts 
tumor growth [24]. Understanding the mechanism of action of these drugs would be of high 
impact for the scientific and medical community and aid the process to render SH-BC-893 
clinically usable. While the phosphoproteomic data greatly enhanced the current understanding 
of PP2A activation by SH-BC-893 and C2-ceramide, not all observed alterations of the 
phosphoproteome appeared to depend on PP2A activation, indicating functional off-target 
effects. Chemical proteomics and genomics could complete the picture of SH-BC-893’s 
mechanism of action and provide the information necessary to assess the drug’s applicability to 
real life. Both chemo-proteomics and chemo-genomics are orthogonal techniques that assess 
protein binders and genetic interactors of small molecules, respectively. Together, crispr-cas9 
based chemogenomics as described by Bertomeu et al. (2018), and affinity-based enrichment of 
drug binders as described by Klaeger et al. (2017), could link the observed phosphoprotoemics 
data to biochemical interactions taking place upon drug treatment [25, 26]. Aiming for a 
complete understanding of the mechanism of action by which SH-BC-893 starves cancer cells 
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should be the next step to investigate this novel therapeutic approach. Implementation of these 
techniques would not only be useful for the study of SH-BC-893 in particular, but the developed 
assays would also display a complete platform that could be used together with 
phosphoproteomic profiling to perform drug discovery on a larger scale.  
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